

## **Ricardo Azziz, MD, MPH, MBA**



A educator-scientist-executive with over 20 years of leadership experience in higher education, research, and healthcare, Dr. Azziz serves as President of the Georgia Regents University (GRU), one of four comprehensive public research universities in Georgia, and CEO of the Georgia Regents Health System (GRHS); managing a greater than \$1.3 billion integrated and aligned enterprise with over 1,000 full-time faculty, 8500 students, and 10,000 employees; and four campuses in the Central Savannah River Area, five other campuses throughout Georgia, and over 1000 training sites.

GRU includes nine colleges/schools (the Colleges of Allied Health Sciences, Arts, Humanities & Social Sciences, Business, Dental Medicine, Education, Nursing, and Science & Mathematics, the Graduate School, and the Medical College of Georgia); a growing NCAA Div. II athletics program (in the Peachbelt Conference) and an NCAA Div. I golf program, which earned back-to-back national championships in 2010 & 2011. Graduate, post-graduate and professional students account for approximately 35% of the student body.

GRU also serves as home to Georgia's public academic health center, including the affiliated GRHS, an integrated enterprise which includes a 400+ multispecialty physician faculty practice, a 480+ bed general adult acute care hospital, a 160 bed children's hospital, and various outpatient facilities throughout the region. In addition to serving as CEO of the Health System, Dr. Azziz serves as Chair of the Boards of Directors of GRHS, the Georgia Regents Medical Center, and the Roosevelt Warm Springs Rehabilitation & Specialty Hospitals, responsible for the coordination and alignment of the entire clinical enterprise.

Previously, Dr. Azziz served as president of the Georgia Health Sciences University (GHSU), and was tasked then with creating the state's only public academic health center, now including GRHS. He was then tapped to lead the consolidation of GHSU and Augusta State University (ASU) to create GRU, successfully receiving full SACS-COC approval in record time. The consolidation has been a unique and transformative initiative with state-wide and national implications, which provided an opportunity to analyze, understand, enhance, and innovate in all areas of the university.

Under his leadership GRU has experienced significant growth in research and educational programs; in student retention, progression and success; in capital facilities; and in philanthropy, in an economic environment that has seen, among other challenges, a 30% decrease in state formula support. In addition, he led the creation of a system of shared administrative services, greater use of imbedded metrics, and enhanced leadership alignment to maximize the effectiveness and efficiency of administrative support for the university.

Dr. Azziz is also an internationally recognized clinical translational scientist, developing over the past 25 years an important program in androgen excess disorders research. Among other duties, he previously served as Assistant Dean, Clinical & Translational Sciences and Deputy Director for the Clinical & Translational Sciences Institute, UCLA, tasked with, among other charges, coordinating the efforts of the four partner institutions in the consortium. He also served as Director of the Center for Androgen Related Disorders and Interim Director, the General Clinical Research Center (GCRC), Cedars Sinai Medical Center in Los Angeles.

Dr. Azziz is a champion for faculty and leadership development, and enhanced diversity and inclusion, in academics, including the development of emerging leaders in academic administration, and of young and under-represented scientists. He serves as Senior Mentor in the Network of Minority Research Investigators, NIDDK/NIH.

Finally, Dr. Azziz is also an accomplished visual artist, in the surrealistic thematic.

July 15, 2014

Jerry H. Baker  
Baker and Associates, LLC  
4799 Olde Town Parkway, Suite 202  
Marietta, GA 30068

**Re: Position, President, University of Nevada, Las Vegas**

Jerry:

Very much enjoyed our conversation a few days ago regarding the position of President, University of Nevada, Las Vegas, and appreciated your insight and direction. As mentioned, I am beginning my 5<sup>th</sup> year as university president, initially having served as president of Georgia Health Sciences University and, following the university's consolidation, being appointed president of Georgia Regents University (GRU). And as also noted, I am quite happy in my current position, having achieved important and recognized success in a number of high level transformative efforts to the benefit of our students, faculty, staff, local community and Georgia, and with the opportunity to continue to grow our university with a focus on its greater visibility and excellence. However, I do regard the opportunity being offered by UNLV to greatly impact the economy, the workforce and the future of the state of Nevada and the nation as a whole, quite interesting and exciting.

Of note, GRU is one of Georgia's four public broad-based research universities, with ~9000 students, over 1000 faculty, 9 colleges, an NCAA DIV II athletics program (and an NCAA Div I golf program), eight campuses and over 1000 training sites in the local area and statewide, and with recognized excellence in the health sciences, including housing the state's only public academic health center. In addition, I serve as CEO of the Georgia Regents Health System, an enterprise which includes an adult critical care Level 1 trauma hospital, a children's hospital (the 2<sup>nd</sup> largest in Georgia), various outpatient facilities, and a medical staff of ~500 physician-faculty. In total, I oversee a yearly budget that exceeds \$1.3 billion, with over 10,000 employees, and a greater than \$2.2 billion in economic impact.

While I know you will understand if my knowledge of UNLV is somewhat superficial, garnered mostly from online and published data, I would like to highlight below a few accomplishments so far as president that may have a bearing on the aims of the Board of Regents of the Nevada System of Higher Education to ensure that UNLV continues to provide affordable education to its student population, drives and supports increased diversity and inclusiveness in student, staff and faculty, enhances its economic impact state-wide, establishes a high quality medical school with the ready opportunity of national recognition, continues to develop its research programs to achieve the goal of being recognized as a Carnegie very high research institution, and increase the university's visibility and rankings. All while garnering the necessary support and engagement from the university's faculty and staff, the Board of Regents itself, the state's legislative and elected leaders, the local and state-wide communities, philanthropic investors, and corporate and industry partners.

A few of the accomplishments achieved as university president so far includes:

- Successfully consolidating two universities to create GRU, without additional resources provided, with SACS approval reflecting no recommendations, and with a fully engaged and combined faculty.
- Creating a closely aligned and integrated health system and academic health center, while preserving corporate integrity and state-corporate separation.
- Creating a system of shared administrative services, improving depth and quality of services at lower cost.
- Successfully growing academic and clinical programs in a very difficult economic environment, which saw over a 30% cut in state support over the past 5 years.
- Revitalizing philanthropy, despite the difficult environment brought upon by the consolidation, nearly tripling yearly contributions, and achieving the largest donation to a capital project in the university's history and, separately, the largest philanthropic gift ever given to a public institution in Georgia (\$66M).
- Continuing to grow our research programs, recruiting over 100 new scientists and increasing the institution's NIH funding ranking from 71<sup>st</sup> to 66<sup>th</sup> nationally.
- Engaging the Board or Regents, the governor's office, state and federal elected officials, and the local community around the vision of a greater university, with significant political and financial return.
- Improving student success, raising the 6-year graduation rate from 22% to 29% using a variety of targeted interventions, and increased the number of new freshman that successfully completed 15 credit-hours or more per semester from 4% to 42; and improving incoming student GPA and freshman index (composite measure of student preparedness).
- Creating unique corporate partnerships, including a 15-year alliance with Royal Philips valued at \$350 million to enhance equipment placement/replacement, clinical throughput, and health services research.
- Initiating, overseeing, identifying funding and shepherding various capital projects including a \$75 million new medical education building with a state-of-the art interprofessional simulation center, a \$65 million cancer research building, a \$35 million renovation of our old college of dental medicine building to create an interprofessional enterprise-wide professional administration center, the submission of a Certificate of Need application for a \$185 million new hospital in an adjacent community (awaiting decision), and the unification of two disparate physical plants as the university underwent consolidation.
- Increasing diversity and inclusiveness efforts, proceeding to create the university's first Office of Diversity & Inclusion; an initiative that led to a 9% increase in under-represented minority students in the health sciences, to the university garnering the 2014 Award for Diversity and Inclusion from the NCAA/MOAA, and to the Office VP honored with the 2014 INSIGHT Into Diversity magazine's Diversity Visionary Award.
- And achieving all the above and more in record time (less than 48 months) with maximum faculty and community engagement and support.

Page 3

Baker

In all, my experience as university president leading the difficult and complex process of university consolidation, of health system creation, and the establishment of a shared administrative services, combined with my service as a SACS reviewer and Trustee has ensured a deep and detailed understanding of the operations, business, and future direction of higher education, including the need to create unique partnerships and alliances with the local, governmental, corporate, and philanthropic communities to ensure the desired economic impact amidst an environment of declining resources and greater regulatory pressures .

In addition, my long experience with medical education and federally funded research places me in a strong position to be able to guide UNLV towards growing its research platform, achieving Carnegie designation as a very high research institution, and establishing a successful and nationally relevant medical school.

In closing, attached are copies of my curriculum vitae and of a resume that more extensively details some of the successes achieved during the past four years. Finally, as you and I discussed, as a sitting president with much to do ahead, I would appreciate maximum efforts to ensure the confidentiality of these inquiries.

Please do not hesitate to let me know if you need any further information.

Best regards,

Ricardo Azziz  
President, Georgia Regents University  
CEO, Georgia Regents Health System

Incl: R. Azziz Resume  
R. Azziz CV

## **RICARDO AZZIZ, MD, MPH, MBA**

*Professor, Obstetrics & Gynecology, Medicine, and Medical Humanities  
President, Georgia Regents University, and CEO, Georgia Regents Health System*

**OVERVIEW:** A scientist-educator-executive with over 20 years of leadership experience in higher education, research, and healthcare, Dr. Azziz serves as founding President of Georgia Regents University (GRU) and CEO of the Georgia Regents Health System (GRHS), a greater than \$1.3 billion integrated and aligned enterprise with over 1,000 full-time faculty, 9000 students, and 10,000 employees, four campuses in the Central Savannah River Area, and five other campuses and over 1000 training sites state-wide. GRU includes nine colleges, a growing NCAA Div. II (with NCAA Div. I golf) athletics program.

Previously, Dr. Azziz served as president of the Georgia Health Sciences University (GHSU), and was tasked then with creating the state's only public academic health center, now including the GRHS. He was then tapped to lead the consolidation of GHSU and Augusta State University (ASU) to create GRU, successfully receiving full SACS-COC approval in record time. The consolidation has been a unique and transformative initiative with state-wide and national implications, providing an opportunity to analyze, understand, enhance, and innovate in all areas of the university.

Under his leadership the university has experienced significant growth in research and educational programs, in student success, and in philanthropy, in an economic environment that has seen, among other challenges, a 30% decrease in state support. In addition, he has led the creation of a shared administrative services system, greater use of imbedded metrics, and enhanced leadership alignment, shared risk, and accountability.

**CAREER OBJECTIVE:** To provide strategic, creative, and visionary leadership in academia --- with an emphasis on academic excellence; the provision of superior educational and training programs; the growth of innovative and transformative translational research and discovery programs; and the development of an exceptional and diverse body of faculty and students --- through fiscally responsible management, the implementation of proactive sustainable growth strategies, the development of philanthropic opportunities, the active management of external and governmental relations, the alignment of objectives and incentives, the implementation of faculty and leadership development, the development of a culture of civic and community respect and engagement, and the planned and fair recruitment and retention of faculty, staff, and students.

### **EDUCATION:**

- MBA - University of Alabama at Birmingham (UAB), School of Business, Birmingham, AL, 2000
- MPH - UAB, School of Public Health, Birmingham, AL, 1995
- MD - The Pennsylvania State Univ. College of Medicine, Hershey, PA, 1981
- BS, Biology/Premed - The University of Puerto Rico, Mayaguez, PR, 1977 (*Magna Cum Laude*)

### **SELECT CURRENT POSITIONS:**

- President, Georgia Regents University (GRU), Augusta, GA, 2013 - Present
- CEO, and Chair, Board of Directors, Georgia Regents Health System (GRHS), 2010 - Present
- Chair, Board of Directors, Georgia Regents Medical Center, 2010 - Present
- Chair, Board of Directors, Georgia Regents Research Institute, 2010 - Present

### **SELECT PAST POSITIONS:**

- **Georgia Health Sciences University (GHSU), Augusta, GA** (formerly the Medical College of Georgia)
  - President, 2010-13
- **The David Geffen School of Medicine at UCLA (UCLA), Los Angeles, CA:**
  - Professor, Depts. of Ob/Gyn and Medicine and Vice-Chair, Dept. of Ob/Gyn, 2002-10
  - Assistant Dean, Clinical & Translational Sciences, and Deputy Director, Clinical & Translational Sciences Institute, 2008-10
- **Cedars-Sinai Medical Center (CSMC), Los Angeles, CA:**
  - Chair, Dept. of Ob/Gyn, and co-Director, Women's & Children's Service Line, 2002-10
  - Director, Center for Androgen Related Disorders, 2003-10
  - Interim Director, General Clinical Research Center, 2008-09

## HIGHLIGHTS OF CURRENT LEADERSHIP ACHIEVEMENTS:

Served as president of GHSU, tasked with creating the state's only public academic health center, now including GRHS, rebranding the university (from Medical College of Georgia to GHSU) and the reorganization of the university and health system administrative services and structure. Then led the consolidation of GHSU and the Augusta State (ASU) Universities to create GRU, one of four public comprehensive research universities in Georgia, a unique and transformative initiative with state-wide and national implications, providing an opportunity to analyze, understand, enhance, and innovate in all areas of the university. Under his leadership the university has experienced significant and rapid growth in research and educational programs, in student success, and in philanthropy, in an economic environment that has seen, among other challenges, a 30% decrease in state support over the past five years.

**This transformation is being achieved through:** a process of clear envisioning; increased emphasis on academic and clinical excellence and quality; intensive communication and presidential engagement; proactive and timely strategic planning; greater informed transparency; extensive faculty, student, staff and other stakeholder engagement; enhanced faculty and staff delegated authority and accountability; rigorous administrator recruitment, accountability, and team-building; an emphasis on academic and leadership development programs; the establishment of institution-wide initiatives to foster greater operational efficiency and more accurate, transparent, and user-friendly faculty productivity and fiscal models; rigorous project management; an emphasis on developing collaborative partnerships to further the institution's strategic vision; expanded customer service orientation and training; and careful financial and scenario planning.

### Selected accomplishments of the current administration include:

- **Strategic Visioning & Planning:** Set a clear vision for the enterprise, engaging not only the entire campus community, but also local and state stakeholders; restated and aligned mission, vision, and values of all component entities; completed a rapid strategic engagement effort in first 4 months of administration and addressed over 100 initiatives identified; oversaw the completion of the institution's first enterprise-wide long-term strategic plan ('*Transformation 2020*') which primarily focused on the health sciences/professions, and shortly thereafter oversaw the completion of an updated strategic plan ('*Transition Forward*') for the new university (<http://www.gru.edu/planning/transitionforward/index.php>).
- **Finance & Administration:** Successfully managed the enterprise's \$1.3 billion budget, achieving university growth and stability in an environment of continued budgetary challenges, including a >30% reduction in state operating appropriations over the past 5 years, and increasing unfunded mandates (consolidation, rebranding, staff/faculty salary increases and equity, etc.), while maintaining a very low university debt ratio. Ensured Health System operating margins and continuing "A" ratings for the GR Medical Center from S&P and Moody's, despite a negative outlook on the entire higher education and health sectors, cumulative additional burden of more than \$80M due to decreased state support/reimbursements and increased unreimbursed care and the economic downturn. Implemented the use of an enterprise-wide metric-based dashboard; proactively managed Supply Chain and Labor reductions; established an enterprise-wide budgeting process, an advisory Enterprise Budget Committee, and a Business Development Office; and established a funding plan to provide more than \$700M thru FY20 to support enterprise-wide growth initiatives without affecting regular operational needs. Through proactive planning and project management created an overarching Health System (HS), and integrated and restructured the University and HS administration to create an aligned and integrated, yet separate, administrative support structure, resulting in Georgia's only public academic health center (AHC); and led the complex process of consolidating ASU and GHSU to form GRU without any interruptions in operations or payroll.
- **Capital Projects & Facilities:** Initiated the development of a facilities master plan for GRU, to be completed early 2015; completed research and educational space utilization study, developing a common inventory of space utilization data for the enterprise; began campus beautification plan; Obtained funding and philanthropic support for the construction of over \$200M in new building space (a \$76.5M 177,000 sf. new Education Commons academic building, including a \$15M state-of-the art interdisciplinary simulation center, to be opened Fall of 2014; a \$62M 100,000 sf., new research cancer building, to serve as anchor for an integrated Comprehensive Cancer Center complex, to open Fall of 2017; the \$50M refurbishing of the old Dental School Building, to yield 2 million sf. of new administrative

- and clinical space, and a new \$6M Ronald McDonald House, adjacent to CHOG); negotiated the transfer of a highly desirable 16-acre property on the Savannah River in downtown Augusta to create a signature campus for the University; and obtained financial & community support for a traffic calming and beautification plan for a politically sensitive thoroughfare bisecting the campus.
- **Advancement & Philanthropy:** Restructured the Advancement Office; negotiated resolution of a long-term litigation with the university's principal philanthropic foundation; formulated a multiple foundation model; initiated the silent phase of the institution's first ever capital campaign; leveraged and engaged local and state communities; and despite an environment strained by the consolidation and the rebranding of the university, raised the most philanthropic dollars the institution has seen (>\$40M in FY12 and >\$80M in FY13, including a \$66M bequest, the single largest gift given to a public institution in Georgia; a \$10M donation, the largest single capital donation to the institution; an \$8M gift from the Woodruff Foundation, the largest to any educational institution outside of Atlanta; and \$6M from the Masters Tournament Foundation).
  - **Government, External, and Community Relations:** Work closely with state legislators, both local and throughout the state (the Georgia State Assembly meets yearly) and the Governor's office on a continuous basis to secure funding for the university and for specific associated projects, including not only ensuring operational support for university instruction and faculty, but also support for the creation of the integrated health system, consolidation of the university, an eight-year plan for the University and for health education in the state (see <http://www.gru.edu/planning/8-year-2011.php>), the creation of the second NCI-designated cancer center in Georgia at GRU, and the funding of various capital projects. Launched an Office of Federal Affairs. Have undertaken extensive community and state-wide outreach efforts, which have ensured support for the new university, its strategies and directions, including that of the university, philanthropic and local communities, and of leaders in the state executive and State Assembly, USG Board of Regents, regional congressional leaders, and local city leaders, Chambers of Commerce, Economic Authorities.
  - **Strategic Affiliations & Partnerships:** Furthered research affiliations with federal, state, and private entities; developed affiliation agreements with a number higher education and research institutions in China, including the establishment of the first *Confucius Institute* in North America focused on traditional Chinese Medicine; reinitiated long-dormant teaching affiliations with local healthcare providers/hospitals; oversaw the establishment of the Georgia Regional Academic Community Health Information Exchange (GRACHIE), a state-wide health information exchange network; developed plans and implemented GRU's agreement to manage the historic Roosevelt Warm Springs Inst. for Rehabilitation; created a unique 15-year, \$350M exclusive affiliation with Royal Philips to provide the latest healthcare technology, added consulting services, and research and educational support (recognized as a '2014 Deal of the Year' by Georgia Bio); and lead the establishment of the 'Jaguar Collaborative', a 14-year \$400 million partnership with Cerner around software management, corporate consulting, and research & education support.
  - **Higher Education Accreditation:** Underwent a successful Southern Association of Colleges & Schools-Commission on Colleges (SACS-COC) reaffirmation while president of GHSU, with only one recommendation; and oversaw the substantive change accreditation process by SACS-COC of GRU after the consolidation, resulting in approval without any recommendations. In addition, oversee the accreditation of multiple specialty, professional and graduate programs. Elected member of the SACS-COC Board of Trustees-Georgia Delegation.
  - **Educational Growth & Excellence in Student Access, Recruitment, and RPG:** Oversaw the expansion of satellite campuses state-wide; crafted with the Governor's office and the USG a long-term vision for health professions education and Graduate Medical Education (GME) in Georgia, and for GRU as the state's academic health center and health sciences university ([www.gru.edu/8-year](http://www.gru.edu/8-year)); initiated needed growth in academic offerings; and operationalized the Office of Institutional Effectiveness. In addition:
    - Expanded technology-infused recruitment activities, including the design & implementation of a strategic Enrollment Management plan, the creation a new Presidential Scholarship program, the development of new 'pipeline' pathway programs, and the expansion of academic enrichment programs.
    - Improved access by establishing partnership with East Georgia State College (a 2-year USG access institution); and separately implementing the 'Gateway Program', to assist gap students (those whose admission scores are insufficient for admission to GRU, but who met those of the former ASU).





Diversity & Inclusivity. Currently ~30% of our student body arises from under-represented minority groups. Considering these efforts GRU received the '2014 Award for Diversity and Inclusion' from the NCAA/MOAA, the 2014 INSIGHT Into Diversity magazine Higher Education Excellence in Diversity (HEED) Award, and was honored as an institution committed to diversity by Minority Access, Inc. at the 15<sup>th</sup> National Role Models Conference, October 3-5, 2014. In addition, our Director of the Office of Diversity & Inclusion was awarded the '2014 INSIGHT Into Diversity magazine's Diversity Visionary Award'. On a personal level, Dr. Azziz continues to serve as Senior Mentor in the NIH/NIDDK's Network of Minority Research Investigators.

- **Risk Management:** Created an Office for Compliance & Enterprise Risk management; and restructured the Office of Emergency Preparedness, effectively managing the increased risk that a rapid transformation and new leadership brings to the institution.
- **Communications & Branding:** Restructured the Communication Office; rebranded the university and HS (twice, the second dictated by the consolidation); and implemented multiple avenues for regular enterprise-wide internal communication to ensure transparency, engagement and support of faculty, staff and students, and other internal and external stakeholders.
- **Clinical Growth & Quality:** Initiated a Quality Campaign engaging all clinical units, increasing "core" quality measures and patient satisfaction ratings; implemented an expanded EHR in time to achieve federal 'Meaningful Use' reimbursement; began to define and implement Service Lines; and underwent an unannounced survey of the Medical Center by The Joint Commission (TJC) in 2010, with reaccreditation & special recognition in 8 programs/units as "Best Practice", and another unannounced TJC site visit in 2013.
- **As community, state-wide and national leader:** In addition to helping craft the state-wide vision for Health Profession Education and Graduate Medical Education (GME) for Georgia, serve(d) on the Governor's Health Insurance Exchange Advisory Committee and the Dept. of Community Health's Georgia Health Information Exchange Board. Serve(d) as a local and state-wide leader in the business community, as member of the Boards of Directors of the Georgia Chamber of Commerce, the Georgia Research Alliance, the Georgia Cancer Coalition, the Central Savannah River Area Regional Development Commission, the Augusta Metro Chamber of Commerce, and Augusta Tomorrow, Inc. Currently serves as member of the Board of Trustees for the Southern Association of Colleges and Schools-Commission on Colleges (SACS-COC), the regional accrediting body for institutions of higher education.
- **As faculty and scientist:** Developed an ongoing internationally recognized program of investigation in androgen excess disorders in women, funded by the NIH for the past 25 years; generating more than 600 publications, reviews and chapters, and various texts; training numerous fellows, and doctoral and postdoctoral students; and recognized for these efforts by receiving the Society for Gynecologic Investigation's President's Achievement Award for Clinical Research in 2000, and being elected member of the Association of American Physicians in 2014, one of only four obstetrician-gynecologists in the nation to receive this distinction. Current Web of Science H-index=51.

**FOR MORE THOUGHTS AND COMMENTARY BY DR. AZZIZ SEE:**

- Sculpting in Clay: Reflections on Leadership and Transformation blogs (<http://azziz.gru.edu/>)
- Huffington Post blogs (<http://www.huffingtonpost.com/dr-ricardo-azziz/>)
- Works of art ([www.razzizstudio.com](http://www.razzizstudio.com))

**MISCELLANEOUS:** Fluent in Spanish

## **CURRICULUM VITAE - Ricardo Azziz, M.D., M.P.H., M.B.A.**



A educator-scientist-executive with over 20 years of leadership experience in higher education, research, and healthcare, Dr. Azziz serves as President of the Georgia Regents University (GRU), one of four comprehensive public research universities in Georgia, and CEO of the Georgia Regents Health System (GRHS); managing a greater than \$1.3 billion integrated and aligned enterprise with over 1,000 full-time faculty, 9000 students, and 10,000 employees, four campuses in the Central Savannah River Area, five other campuses throughout Georgia, and over 1000 training sites.

GRU includes nine colleges/schools (the Colleges of Allied Health Sciences, Arts, Humanities & Social Sciences, Business, Dental Medicine, Education, Nursing, and Science & Mathematics, the Graduate School, and the Medical College of Georgia) and a growing NCAA Div. II athletics program (Peachbelt Conference) and an NCAA Div. I golf program, earning back-to-back national championships in

2010 & 2011. Graduate and post-graduate students account for approximately 35% of the student body.

GRU also serves as home to Georgia's public academic health center, including the affiliated GRHS, an integrated enterprise which includes a 400+ multispecialty physician faculty practice, a 480+ bed general adult acute care hospital, a 160 bed children's hospital, and various outpatient facilities throughout the region. In addition to serving as CEO of the Health System, Dr. Azziz serves as Chair of the Boards of Directors of GRHS, the Georgia Regents Medical Center, and the Roosevelt Warm Springs Rehabilitation & Specialty Hospitals, responsible for the coordination and alignment of the entire clinical enterprise.

Previously, Dr. Azziz served as president of the Georgia Health Sciences University (GHSU), and was tasked then with creating the state's only public academic health center, now including GRHS. He was then tapped to lead the consolidation of GHSU and Augusta State University (ASU) to create GRU, successfully receiving full SACS-COC approval in record time. The consolidation has been a unique and transformative initiative with state-wide and national implications, providing an opportunity to analyze, understand, enhance, and innovate in all areas of the university.

Under his leadership GRU has experienced significant growth in research and educational programs, in student success, in capital facilities, and in philanthropy, in an economic environment that has seen, among other challenges, a 30% decrease in state support. In addition, he led the creation of a system of shared administrative services, greater use of imbedded metrics, and enhanced leadership alignment.

Among other duties, previously Dr. Azziz served as Assistant Dean for Clinical & Translational Sciences (CTS) and Deputy Director for the CTS Institute at UCLA, tasked with, among other charges, coordinating the efforts of the four partner institutions in the consortium. Dr. Azziz is also an accomplished visual artist; and an internationally recognized clinical & translational researcher, developing an important program in androgen excess research, funded by the NIH since 1988.

## **PROFESSIONAL APPOINTMENTS:**

2104 – Present	Chair, Board of Dir., Roosevelt Warm Springs Rehab. & Specialty Hosp., Inc.
2013 – Present	Founding President, Georgia Regents University (GRU), Augusta, GA (arising from the consolidation of GHSU and Augusta State University)
2010 – Present	CEO, and Chair, Board of Directors, Georgia Regents Health System, (formerly the Georgia Health Sciences Health System)
2010 – Present	Chair, Board of Directors, Georgia Regents Medical Center (formerly the Georgia Health Sciences Medical Center)
2010 – Present	Chair, Board of Directors, GRU Research Institute, Inc.
2010 – Present	Professor, Depts. of Obstetrics & Gynecology (Ob/Gyn), Medicine, and Medical Humanities, GRU
2010 – 2013	President, Georgia Health Sciences University (GHSU), Augusta, GA (formerly the Medical College of Georgia)
2008 – 2010	Assistant Dean, Clinical & Translational Sciences, and Deputy Director, Clinical & Translational Sciences Institute, the David Geffen School of Medicine, University of California Los Angeles (UCLA)
2003 – 2010	Co-Director, Reproductive Endocrinology & Infertility Fellowship Training Program, Dept. of Ob/Gyn, UCLA
2002 – 2010	Vice-Chair, Dept. of Ob/Gyn, UCLA
2002 – 2010	Professor, Depts. of Ob/Gyn, and Medicine, UCLA <i>Step III (02-05), Step IV (05-07), Step V (07-09), Step VI (09-10)</i>
2002 – 2010	Chair, Dept. of Ob/Gyn, and co-Director, Women's & Children's Service Line, Cedars-Sinai Medical Center (CSMC), Los Angeles, CA
2008 – 2009	Acting Director, General Clinical Research Center, CSMC
2003 – 2010	Director, Center for Androgen-Related Disorders, CSMC
2002 – 2007	Director, Div. of Reprod. Endocrinology & Infertility, Dept. of Ob/Gyn, CSMC
2002 – 2007	Director, Ob/Gyn Residency Training Program, CSMC
1995 – 2002	Professor, Dept. of Medicine, and Professor (Tenured), Dept. of Ob/Gyn, University of Alabama at Birmingham (UAB)
1992 – 2002	Director, Reproductive Endocrinology & Infertility Training Fellowship Program, Dept. of Ob/Gyn, UAB
1991 – 1995	Associate Professor (Tenured), Dept. of Ob/Gyn, UAB
1987 – 1991	Assistant Professor, Dept. of Ob/Gyn, UAB
1985 – 1987	Instructor, Dept. of Gyn/Ob, The Johns Hopkins U. Sch. of Medicine, Baltimore, MD

**EDUCATION:**

The University of Alabama at Birmingham School of Business Birmingham, AL	M.B.A. 4/97 - 6/00 Graduated with honors (and inducted into the Beta Gamma Sigma Honor Society of the AACSB)
The University of Alabama at Birmingham School of Public Health Birmingham, AL	M.P.H., General Theory and Practice 3/91 - 3/95
The Johns Hopkins Hospital Department of Gynecology and Obstetrics Baltimore, Maryland	Postgraduate Fellowship in Reproductive Endocrinology and Infertility 7/85 - 6/87
The Georgetown University Hospital Department of Obstetrics and Gynecology Washington, D. C.	Internship 7/81 - 6/82 Residency 7/82 - 6/85
The Pennsylvania State University College of Medicine Hershey, Pennsylvania	M.D., 8/77 - 6/81
The University of Puerto Rico Mayaguez, Puerto Rico	B.S., Biology/Premed, 8/74 - 7/77 Magna Cum Laude (degree issued 6/79)

**CERTIFICATIONS AND LICENSURE:**

National Board of Medical Examiners, Inc.: Diplomate, 1982  
American Board of Ob/Gyn, Inc.: Certified, 1988 - 98; Recertified 1996 - 2008, and 2008 - 2014  
American Board of Ob/Gyn, Inc.: Certified Subspecialty, Reproductive Endocrinology  
and Infertility, 1989 - 1999; Recertified, 1996 - 2008, and 2008 - 2014  
Accreditation Council for Gynecologic Endoscopy, Inc.: Certified, 2000 - Present  
Fellow, American College of Obstetricians and Gynecologists, 1989 - Present  
Fellow, American College of Surgeons, 1991 - Present

**Medical Licenses:**

District of Columbia: 9/22/1983 - 1988  
Maryland: 3/27/1985 - 1992  
Virginia: 7/28/1983 - Present  
Alabama: 4/22/1987- Present  
California: 7/24/2002 – Present  
Georgia: 7/01/2010 – Present

**HOSPITAL POSITIONS:**

Attending Staff, Georgia Regents Medical Center  
Courtesy staff, UCLA Medical Center, Westwood, 2005 - 2010  
Attending staff, Cedars-Sinai Medical Center, 2002 - 2010  
Full staff, University Hospital, Birmingham, AL, 1987 - 2002  
Full staff, Cooper Green Hospital, Birmingham, AL, 1987 - 2002

Courtesy staff, Baptist Medical Center-Montclair, Birmingham, AL, 1989 - 2002  
Courtesy staff, Brookwood Medical Center, Birmingham, AL, 1989 - 2002  
Courtesy staff, St. Vincent's Hospital, Birmingham, AL, 1999 - 2002  
Courtesy staff, Healthsouth Medical Center, Birmingham, AL, 1999 - 2002

### **SELECTED PROFESSIONAL ASSOCIATIONS: MEMBERSHIP AND RESPONSIBILITIES:**

American Board of Obstetrics and Gynecology, Inc.  
Associate Examiner, General Ob/Gyn Boards, 1995 - 1997; Examiner, Reproductive Endocrinology  
Subspecialty Boards, 1997, 1999, 2007  
American College of Obstetricians and Gynecologists, Fellow, 1989 - Present  
Junior Fellows Section Chair, District of Columbia, 1983 - 1984  
Junior Fellows, District IV, Secretary-Treasurer, 1984 -1985, and Chair-elect, 1985 - 1986  
American College of Surgeons, Fellow, 1991 - Present  
American Council of Education, 2011 - Present  
American Association of Gynecologic Laparoscopists, 1987 - 2010  
American Gynecologic & Obstetrical Society, 2007 - Present  
American Society for Reproductive Medicine (formerly the American Fertility Society), 1985 - Present  
Board of Directors, 1999 - 2001, and 2004 - 2005  
Androgen Excess & PCOS Society (formerly the Androgen Excess Society),  
Founder and Executive Director, 2002 – 2007; Senior Executive Director, 2007 - Present  
Association of Professors of Gynecology and Obstetrics, 1991 - 2010  
Endocrine Society, 1990 - Present  
Society for Gynecologic Investigation, 1994 - Present  
Society of Reproductive Endocrinology and Infertility, 1990 – 2009; Director-at-Large, 1997 - 1999  
Society of Reproductive Surgeons, 1993 – Present; Board of Dir. 2001 - 2007; President, 2004 – 2005

### **SELECTED EDITORIAL AND JOURNAL REVIEW RESPONSIBILITIES:**

Journal of Clinical Endocrinology and Metabolism, Editorial Board, 1993 - 1996 and 2005 - 2008  
Fertility and Sterility, Editorial Board, 1999 - 2002, and Editorial Advisory Board, 2002 - 2007  
Editor, "Patient's Bookshelf" column for Fertility News, newsletter of ASRM, 1989 - 1992  
*Ad Hoc Reviewer:* Journal of Clinical Endocrinology and Metabolism, Fertility and Sterility, Obstetrics and Gynecology, American Journal of Obstetrics and Gynecology, Gynecologic Endocrinology, Clinical Endocrinology, The New England Journal of Medicine, JAMA, among others.

### **SELECTED LOCAL AND STATE APPOINTMENTS**

Georgia Health Insurance Exchange Advisory Committee, Governor's Office (appointed by Gov. Deal),  
2011 – 2012; Governance Subcommittee Member, 2011 – 2012  
Augusta Metro Chamber of Commerce, Board of Directors, 2011 – Present  
Georgia Chamber of Commerce, Board of Directors, 2012 – Present  
Georgia Research Alliance Board of Directors, 2010 – Present  
CerviCusco Board of Directors, 2010 - 2013  
Augusta Tomorrow, Inc. Board of Directors, 2010 – 2012  
Georgia Cancer Coalition Board of Directors, 2010 – 2011  
CSRA Regional Development Commission (RDC), Comprehensive Econ. Dev. Strategy Comm., 2011  
Georgia Health Information Exchange Board, Georgia Dept. of Community Health, 2011  
Independent Citizen's Oversight Committee (ICOC) of the California Institute of Regenerative Medicine  
(appointed by Gov. Schwarzenegger), 2006 - 2010; Finance Subcommittee, 2007 - 2010

**SELECTED NATIONAL/REGIONAL APPOINTMENTS:**

Council on Competitiveness, member, 2014 - Present

Southern Association of Colleges & Schools-Commission on Colleges (SACS-COC)

Member, On-site Reaffirmation Committee, 2014 & 2015

Board of Trustees-Georgia Delegation, 2014 - Present

American Association of Medical Colleges (AAMC)

Council of Academic Societies (CAS), representative for ASRM, 2009 - 2012

Medical Leadership Council, 2010 - Present

American Association of State Colleges and Universities (AASCU), 2103 – Present

Member, Committee on Economic and Work Force Development

Member, Hispanic Presidents Caucus

Association of Academic Health Centers, member, 2011 - Present

National Institutes of Health

Speaker, the NIH Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome, NICHD/  
National Institutes of Health Office of Disease Prevention, 2012

Member, Data Safety Monitoring Board, Reproductive Medicine Network, NICHD/NIH, 2007 - 2010

Member, Advisory Panel, National Cooperative Program for Infertility Research (NCPPIR), 2005 - 2006

Member, Reproductive Endocrinology Study Section, 2000 - 2004

Member, NIH Pediatric Clinical Research Center Site Visit Advisory Team, 1996

Senior mentor, Network of Minority Research Investigators (NMRI), 2005 – Present

Member (06-09) and Chair (2008) of the Planning Committee for the annual NMRI workshop

Ad Hoc member NIH study sections: SCCPRIR (U54 Reproduction Research Centers) Centers, 2013;

Developmental Pharmacology, 2008; FIRCA and GRIP in Behavioral and Social Sciences, 2008;

Clinical & Integrative Diabetes & Obesity (CIDO), 2007; Integrative & Clinical Endocrinology &

Reproduction (ICER), 2007, 2008; Integrated Physiology of Obesity & Diabetes (IPOD), 2004; and

SBIR/STTR Reproductive Endocrinology, 1999 study sections

U.S. Food & Drug Administration

Reproductive Health Drugs Advisory Committee; Member, 1996 - 2000; Chair, 1999 - 2000

Consultant, General and Plastic Surgery Devices Panel, 1997; and Endocrinologic & Metabolic Drugs  
Advisory Committee, 1997

**PAST INSTITUTIONAL SERVICE:**

**CSMC:**

Member - Centers of Excellences Oversight Committee 2008 - 2010

Member - CSMC Graduate Program Steering Committee 2008 - 2010

Member - Medical Executive Committee (MEC) 2002 - 2010

Member - Med. Ctr. Management Group (MCMG) 2002 - 2010

Member - Executive Management Committee (EMC) 2002 - 2010

Member - Women's Health Executive Advisory Board 2002 - 2010

Member - Faculty Academic Advisory Committee 2002 - 2010

Member - President's Academic Clinical Chairs Committee 2002 - 2010

Member - Capacity Management Leadership Group 2003 - 2010

Member - Quality Council, Significant Adverse Events Committee 2002 - 2010

Chair - OB/GYN Performance Improvement Committee (PIC) 2002 - 2010

Co-Chair - Post-op Prophylactic Antibiotic Duration & Antibiotic Selection Team 2002 - 2010

Acting Director - General Clinical Research Center 2007 - 2008

Chair - Institutional Chairs Committee 2004 - 2006

Chair - New Research Building Planning Committee 2005 - 2006

Member - Executive Committee of the Medical Center Board of Trustees 2004 - 2006

Member - Steering Committee of the Committee for the Accreditation of the Human Research Protection Program (CAHRPP)	2003 - 2003
Member - Physician/Medical Center Compact Committee	2003 - 2005
Member - Grant & Funding Accounting/Grant & Contract Services (GFA/GCS) Redesign Task Force	2003 - 2004
Member - Board of Directors, Medical Policy Committee	2004 - 2010
Member - SAE Oversight committee	2003 - 2010
Member - Medical Center Quality Council	2004 - 2010
Member - Time and Effort Reporting Redesign Task Force	2005 - 2010
Member - Faculty Productivity Model Task Force	2006 - 2010
Member - Search Committees (various)	

**UCLA:**

Member - Faculty Partners for Diversity	2009 - 2010
Member - UCLA Council of Advisors	2009 - 2010
Member - Ten-Year Review Committee, Chair of Family Medicine	2009 - 2010
Representative, Dept. of Medicine - Legislative Assembly, Academic Senate	2007 - 2010

**UAB:**

Member - Medical School Admissions Interview Committee	1997 - 2002
Director - Reproductive Endocrinology Endoscopy Unit	1990 - 2002
Member - The Kirklin Clinic Operating Room Committee	1993 - 1999
Member - Departmental Quality Improvement Committee	1991 - 1997
Member - Patient Care Initiative Review and Critique Panel	1995 - 1996
Chair - Marketing Subcommittee of the Faculty Practice Committee	1992 - 1995
Chair - Outpatient Faculty Practice Billing Charges and Reporting Committee	1992 - 1993

**PAST SELECTED INSTITUTIONAL TEACHING ACTIVITIES:**

**CSMC:**

Questioner, CSMC M&M Ob/Gyn Resident Rounds	2002 - 2010
Lecturer & Coordinator, UCLA/CSMC REI Fellow Weekly Lecture	2002 - 2010
Lecturer & Coordinator, CSMC, <i>Young Investigator's Academic Dev. Course</i>	2004 - 2010
Lecturer, CSMC Ob/Gyn Resident Operative Endoscopy	2003 - 2007
Lecturer, CSMC Ob/Gyn Core lecture Series	2002 - 2006
Lecturer, CSMC Ob/Gyn Resident Monthly Chairman Rounds	2002 - 2005

**UCLA:**

Lecturer, UCLA Year II Medical Student - GI, Endocrine and Reproductive Medicine course (HBD 407, Block 7)	2005 - 2010
Lecturer, UCLA School of Public Health Executive MPH Program (HS431- Organization and Management Processes)	2009
Lecturer, UCLA Year III Medical Student Ob/Gyn Rotation,	2002 - 2007
Mentor, Medicine 99 (Fall) and Medicine 199 (Winter and Spring) – Ryan Shilian	2004 - 2005
Mentor, Honors 99 (Fall and Spring) – Margaret Nguyen	2004 - 2005

**UAB:**

Lecturer, Graduate School	1994 - 2002
Course Master – Ob/Gyn Resident Operative Endoscopy	1990 - 2002
Co-Chair, Medical Student Teaching Committee	1987 - 1990
Lecturer, Third Year Medical Student Ob/Gyn Rotation	1990 - 2002
Lecturer, Integrative Biomedical Sciences Program	1998 - 2002

## **HONORS AND AWARDS:**

- Phi Kappa Phi Society, University of Puerto Rico, 1973 - Present
- Dean's List - University of Puerto Rico at Mayaguez, 1974 - 1977
- Honorable Mention, American Red Cross, Puerto Rico Chapter, for community work, 1974
- CIBA award for community and educational efforts, Penn State University College of Medicine, 1979
- Who's Who among Hispanic-Americans, First Edition, Gale Research Inc., New York, NY, 1991
- Cheston M. Berlin Award, Penn State College of Medicine Alumni Society, for outstanding service, 1992
- Honorary Member, Argentinean Society of Sterility and Fertility, 1994 - Present
- The Best Doctors for Women, Good Housekeeping magazine, August, 1997
- Honorary Fellow, Miami Obstetrical and Gynecologic Society, 1998
- Honorary Foreign Member, Sociedad Argentina de Ginecología Infanto-Juvenil, 2000
- Society for Gynecologic Investigation President's Achievement Award for Clinical Research, 2000
- Beta Gamma Sigma Honor Society of the Association to Advance Collegiate Schools of Business (AACSB), 2000
- The Best Doctors in America, published by Woodward/White, Inc., Aiken, SC. 1995 & 2001
- America's Top Doctors, published by Castle Connolly Medical Ltd, New York, NY, 2001 - Present
- The Best Doctors for Families-Coast to Coast, Ladies Home Journal, May, 2002
- Guide to America's Top Obstetricians and Gynecologists, Consumer's Research Council of America, Washington, DC, 2004-2005
- Recipient of the endowed The Helping Hand of Los Angeles Chair in Obstetrics and Gynecology, 2002
- The Endocrine Society's Outstanding Reviewer Recognition Award for Outstanding Achievements by a Reviewer of the Journal of Clinical Endocrinology & Metabolism, 2006
- Top Infertility Specialists, Women's Health magazine, November 2008
- U.S. News & World Report Top Doctors by U.S. News Media Group, 2011
- Resolution of recognition for leadership by the Development Authority of Richmond Co. (DARC), 2012.
- Top 100 Leaders in Health Care, Atlanta Business Chronicle, January 25-31, 2013.
- 100 Most Influential Georgians, Georgia Trend magazine, 2011 – 2014
- Elected member of the Association of American Physicians, one of only four Ob/Gyns in the nation to receive this distinction (founded in 1885 for the advancement of scientific and practical medicine, the AAP honors individuals who have attained excellence in the pursuit of medical knowledge, and the advancement through experimentation and discovery of basic and clinical science and their application to clinical medicine), 2014 - Present
- Alumni Fellow Award of the Pennsylvania State University (PSU) Alumni Association, the highest honor conferred by the PSU Alumni Association, 2014
- Honorary Member, Middle East Fertility Society, 2014

## **OTHER APPOINTMENTS:**

Student Representative for the College of Arts and Sciences and Department of Biology and to the Board of Discipline, University of Puerto Rico, Mayaguez, 1975-1977

American Medical Student Association, 1979-1981; Chair, Minority Section, 1979-1981; Member, Board of Trustees, 1980-1981

Student Representative, Pennsylvania Medical Society Delegation, American Medical Assoc., 1980-1981  
Alumni Society, Pennsylvania State University College of Medicine

Member Board of Trustees, 1984-1992; President Board of Trustees, 1989-1992



## **BIBLIOGRAPHY**

### **PUBLICATIONS - Peer-reviewed Articles:**

1. **Azziz R.** The Hispanic patient. Penn Med 64:22-25, 1981 (PMID: 7254865).
2. **Azziz R.** Adenomyosis in pregnancy: A review. J Reprod Med 31:2240-227, 1986 (PMID: 3712359).
3. **Azziz R, Mulaikal RM, Migeon CJ, Jones Jr HW, Rock JA.** Congenital adrenal hyperplasia: Long-term results following vaginal reconstruction. Fertil Steril 46:1011, 1986 (PMID: 3491007).
4. **Rock JA, Azziz R.** Genital anomalies in childhood. Clin Obstet Gynecol. 30:682-696, 1987 (PMID: 3308257).
5. **Azziz R, Smith S, Fabro S.** The development and use of a standard symphysial-fundal height growth curve in the prediction of small for gestational age (SGA) neonates. Int J Gynecol Obstet 26:81-87, 1987 (PMID:2892743)
6. **Azziz R, Cummings J, Naeye R.** Acute myometritis and chorioamnionitis during cesarean section of asymptomatic women. Am J Obstet Gynecol 159:1137-9, 1988 (PMID: 3189448).
7. **Azziz R, Gay F.** The treatment of hyperandrogenism with oral contraceptives. Sem Reprod Endo 7:246-254, 1989.
8. **Azziz R.** Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril 52:703-725, 1989 (PMID: 2680625).
9. **Azziz R.** Adenomyosis: Current perspective. Obstet Gynecol Clin North Am. 16:221-235, 1989 (PMID: 2664619).
10. **Azziz R, Steinkampf MP, Murphy A.** Postoperative recuperation: Relation to the extent of endoscopic surgery. Fertil Steril 51:1061-1064, 1989 (PMID: 2524405).
11. **Azziz R, Zacur HA.** 21-Hydroxylase deficiency in female hyperandrogenemia: Screening and diagnosis. J Clin Endocrinol Metab 69:577-584, 1989 (PMID: 2547827).
12. **Azziz R, Ladda RL.** Dexamethasone receptor levels in palatal and lung fibroblasts of adult A/J and C57BL/6J mice: Relationships to glucocorticoid-induced cleft palate. Cleft Palate J 27:388-391, 1990 (PMID: 2253386).
13. **Azziz R, Wells G, Acton RT, Zacur HA.** Pseudogene/functional gene ratio in late-onset 21-hydroxylase deficient adrenal hyperplasia. Am J Obstet Gynecol. 162: 633-638, 1990 (PMID: 2316563).
14. **Azziz R, Rafi A, Smith B, Bradley Jr E, Zacur HA.** On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism. J Clin Endocrinol Metab 70:431-436, 1990 (PMID: 2137133).
15. **Azziz R, Jones Jr HW, Rock JA.** Androgen-insensitivity syndrome: Long-term results of surgical vaginal creation. J Gynecol Surg 6:23-26, 1990 (PMID: 21351049).
16. **Azziz R, Bradley E Jr, Huth J, Parker CR Jr, Boots LR, Zacur HA.** Acute adrenocorticotropin-(1-24) (ACTH) adrenal stimulation in eumenorrheic women: Reproducibility and effect of ACTH dose, subject weight and sampling time. J Clin Endocrinol Metab 70: 1273-1279, 1990 (PMID: 2139878).
17. **Wells G, Azziz R.** 21-hydroxylase late-onset adrenal hyperplasia: Mutation at codon 281 is not ubiquitous. Fertil Steril 54:819-823, 1990 (PMID: 2226916).
18. **Azziz R, Koulianos G.** Adrenal androgens and reproductive aging in females. Sem Reprod Endo 9:249-260, 1991.
19. **Azziz R.** When is late-onset adrenal hyperplasia not late-onset adrenal hyperplasia? Adolesc Pediatr Gynecol 4:211-214, 1991.
20. **Azziz R, Boots LR, Parker Jr CR, Bradley Jr E, Zacur HA.** 11 $\beta$ -hydroxylase deficiency in hyperandrogenism. Fertil Steril 55:733-741, 1991 (PMID: 2009997).
21. **Azziz R, Gay F, Potter SR, Bradley Jr E, Boots LR.** Effect of prolonged hypertestosteronemia on adrenocortical biosynthesis in oophorectomized women. J Clin Endocrinol Metab 72:1025-1030, 1991 (PMID: 1850751).

22. **Azziz R**, Murphy AA, Rosenberg SM, Patton Jr GW. Use of an oxidized, regenerated cellulose absorbable adhesion barrier at laparoscopy. J Reprod Med 36:479-482, 1991 (PMID: 1834835).
23. **Azziz R**, Kenney PJ. Magnetic resonance imaging of the adrenal gland in women with late-onset adrenal hyperplasia. Fertil Steril 56:142-144, 1991 (PMID: 2065794).
24. **Azziz R**, Zacur HA, Parker Jr CR, Bradley Jr E, Boots LR. Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women. Fertil Steril 56:427-433, 1991 (PMID: 1894020).
25. Hammond DR, Blackwell RE, Younger JB, **Azziz R**, Steinkampf MP. Monitoring techniques to predict ovulation: Evaluation of patient acceptance. Am J Gynecol Health 5:88-91, 1991.
26. **Azziz R**, Wells G, Boots LR, Zacur HA, Acton RT. Abnormalities of 21-hydroxylase gene ratio and adrenal steroidogenesis in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to acute adrenal stimulation. J Clin Endocrinol Metab 73:1327-1331, 1991 (PMID: 1955515).
27. Buyalos RP, Bradley Jr EL, Judd HL, Zacur HA, **Azziz R**. No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease. Fertil Steril 56:1179-1182, 1991 (PMID: 1835937).
28. Maruri F, **Azziz R**. Laparoscopic surgery for ectopic pregnancies: Technology assessment and public health implication. Fertil Steril 59:487-498, 1992 (PMID: 8458446).
29. Buyalos RP, Funari V, **Azziz R**, Watson J, Martinez-Maza O. Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Fertil Steril 58:302-306, 1992 (PMID: 1633894).
30. Owerbach D, Sherman L, Ballard A, **Azziz R**. Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency. Mol Endocrinol 6:1211-1215, 1992 (PMID: 1406699).
31. **Azziz R**, Guest Editor, "Androgen Excess-I", Sem Reprod Endo 11:307-360, 1993.
32. **Azziz R**. Adrenocortical dysfunction in androgen excess. Sem Reprod Endo 11:353-358, 1993.
33. **Azziz R**. Editors formulation: The late-onset adrenal hyperplasias: An example of molecular biology applied to the study of androgen excess disorders. Sem Reprod Endo 11:359-360, 1993.
34. **Azziz R**, Bradley Jr. EL, Potter HD, Boots LR. 3 $\beta$ -Hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am J Obstet Gynecol 168:889-895, 1993 (PMID: 8456898).
35. **Azziz R**. The Interceed (TC7) Adhesion Barrier Study Group II. Pelvic sidewall adhesion reformation: Microsurgery alone or with Interceed<sup>®</sup> Absorbable Adhesion Barrier. Surg Gynecol Obstet 177: 135-139, 1993 (PMID: 8342092).
36. Wells G, Acton RT Jr, **Azziz R**. Concordance of 21-hydroxylase gene ratio, HLA-haplotyping and adrenal testing in a family with late-onset adrenal hyperplasia. J Reprod Med 38: 615-620, 1993 (PMID: 8410868).
37. **Azziz R**, Guest Editor, "Androgen Excess-II", Sem Reprod Endo 12:1-52, 1994.
38. **Azziz R**. Editor's formulation: Towards a working classification of androgen excess disorders. Sem Reprod Endo 12:51-52, 1994.
39. **Azziz R**, Dewailly D, Owerbach D. Non-classic adrenal hyperplasia: Current concepts. J Clin Endocrinol Metab 78:810-815, 1994 (PMID: 8157702).
40. Moller DE, Cohen O, Yamaguchi Y, **Azziz R**, Grigorescu F, Eberle A, Flier JS. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 43:247-255, 1994 (PMID: 8288049).
41. **Azziz R**. The hyperandrogenic-insulin resistant-acanthosis nigricans (HAIRAN) syndrome: Therapeutic response. Fertil Steril 61:570-572, 1994 (PMID: 8137990).
42. **Azziz R**, Dewailly D, Owerbach D. Non-classic adrenal hyperplasia: Current concepts. J Clin Endocrinol Metab 78:810-815, 1994 (PMID: 8157702).
43. **Azziz R**, Potter HD, Bradley Jr EL, Boots LR.  $\Delta^5$ -Androstene-3 $\beta$ ,17 $\beta$ -diol in healthy eumenorrheic women: Relationship to body mass and hormonal profile. Fertil Steril 62:321-6, 1994 (PMID: 8034079).

44. **Azziz R**, Deal CL, Potter HD, Gargosky SE, Rosenfeld RG. Regulation of extra-gonadal insulin-like growth factor binding protein-3 by testosterone in oophorectomized women. J Clin Endocrinol Metab 79: 1747-1751, 1994 (PMID: 7527410).
45. **Azziz R**. 21-Hydroxylase deficient non-classic adrenal hyperplasia. Endocrinologist 5:297-303, 1995.
46. **Azziz R**, Section Editor, "Fertility and infertility", Curr Opin Obstet Gynecol 5:225-227, 1993.
47. Knochenhauer ES, **Azziz R**. Current advances in the diagnosis and treatment of the hirsute patient. Curr Opin Obstet Gynecol 7:344-350, 1995 (PMID: 8541452).
48. **Azziz R**, Bradley Jr EL, Potter HD, Parker Jr CR, Boots LR. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women. Am J Obstet Gynecol 172:1251-6, 1995 (PMID: 7726265).
49. **Azziz R**, Owerbach D. Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to acute adrenal stimulation. Am J Obstet Gynecol 172: 914-918, 1995 (PMID: 7892885).
50. **Azziz R**, Bradley Jr EL, Potter HD, Boots L. Adrenocortical hyperactivity and androgen excess in hyperandrogenism: Lack of role for 17-hydroxylase and 17,20-lyase dysregulation. J Clin Endocrinol Metab 80: 400-405, 1995 (PMID: 7852496).
51. **Azziz R**, Ochoa TM, Bradley Jr EL, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: A prospective randomized study. J Clin Endocrinol Metab 80: 3406-3411, 1995 (PMID: 8530573).
52. Trueth MS, Hunter GS, **Azziz R**, Kekes-Szabo T, Goran M. Sex hormone response after resistive training in healthy older women. FASEB J 9(4) Part II:A995, 1995.
53. **Azziz R**, Slayden SM. The 21-hydroxylase-deficient adrenal hyperplasias: more than ACTH oversecretion. J Soc Gynecol Invest 3:297-302, 1996 (PMID: 8923412).
54. Parker CR Jr, **Azziz R**, Potter HD, Boots LR. Adrenal androgen production in response to adrenocorticotropin infusions in men. Endocr Res 22:717-722, 1996 (PMID: 8969932).
55. **Azziz R**. Letter to the Editor: Detection of CAH heterozygotes. Fertil Steril 1997; 68:183 (PMID: 9207613).
56. Knochenhauer ES, Cortet-Rudelli C, Cunnigham RD, Conway-Myers BA, Dewailly D, **Azziz R**. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab 82:479-485, 1997 (PMID: 9024240).
57. Allen SE, Potter HD, **Azziz R**. Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women. Fertil Steril 67:569-572; 1997 (PMID: 9091350).
58. **Azziz R**. Letter to the Editor: Detection of CAH heterozygotes. Fertil Steril 1997; 68:183 (PMID: 9207613).
59. Buyalos RP, Geffner ME, **Azziz R**, Judd HL. Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovarian syndrome. Hum Reprod 12:1138-1141, 1997 (PMID: 9221990).
60. Joehar K, Geley S, Strasser-Wozak EMC, Kofler R, **Azziz R**, Wollman A, Schmitt K, White P. CYP11B1 mutations causing nonclassic congenital adrenal hyperplasia due to 11 $\beta$ -hydroxylase deficiency. Hum Mol Genet 6:1829-34, 1997 (PMID: 9302260).
61. Kahsar-Miller M, **Azziz R**. The development of the polycystic ovary syndrome: Family history as a risk factor. Trends Endocrinol Metab 9:55-61, 1998 (PMID: 18406241).
62. Moran C, Knochenhauer ES, **Azziz R**. Non-classic adrenal hyperplasia in hyperandrogenism: A reappraisal. J Endocrinol Invest 21:707-720, 1998 (PMID: 9854689).
63. Boots LR, Potter S, Potter HD, **Azziz R**. Measurement of total serum testosterone levels using commercially available kits: High degree of between-kit variability. Fertil Steril 69:286-92, 1998 (PMID: 9496343).

64. Slayden SM, Crabbe L, Bae S, Potter HD, **Azziz R**, Parker Jr CR. The effect of 17 $\beta$ -estradiol on adrenocortical sensitivity, responsiveness, and steroidogenesis in postmenopausal women J Clin Endocrinol Metab 83:519-524, 1998 (PMID: 9467568).
65. Falany JL, **Azziz R**, Falany CN. Identification and characterization of cytosolic sulfotransferases in normal human endometrium. Chem Biol Interact 109:329-339, 1998 (PMID: 9566756).
66. **Azziz R**, Rittmaster RS, Fox LM, Bradley Jr. EL, Potter HD, Boots LR. The role of the ovary in the adrenal androgen excess of hyperandrogenic women. Fertil Steril 69:851-9, 1998 (PMID: 9591492).
67. **Azziz R**, Rittmaster RS, Fox LM, Bradley Jr. EL, Potter HD, Boots LR. Author Reply: Effect of ovarian steroid production on adrenal steroidogenesis? Fertil Steril 70: 1187-89, 1998.
68. **Azziz R**, Black V, Hines GA, Fox LM, Bradley Jr E, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: Sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 83: 2317-2323, 1998 (PMID: 9661602).
69. **Azziz R**, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR. Idiopathic hirsutism: An uncommon cause of hirsutism in Alabama. Fertil Steril 70: 274-8, 1998 (PMID: 9696220).
70. Cronin L, Guyatt G, Griffith L, Wong E, **Azziz R**, Futterweit W, Cook D, Dunaif A. Development of a health-related quality of life questionnaire for women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:1976-1987, 1998 (PMID: 9626128).
71. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, **Azziz R**. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the Southeastern United States: A prospective study. J Clin Endocrinol Metab 83:3078-3082, 1998 (PMID: 9745406).
72. Knochenhauer ES, Boots LR, Potter HD, **Azziz R**. Differential binding of estradiol (E<sub>2</sub>) and testosterone to sex-hormone binding globulin in relation to circulating E<sub>2</sub> levels. J Reprod Med 43:665-670, 1998 (PMID: 9749416).
73. Buyalos RP, Grice JE, Jackson RV, Hockings GI, Torpy DJ, Fox LM, Boots LR, **Azziz R**. Androgen response to hypothalamic-pituitary-adrenal stimulation with naloxone in women with myotonic muscular dystrophy. J Clin Endocrinol Metab 83:3219-3224, 1998 (PMID: 9745431).
74. Kahsar-Miller M, **Azziz R**. Heritability and the risk of developing androgen excess. J Steroid Biochem Mol Biol 69:261-268, 1999 (PMID: 10419000).
75. Kahsar-Miller M, Boots LR, **Azziz R**. A dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome. Fertil Steril 71:436-8, 1999 (PMID: 10065778).
76. Moran C, Knochenhauer ES, Boots LR, **Azziz R**. Adrenal androgen excess in hyperandrogenism: Relation to age and body mass. Fertil Steril 71:671-4, 1999 (PMID: 10202877).
77. **Azziz R**, Black VY, Hines GA, Boots LR. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab 84:946-50, 1999 (PMID: 10084576).
78. Hines GA, **Azziz R**. Impact of architectural disruption on adrenocortical steroidogenesis. J Clin Endocrinol Metab 84:1017-21, 1999 (PMID: 10084589).
79. Urbanek M, Legro RS, Driscoll DA, **Azziz R**, Ehrmann DA, Norman RJ, Strauss JF III, Speilman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 96:8573-8578, 1999 (PMID: 10411917).
80. Farah L, Lazenby AJ, Boots LR, **Azziz R**, and the Alabama Professional Electrology Association Study Group. Prevalence of the polycystic ovary syndrome among women seeking treatment from community electrologists. J Reprod Med 44:870-4, 1999 (PMID: 10554748).
81. Moran C, Potter HD, Reyna R, Boots LR, **Azziz R**. Prevalence of 3 $\beta$ -hydroxysteroid dehydrogenase deficient non-classic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. Am J Obstet Gynecol 181:596-600, 1999 (PMID: 10486469).
82. **Azziz R**, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: A prospective study. Fertil Steril 72:915-25, 1999 (PMID: 10561000).

83. Huerta R, Dewailly D, Decanter C, Knochenhauer ES, Boots LR, **Azziz R**. Serum 11 $\beta$ -hydroxyandrostenedione and  $\Delta^5$ -androstenediol as markers of adrenal androgen production: Studies in 21-hydroxylase deficient non-classic adrenal hyperplasia. Fertil Steril 72:996-1000, 1999 (PMID: 10593370).
84. Waggoner W, Boots LR, **Azziz R**. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: A populational study. Gynecol Endocrinol 13:1-7, 1999. (PMID: 10685333)
85. **Azziz R**, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocrine Reviews 21:347-362, 2000 (PMID: 10950156).
86. **Azziz R**. Adrenal androgen excess in the polycystic ovary syndrome. Endocrinologist 10:245-254, 2000.
87. **Azziz R**. Editorial: The time has come to simplify the evaluation of the hirsute patient. Fertil Steril 74:870-872, 2000 (PMID: 11056223).
88. **Azziz R**, Saenger P. Meeting report: The Second International Symposium on the Developmental Aspects of Androgen Excess, Toronto, Canada, 20 June 2000. Trends Endocrinol Metab 11:338-40, 2000 (PMID: 11273567).
89. Sanchez L, **Azziz R**. Síndrome de ovario poliquístico, evaluación diagnóstica, tratamiento y pronóstico. Rev Obstet Ginecol Venez 60:47-57, 2000.
90. **Azziz R**, Kahsar-Miller M. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab 13 (Suppl. 5):1303-1306, 2000 (PMID: 11117675).
91. Parker Cr, Slayden SM, **Azziz R**, Crabbe SL, Hines GA, Potter HD, Boots LR, Bae S. Effects of aging on adrenal function in the human: Responsiveness and sensitivity of adrenal androgens and cortisol to ACTH in premenopausal and postmenopausal women. J Clin Endocrinol Metab 85:48-54, 2000 (PMID: 10634362).
92. Huerta R, Dewailly D, Decanter C, Knochenhauer ES, Boots LR, **Azziz R**. Adrenocortical hyper-responsivity to ACTH: A mechanism favoring the normal production of cortisol in 21-hydroxylase deficient non-classic adrenal hyperplasia. Fertil Steril 74:329-34, 2000 (PMID: 10927053).
93. Romaguera J, Moran C, Diaz-Montes TP, Cruz RI, Boots LR, **Azziz R**. Prevalence of 21-hydroxylase deficient non-classic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. Fertil Steril 74:59-62, 2000 (PMID: 10899497).
94. Moran C, **Azziz R**, Carmina E, Dewailly D, Fruzzetti F, Ibañez L, Knochenhauer ES, Marcondes JAM, Mendonca BB, Pignatelli D, Pugeat M, Rohmer V, Speiser PW, Witchel SF. 21-Hydroxylase deficient non-classic adrenal hyperplasia is a progressive disorder: A multicenter study. Am J Obstet Gynecol 183:1468-1474, 2000 (PMID: 11120512).
95. Knochenhauer ES, Black V, Hines G, Conway-Myers BA, **Azziz R**. Examination of the chin or lower abdomen only for the prediction of hirsutism. Fertil Steril 74:980-3, 2000 (PMID: 11056244).
96. Speiser PW, Knochenhauer ES, Dewailly D, Fruzzetti F, Marcondes JAM, **Azziz R**. A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype. Mol Genet Metab 71:527-534, 2000 (PMID: 11073721).
97. Kahsar-Miller M, **Azziz R**, Feingold E, Witchel SF. A variant of the glucocorticoid receptor gene is not associated with adrenal androgen excess in the polycystic ovary syndrome. Fertil Steril 74:1237-1240, 2000. (PMID: 11119758).
98. Moran C, Huerta R, **Azziz R**. Tratamiento de los trastornos de la fertilidad antes de las técnicas de reproducción asistida. Ginecol Obstet Mex 69:167-71, 2001 (PMID: 11452416).
99. Knochenhauer ES, **Azziz R**. Ovarian hormones and adrenal androgens during women's lifespan. J Am Acad Dermatol 45:S105-15, 2001 (PMID: 11511860).
100. **Azziz R**, Ehrmann D, Legro RS, Whitcomb RW, Fereshetian AG, O'Keefe M, Ghazzi MN, for the PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626-1632, 2001 (PMID: 11297595).

101. Kahsar-Miller M, Nixon C, Boots LR, Go RCP, **Azziz R**. Prevalence of the polycystic ovary syndrome (PCOS) among first degree relatives of patients with PCOS. Fertil Steril 75:53-8, 2001. (PMID: 11163816).
102. Slayden SM, Moran C, Sams Jr. WM, Boots LR, **Azziz R**. Hyperandrogenemia is a frequent cause of acne, regardless of age of presentation. Fertil Steril 75:889-892, 2001 (PMID: 11334899).
103. Moran C, Huerta R, Conway-Myers BA, Hines GA, **Azziz R**. Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovary syndrome. Fertil Steril 75:625-8, 2001 (PMID: 11239554).
104. Moran C, **Azziz R**. Reply of the authors: Why can't a man be more like a mouse? Fertil Steril 76:856, 2001.
105. **Azziz R**, Fox LM, Zacur HA, Parker Jr CR, Boots LR. Adrenocortical secretion of dehydroepiandrosterone in healthy women: Highly variable response to ACTH. J Clin Endocrinol Metab 86:2513-7, 2001 (PMID: 11397848).
106. Hines G, Moran C, Huerta R, Folgman K, **Azziz R**. Facial and abdominal hair growth in hirsutism: A computerized evaluation. J Am Acad Derm 45:846-850, 2001 (PMID: 11712028).
107. Reyna R, Traynor KD, Hines G, Boots LR, **Azziz R**. Repeated freezing and thawing does not generally alter assay results for several commonly studied reproductive hormones. Fertil Steril 76:823-5, 2001 (PMID: 11591421).
108. Hines GA, Smith ER, **Azziz R**. Influence of insulin and testosterone on adrenocortical steroidogenesis *in vitro*: Preliminary studies. Fertil Steril 76:730-5, 2001 (PMID: 11591406).
109. Kahsar-Miller MD, Conway-Myers BA, Boots LR, **Azziz R**. Steroidogenic acute regulatory protein (StAR) in ovaries of normal and polycystic ovary syndrome women. Am J Obstet Gynecol 185:1381-1387, 2001 (PMID: 11744913).
110. **Azziz R**, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Authors' response: troglitazone use in polycystic ovary syndrome. J Clin Endocrinol Metab 86:5090-1, 2001.
111. Jeffress J, **Azziz R**, Adamson D, Rebar R. Editorial: Isn't it time to demand public disclosure of health insurance benefits? Fertil Steril 77:216-7, 2002 (PMID: 11821073).
112. Sanchez LA, Perez M, **Azziz R**. Laser hair reduction in the hirsute patient: A critical assessment. Hum Reprod Update 8:169-181, 2002 (PMID: 12099632).
113. Ovalle F, **Azziz R**. Insulin resistance, the polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095-105, 2002 (PMID: 12057712).
114. **Azziz R**. Editorial: Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab 87:4085-7, 2002 (PMID: 12213851).
115. **Azziz R**. Adrenal androgens in the polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 9:469-474, 2002.
116. **Azziz R**. Editorial: Reproductive surgeons and the SRS: obsolete? Fertil Steril 78:916-7, 2002 (PMID: 12413973).
117. Sánchez LA, Morán C, Reyna R, Ochoa T, Boots LR, **Azziz R**. Adrenal progestogen and androgen production in 21-hydroxylase deficient non-classic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation. Fertil Steril 77:750-3, 2002 (PMID: 11937128).
118. **Azziz R**. The evaluation and management of hirsutism. Obstet Gynecol 101:995-1007, 2003 (PMID: 12738163).
119. Moran C, **Azziz R**. 21-Hydroxylase deficient non-classic adrenal hyperplasia: the great pretender. Sem Reprod Med 21:295-300, 2003.
120. **Azziz R**. Editorial: Androgen excess is the key element in the polycystic ovary syndrome. Fertil Steril 80:252-4, 2003 (PMID: 12909479).
121. **Azziz R**. Editorial: We should avoid the indiscriminate use of insulin sensitizers in PCOS. Fertil Steril 80:264-5, 2003 (PMID: 12909483).

122. Yildiz BO, Chang W, **Azziz R**. Polycystic ovary syndrome and ovulation induction. Minerva Ginecol 55:425-39, 2003 (PMID: 14581885).
123. **Azziz R**. Obituary for John Benjamin Younger, Sr., M.D. Fertil Steril 80:225-226, 2003
124. Moran C, **Azziz R**. The role of the adrenal cortex in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28:63-75, 2001 (reprinted in Infertility & Reproductive Medicine Clinics of North America. W.B. Saunders Pub. 14:557-570, 2003) (PMID: 11293004).
125. Woods KS, Reyna R, **Azziz R**. The effect of oral micronized progesterone on androgens levels in women with the polycystic ovary syndrome. Fertil Steril 77:1125-7, 2002 (PMID: 12057716).
126. **Azziz R**, Ehrmann D, Legro, Fereshetian A, O'Keef M, Ghazzi M, for the PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in the polycystic ovary syndrome. Fertil Steril 79:932-7, 2003 (PMID: 12749433).
127. Legro RS, **Azziz R**, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN, for the PCOS/Troglitazone Study Group. Lack of response of dyslipidemia in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 88:5137-44, 2003 (PMID: 14602740).
128. Kahsar-Miller MD, Boots LR, **Azziz R**. The reliability of the interview for predicting the presence of the polycystic ovary syndrome (PCOS) among relatives of patients with PCOS. Gynecol Endocrinol 17:449-454, 2003 (PMID: 14992163).
129. Capelo FO, Kumar A, Steinkampf MP, **Azziz R**. Laparoscopic evaluation following failure to achieve pregnancy after ovulation induction with clomiphene citrate. Fertil Steril 80:1450-3, 2003 (PMID: 14667882).
130. **Azziz R**. PCOS: A diagnostic challenge. Reprod Biomed Online 8:644-648, 2004 ([www.rbmonline.com/Article/1274](http://www.rbmonline.com/Article/1274)) (PMID: 15169578).
131. Capelo FO, Steinkampf MP, Kumar A, **Azziz R**. Reply of the authors: Potential cofounders in the laparoscopic detection of endometriosis. Fertil Steril 81:1722-3, 2004.
132. Farah-Eways LA, Reyna R, Knochenhauer ES, Bartolucci AA, **Azziz R**. Glucose action and adrenocortical biosynthesis In the polycystic ovary syndrome. Fertil Steril 81:120-5, 2004 (PMID: 14711154).
133. Moran C, Reyna R, Boots LS, **Azziz R**. Adrenocortical hyper-responsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil Steril 81:126-31, 2004 (PMID: 14711555).
134. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25, 2004 (also published simultaneously in Hum Reprod 19:41-7, 2004) (PMID: 14711538).
135. **Azziz R**, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KS, Taylor K, Boots LR. Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89:453-62, 2004 (PMID: 14764747).
136. **Azziz R**, Yildiz B, Woods KS, Reyna R, Key TJ, Stephens KC, Knochenhauer ES. The prevalence of polycystic ovary syndrome among unselected consecutive premenopausal women. J Clin Endocrinol Metab 89:2745-9, 2004 (PMID: 15181052).
137. Kahsar-Miller MD, Boots LR, Bartolucci AA, **Azziz R**. The role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in the polycystic ovary syndrome Fertil Steril 82:973-5, 2004 (PMID: 15482786).
138. **Azziz R**, Farah-Eways LA, Moran C, Knochenhauer ES, Potter HD, Boots LR. Early adrenarche in normal prepubertal girls: A prospective longitudinal study. J Pediatr Endocrinol Metab 17:1231-1237, 2004 (PMID: 15506683).
139. Yildiz B, Woods KS, Bartolucci AA, Stanczyk F, **Azziz R**. Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:5558-62, 2004 (PMID: 15531511).

140. Guyatt G, Weaver B, Cronin L, Dooley JA, **Azziz R**. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol 57:1279-87, 2004 (PMID: 15617954).
141. Souter I, Sanchez A, Perez M, Bartolucci AA, **Azziz R**. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 191:1914-20, 2004 (PMID: 15592272).
142. **Azziz R**. Diagnostic criteria for polycystic ovary syndrome: A reappraisal. Fertil Steril 83:1343-1346, 2005 (PMID: 15866567).
143. Ehrmann DA, **Azziz R**, Legro RS, Ghazzi MN, and the PCOS/Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 90:66-71, 2005 (PMID: 15507516).
144. Witchel SF, Kahsar-Miller MS, Aston CE, White C, **Azziz R**. Prevalence of CYP21 mutations and IRS-1 variant among women with the Polycystic Ovary Syndrome and adrenal androgen excess. Fertil Steril 83:371-5, 2005 (PMID: 15705377).
145. Marin C, Bartolucci A, **Azziz R**. The prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83:1454-60, 2005 (PMID: 15866584).
146. Kumar A, Woods KS, Bartolucci AA, **Azziz R**. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol 62:644-49, 2005 (PMID: 15943823).
147. Chang W, Knochenhauer ES, Bartolucci AA, **Azziz R**. Phenotypic spectrum of the polycystic ovary syndrome (PCOS): Clinical and biochemical characterization of the major clinical subgroups. Fertil Steril 83:1717-23, 2005 (PMID: 15950641).
148. Munir I, Yen H-W, Baruth T, Tarkowski R, **Azziz R**, Magoffin DA, Jakimiuk AJ. Resistin stimulation of 17 $\alpha$ -hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab 90:4852-7, 2005 (PMID: 15886251).
149. Goodarzi MO, Quiñones MJ, **Azziz R**, Rotter JI, Hsueh WA, Yang H. Polycystic Ovary Syndrome in Mexican-Americans: Prevalence and association with the severity of insulin resistance Fertil Steril 84:766-9, 2005 (PMID: 16169421).
150. **Azziz R**, Marin C, Hoq L, Badamgarav E, Song P. Economic burden of the polycystic ovary syndrome (PCOS) during the reproductive lifespan. J Clin Endocrinol Metab 90:4650-8, 2005 (PMID: 15944216).
151. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, **Azziz R**, Colao A. Improvement of endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a six-month pilot study. J Clin Endocrinol Metab 90:6072-6, 2005 (PMID: 16118336).
152. **Azziz R**. Reply of the author: How many of the items in the polycystic ovary syndrome can be validated statistically? Fertil Steril 85:530, 2006 (PMID: 16595251).
153. Giudice LC, Legro RS, **Azziz R**. Preface. Best Pract Res Clin Endocrinol Metab 20:vii-viii, 2006.
154. Legro RS, **Azziz R**, Giudice LC. A twenty-first century research agenda for polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 20:331-6, 2006 (PMID: 16772161).
155. Goodarzi MO, **Azziz R**. Diagnosis, epidemiology, and genetics of the Polycystic Ovary Syndrome. Best Pract Res Clin Endocrinol Metab 20:193-205, 2006 (PMID: 16772151).
156. **Azziz R**. Practice Point Commentary: Is the metabolic syndrome more prevalent in women with polycystic ovary syndrome? Nat Clin Pract Endocrinol Metab 2:132-133, 2006 (PMID: 16932270).
157. **Azziz R**. Controversy: Diagnosis of polycystic ovarian syndrome: The Rotterdam criteria are premature. J Clin Endocrinol Metab 91:781-85, 2006 (PMID: 16718211).
158. Carmina E, **Azziz R**. Proceedings of the 2<sup>nd</sup> Special Scientific Meeting of the Androgen Excess Society, Ravello, 2005: Diagnosis, phenotype and prevalence of PCOS. Fertil Steril 86 (Suppl 1):S7-8, 2006 (PMID: 16798288).



159. Orio F, **Azziz R**; Androgen Excess Society Annual Meeting Committee. Report on the Third Annual Meeting of the Androgen Excess Society, San Diego, California, June 3, 2005. Fertil Steril 86:1318-20, 2006 (PMID: 17070190).
160. Ehrmann DA, Liljenquist DR, Kasza K, **Azziz R**, Legro RS, Ghazzi MN, for the PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with Polycystic Ovary Syndrome (PCOS). J Clin Endocrinol Metab 91:48-53, 2006 (PMID: 16249284).
161. deUgarte CM, Bartolucci AA, Woods KS, **Azziz R**. Distribution of facial and body terminal hair in unselected black and white women: Towards a populational definition of hirsutism. J Clin Endocrinol Metab 91:1345-50, 2006 (PMID: 16449347).
162. Douglas CC, Gower BA, Darnell BE, Ovalle F, Oster RA, **Azziz R**. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril 85:679-88, 2006 (PMID: 16500338).
163. Pall M, Stephens K, **Azziz R**. Family size in the polycystic ovary syndrome. Fertil Steril 85:1837-9, 2006 (PMID: 16650417).
164. Ghadir S, **Azziz R**. Reproducibility of the adrenal androgen response to adrenocorticotrophic hormone stimulation. Fertil Steril 86:484-6, 2006 (PMID: 16769063).
165. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, **Azziz R**. Variants in the 5 $\alpha$ -Reductase Type 1 and Type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 91:4085-91, 2006 (PMID: 16849416).
166. Douglas CC, Norris LE, Oster RA, Darnell BE, **Azziz R**, Gower BA. Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil Steril 86:411-7, 2006 (PMID: 16762348).
167. Moran C\*, **Azziz R**\*, Carmina E, Escobar-Morreale H, Dewailly D, Fruzzetti F, Ibañez L, Marcondes JAM, Mendonca BB, Pignatelli D, Pugeat M, Rohmer V, Speiser PW, Witchel SF. Reproductive outcome of women with 21-hydroxylase deficient non-classic adrenal hyperplasia: A multicenter study. J Clin Endocrinol Metab 91:3451-6, 2006 (PMID: 16822826).  
*\*Denotes equal credit for first authorship.*
168. Yildiz BO, Goodarzi MO, Guo X, Rotter JI, **Azziz R**. Heritability of dehydroepiandrosterone sulfate among polycystic ovary syndrome women and their sisters. Fertil Steril 86:1688-93, 2006 (PMID: 17074350).
169. **Azziz R**, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Androgen Excess Society. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237-45, 2006 (PMID: 16940456).
170. Trivax B, **Azziz R**. Diagnosis of the Polycystic Ovary Syndrome. Clin Obstet Gynecol 50:168-177, 2007 (PMID: 17304034).
171. Yildiz BO, **Azziz R**. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 8:331-42, 2007 (PMID: 17932770).
172. Rosner W, Auchus RJ, **Azziz R**, Sluss PM, Raff H. Utility, limitations and pitfalls in measuring testosterone: An Endocrine Society Position Statement. J Clin Endocrinol Metab 92:405-413, 2007 (PMID: 17090633).
173. Goodarzi MO, Guo X, Yildiz BO, Stanczyk FZ, **Azziz R**. Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. Am J Obstet Gynecol 196:398.e1-5; discussion 398.e5-6, 2007 (PMID: 17403434).
174. Antoine HJ, Pall M, Trader BC, Chen Y-D I, **Azziz R**, Goodarzi MO. Genetic variants in peroxisome proliferator-activated receptor-gamma influence insulin resistance and testosterone levels in normal women but not those with polycystic ovary syndrome. Fertil Steril 87:862-9, 2007 (PMID: 17141766).

175. Goodarzi MO, Antoine HJ, Pall M, Cui J, Guo X, **Azziz R**. Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. Fertil Steril 87:1473-6, 2007 (PMID: 17270183).
176. Goodarzi MO, Antoine HJ, **Azziz R**. Genes for enzymes regulating DHEA sulfonation are associated with levels of DHEA-sulfate in polycystic ovary syndrome. J Clin Endocrinol Metab 92:2659-64, 2007 (PMID: 17426092).
177. Spencer J, Kumar A, **Azziz R**. Effect of race and obesity on the age-associated decline of androgens in reproductive-age women. J Clin Endocrinol Metab 92:4730-3, 2007 (PMID: 17895325).
178. **Azziz R**. Diagnosing the diagnosis: Why we must standardize the defining features of PCOS. Ann Clin Biochem 45:3-5, 2008 (PMID: 18275667).
179. **Azziz R**. Editorial: PCOS is a family affair. J Clin Endocrinol Metab 93:1579-81, 2008 (PMID: 18463352).
180. Mathur R, Levin O, **Azziz R**. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag 4(2):487-92, 2008 (PMID: 18728832).
181. Goodarzi MO, **Azziz R**. Letter to the Editor: Metformin use in polycystic ovary syndrome: metabolic benefits and diabetes prevention. Am J Med 121:e9, 2008 (PMID: 18691471).
182. Yildiz BO, Knochenhauer ES, **Azziz R**. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93:162-8, 2008 (PMID: 17925334).
183. Goodarzi MO, Jones MR, Antoine HJ, Pal M, Chen Y-D L, **Azziz R**. Non-replication of the type 5  $17\beta$ -hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. J Clin Endocrinol Clin 93:300-3, 2008 (PMID: 17940109).
184. Abenhaim HA, **Azziz R**, Hu J, Bartolucci A, Tulandi T. Socioeconomic and racial predictors of undergoing laparoscopic hysterectomy for benign disease: analysis of 341,487 hysterectomies. J Minim Invasive Gynecol 15:11-5, 2008 (PMID: 18262137).
185. Shaw LJ, Bairey Merz CN, **Azziz R**, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-DeHoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Post-Menopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health – National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 93:1276-84, 2008 (PMID: 18182456).
186. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group March 2–3, 2007, Thessaloniki, Greece. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 23:462-77, 2008 (PMID: 18308833).
187. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group March 2–3, 2007, Thessaloniki, Greece. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505-22, 2008 (PMID: 18243179).
188. Shah NA, Antoine HJ, Pall M, Taylor KD, **Azziz R**, Goodarzi MO. Association of androgen receptor CAG repeat polymorphism and Polycystic Ovary Syndrome. J Clin Endocrinol Metab 93:1939-45, 2008 (PMID: 18303071).
189. Goodarzi MO, Xu N, Antoine HJ, Cui J, Guo X, Chen Y-I, **Azziz R**. Small glutamine-rich tetratricopeptide repeat containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome. Hum Reprod 23:1214-9, 2008 (PMID: 18332089).
190. Lwin R, Darnell B, Oster R, Lawrence J, Foster J, **Azziz R**, Gower BA. The effect of oral estrogen on substrate utilization and body composition in postmenopausal women. Fertil Steril 90:1275-8, 2008 (PMID: 18001731).
191. Goodarzi MO, **Azziz R**. Letter to the Editor: Metformin use in polycystic ovary syndrome: metabolic benefits and diabetes prevention. Am J Med 121:e9, 2008 (PMID: 18691471).

192. Goodarzi MO, Maher JF, Cui J, Guo X, Taylor KD, **Azziz R**. *FEM1A* and *FEM1B*: Novel candidate genes for polycystic ovary syndrome. Hum Reprod 23:2842-9, 2008 (PMID: 18757445).
193. Braunstein GD, Bairey-Merz CN, Johnson BD, Stanczyk FZ, Bittner V, Berga SL, Shaw L, Hodgson TK, Paul-Labrador M, **Azziz R**. Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab 93:4268-75, 2008 (PMID: 18728170).
194. Goodarzi MO, Jones MR, Chen Y-D I, **Azziz R**. *AKT2*: First evidence of genetic association with Polycystic Ovary Syndrome. Diabetes Care 31:2284-7, 2008 (PMID: 18768676).
195. Mathur R, Alexander CJ, Yano J, Trivax B, **Azziz R**. Use of metformin in the polycystic ovary syndrome. Am J Obstet Gynecol 199:596-609, 2008 (PMID: 19084097).
196. Chang W, Goodarzi MO, Williams H, Magoffin DA, Pall M, **Azziz R**. Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril 90:2291-7, 2008 (PMID: 18178198).
197. Ogunyemi D, Alexander C, **Azziz R**, Finke D, Hurley E. Giving feedback (The Good and the Bad). MedEdPORTAL; 2009
198. Brennan K, Huang A, **Azziz R**. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 91:1848-52, 2009 (PMID: 18439591).
199. Brennan K, Huang A, **Azziz R**. Reply of the Authors: Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 91(5):1848-52, 2009 (PMID: 18439591).
200. **Azziz R**, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; and Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report. Fertil Steril 91:456-88, 2009 (PMID: 18950759).
201. **Azziz R**, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; The Androgen Excess and PCOS Society. Reply of the Authors. Fertil Steril. May 28 [E-pub], 2009.
202. Sproul K, Jones MR, Cui J, Guo X, **Azziz R**, Goodarzi MO. Variants in genes for AMP-activated protein kinase (AMPK) subunits influence polycystic ovary syndrome susceptibility and insulin levels in affected women. Eur J Endocrinol 161:405-9, 2009 (PMID: 19574280).
203. Pall M, Nguyen M, Magoffin D, **Azziz R**. Effect of sex steroids and insulin on DHEAS production by HEPG2 cells. Fertil Steril 91:2551-6, 2009 (PMID: 18554595).
204. Kumar A, Magoffin D, Munir I, **Azziz R**. Effect of insulin and testosterone on androgen production and transcription of *SULT2A1* in the NCI-H295R adrenocortical cell line. Fertil Steril 92:793-7, 2009 (PMID: 18684447).
205. Landay M, Huang A, **Azziz R**. The degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 92:643-7, 2009 (PMID: 18722607).
206. Ketefian A, Hu J, Bartolucci AA, **Azziz R**, for the Society of Reproductive Surgeons, Inc. Fifteen-year trend in the inpatient utilization of reproductive surgery in women: Analysis of the healthcare cost and utilization project (HCUP) data. Fertil Steril 92:727-35, 2009 (PMID: 18823883).
207. Merz CN, Johnson BD, Berga SL, Braunstein GD, **Azziz R**, Yang Y-C, Reis SE, Bittner V, Hodgson TK, Pepine CJ, Sharaf BL, Sopko G, Kelsey SF, for the WISE Study Group. Total estrogen time and obstructive coronary disease in women: Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Womens Health (Larchmt) 18:1315-22, 2009 (PMID: 19702477).

208. Maliqueo M, Sir-Petermann T, Pérez V, Echiburú B, Ladrón de Guevara A, Gálvez C, Crisosto N, **Azziz R**. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 94:3282-88, 2009 (PMID: 19567527).
209. Jones MR, Mathur R, **Azziz R**, Goodarzi MO. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the Type 6 17 $\beta$ -hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab 94:5034-8, 2009 (PMID: 19837928).
210. Pall M, **Azziz R**, Beires J, Pignatelli D. The phenotype of hirsute women: A comparison of polycystic ovarian syndrome and 21-hydroxylase deficient non-classic adrenal hyperplasia. Fertil Steril 94:684-9, 2010 (PMID: 19726039).
211. Sproul K, Jones MR, Mathur R, **Azziz R**, Goodarzi MO. Association study of four key folliculogenesis genes in polycystic ovary syndrome. Br J Obstet Gynecol 161:405-9, 2009 (PMID: 20236105).
212. Yildiz BO, **Azziz R**, for the Androgen Excess and PCOS Society. Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: Report of the 4th special scientific meeting of the Androgen Excess and PCOS society. Fertil Steril 94:690-3, 2010 (PMID: 19394000). (see: <http://services.aamc.org/30/mededportal/servlet/s/segment/mededportal/?subid=7710>)
213. Bairey Merz CN, Shufelt C, Johnson BD, **Azziz R**, Braunstein GD. Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question. Maturitas. 65(4):297-8, 2010 (PMID: 20089376).
214. Witchel SF, **Azziz R**. Non-Classic Congenital Adrenal Hyperplasia. Int J Ped Endocrinol 2010:1-11, 2010.
215. Speiser PW, **Azziz R**, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HFL, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:4133-60, 2010 (PMID: 20823466).
216. Speiser PW, **Azziz R**, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC. A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol 2010:494173, 2010 (PMID: 20981249).
217. Bairey Merz CN, Shufelt C, Johnson BD, **Azziz R**, Braunstein G. Response to Letter to the Editor, re to editorial entitled "Reproductive Hormone Exposure Timing and Ischemic Heart Disease: Complicated Answers to a Simple Question". Maturitas 65:297-8, 2010 (PMID: 20089376).
218. Auchus RJ, Witchel S, Leight K, Aisenberg J, **Azziz R**, Bachega T, Baker LA, Baratz A, Baskin LS, Berenbaum S, Breault D, Cerame B, Conway GS, Eugster EA, Fracassa S, Gearhart JP, Geffner ME, et al. Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation initiative. Int J Ped Endocrinol 2010: 275213, 2010 (PMID: 2127448).
219. Rosner W, Vesper H; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 95:4542-8, 2010 (PMID: 20926540).
220. Chazenbalk G, Trivax BS, Yildiz BO, Bertolotto C, Mathur R, Heneidi S, **Azziz R**. Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: Role of tumor necrosis factor- $\alpha$ . J Clin Endocrinol Metab 95:935-42, 2010 (PMID: 20089616).

221. Yildiz BO, Bolour S, Woods K, Moore A, **Azziz R**. Visually scoring hirsutism. Hum Reprod Update 2010;16:51-64 (PMID: 19567450).
222. Xu N, **Azziz R**, Goodarzi MO. Epigenetics in Polycystic Ovary Syndrome: A pilot study of global DNA methylation. Fertil Steril 94:781-3.e1; 2010 (PMID: 19939367).
223. Mathur R, Ko A, Hwang L, Low K, **Azziz R**, Pimentel M. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci 55:1085-9, 2010 (PMID: 19697132).
224. Huang A, Brennan K, **Azziz R**. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the NIH 1990 criteria. Fertil Steril 93:1938-41, 2010 (PMID: 19249030).
225. Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, Legro RS, Chua A, **Azziz R**, Spielman RS, Goodarzi MO, Strauss III JF. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS ONE 2011; 6:e16390 (PMID: 21283731).
226. Ketefian A, Hu J, Bartolucci AA, Schlegel P, **Azziz R**. Fifteen-year trend in the inpatient utilization of male reproductive surgery: Analysis of the healthcare cost and utilization project (HCUP) data. BJU Int 107:1118-23, 2011 (PMID: 21438976).
227. Xu N, Taylor KD, **Azziz R**, Goodarzi MO. Variants in the HMG-CoA reductase (*HMGCR*) gene influence component phenotypes in polycystic ovary syndrome. Fertil Steril 94:255-60.e1-2, 2010 (PMID: 19327767).
228. Johnson BD, Dwyer K, Stanczyk FZ, Bittner V, Berga SL, Braunstein GD, **Azziz R**, Yang Y, Bretsky P, Hale G, Bairey Merz CN. The Relationship of Menopausal Status and Rapid Menopausal Transition with Carotid Intima-Media Thickness Progression in Women: A Report from the Los Angeles Atherosclerosis Study (LAAS). J Clin Endocrinol Metab 95:4432-40, 2010 (PMID: 20554714).
229. Shufelt C, Bretsky P, Almeida CM, Johnson BD, Shaw LJ, **Azziz R**, Braunstein GD, Pepine CJ, Bittner V, Vido DA, Stanczyk FZ, Bairey Merz CN. DHEA-S Levels and Cardiovascular Mortality in Post-menopausal Women: Results from the National Institutes of Health – National Heart, Lung, and Blood Institute (NHLBI) – Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 95:4985-92, 2010 (PMID: 20739385).
230. **Azziz R**, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fert Steril 95:1544-8, 2011 (PMID: 20979996).
231. Goodarzi MO, Dumesic DA, Chazenbalk G, **Azziz R**. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219-31, 2011 (PMID: 21263450).
232. Merkin SS, **Azziz R**, Seeman T, Calderon R, Daviglius M, Kiefe C, Matthews K, Sternfeld B, Siscovick D. Socioeconomic status and polycystic ovary syndrome. J Womens Health (Larchmt) 20:413-9, 2011 (PMID: 21323584).
233. Goodarzi MO, Louwers YV, Taylor KD, Jones MR, Cui J, Kwon S, Chen Y-D I, Guo X, Stolk L, Uitterlinden AG, Laven JSE, **Azziz R**. Replication of association of insulin receptor gene polymorphisms with polycystic ovary syndrome. Fertil Steril 95:1736-41.e1-11, 2011 (PMID: 21300347).
234. Chazenbalk G, Bertolotto C, Heneidi S, Aronowitz J, Yoshimura K, Simmons CF, **Azziz R**. Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem/progenitor cells and adipocytes. PLoS ONE 6:e17834, 2011 (PMID: 21483855).
235. Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, Legro RS, Chua A, **Azziz R**, Spielman RS, Goodarzi MO, Strauss JF. Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with PCOS. Fertil Steril 95:2538-2541.e6, 2011 (PMID: 21444075).
236. Jones MR, Chua A, Chen YD, Li X, Krauss RM, Rotter JI, Legro RS, **Azziz R**, Goodarzi MO. Harnessing expression data to identify novel candidate genes in polycystic ovary syndrome. PLoS One 6:e20120, 2011 (PMID: 21611153).

237. Zhao X, Ni R, Li L, Mo Y, Huang J, Huang M, **Azziz R**, Yang D. Defining hirsutism in Chinese women: A cross-sectional study. Fertil Steril 96:792-6, 2011 (PMID: 21762890).
238. Cook H, Brennan K, Azziz R. Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism? Fertil Steril 2011 Nov; 96 (5): 1266-70, (PMID: 21924716).
239. Painovich P, Shufelt C, **Azziz R**, Yang Y, Goodarzi M, Braunstein G, Karlan B, Stewart P, Merz C. A pilot randomized, single blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. Menopause 19:54-61, 2012 (PMID: 21968279).
240. Xu N, Kwon S, Abbott DH, Geller DH, Dumesic DA, **Azziz R**, Guo X, Goodarzi MO. Epigenetic mechanism underlying the development of a polycystic ovary syndrome (PCOS)-like phenotype in prenatally androgenized rhesus monkeys. PLoS ONE 6:e27286, 2011 (PMID: 22076147).
241. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, I Chen YD, Krauss RM, Rotter JI, Ankener W, Legro RS, **Azziz R**, Strauss JF 3rd, Dunaif A, Urbanek M. Replication of Association of DENND1A and THADA Variants with polycystic ovary syndrome in European cohorts. J Med Genet 49:90-5, 2012 (PMID: 22180642).
242. Chua AK, **Azziz R**, Goodarzi MO. Association Study of *CYP17* and *HSD11B1* in Polycystic Ovary Syndrome Utilizing Comprehensive Gene Coverage. Mol Hum Reprod 77:317-22, 2012 (PMID: 22238371).
243. Jones MR, Chua AK, Mengesha EA, Taylor KD, Chen YD, Li X, Krauss RM, Rotter JI; Reproductive Medicine Network, Legro RS, **Azziz R**, Goodarzi MO. Metabolic and cardiovascular genes in polycystic ovary syndrome: a candidate-wide association study (CWAS). Steroids 77:317-22, 2012 (PMID: 22178785).
244. Chazenbalk G, Chen Y-H, Heneidi S, Lee J-M, Pall M, Chen Y-D I, **Azziz R**. Abnormal expression of genes involved in inflammation, lipid metabolism, and *WNT* signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab 97:E765-70, 2012 (PMID: 22344199).
245. Jones M, Xu N, Chazenbalk G, Chua A, Eigler T, Mengesha E, Wang C, Chen Y-H, Xu J, Lee J-M, Pall M, Li X, Chen Y-D, Taylor K, Mathur R, Krauss R, Rotter J, Legro R, **Azziz R**, Goodarzi M. Steroidogenic regulatory factor FOS is underexpressed in Polycystic Ovary Syndrome (PCOS) adipose tissue and associated with PCOS susceptibility. J Clin Endocrinol Metab 2012;97:E1750-7 (PMID: 22723319).
246. Wang R, Goodarzi MO, Wang D, Xiong T, **Azziz R**, Zhang H. Negative association between androgen receptor gene CAG repeat polymorphism and polycystic ovary syndrome? A systematic review and meta-analysis. Mol Hum Reprod 2012;18:498-509 (PMID: 22695532).
247. Wojciechowski P, Lipowska A, Rys P, Ewens KG, Franks S, Tan S, Lerchbaum E, Vcelak J, Strackowski M, **Azziz R**, Barber TM, Hinney A, Obermayer-Pietsch B, Lukasova P, Bendlova B, Kowalska I, Goodarzi MO, Strauss III JF, McCarthy M, Malecki MT. Impact of *FTO* genotypes on weight and body mass index in polycystic ovary syndrome: A systematic review and meta-analysis. Diabetologia 2012;55:2636-45. Erratum in: Diabetologia 2012;55:2858-9 (PMID: 22801903).
248. **Azziz R**, Chang WY, Stanczyk FZ, Woods K. Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome. Fertil Steril 2013 Feb; 99 (2): 599-604 (PMID: 23122827).
249. Davidson PL, **Azziz R\***, Morrison J, Rocha J, Braun J. Identifying and Developing Leadership Competencies in Health Research Organizations: A Pilot Study. J Health Adm Edu, Spring 2012. \*Denotes equal credit for first authorship.
250. Chen Y-H, Heneidi S, Lee J-M, Stepp DW, Layman L, Gamboa GM, Chazenbalk G, **Azziz R**. Increased miRNA-93 inhibits GLUT4 in polycystic ovary syndrome-derived adipocytes. Diabetes 2013;62:2278-86 (PMID: 23493574).

251. Ezeh U, Yildiz BO, **Azziz R**. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab 2013;98:E1088-96 (PMID: 23539721).
252. Gower B, Chandler-Laney P, Ovalle F, Gorree LL, **Azziz R**, Desmond R, Granger W, Goss A, Bates W. Favorable metabolic effects of eucaloric lower-carbohydrate diet in women with PCOS. Clin Endocrinol (Oxf). 2013;79:550-7 (PMID: 23444983).
253. Ezeh U, Mathur R, Dey D, Dumesic DA, **Azziz R**. Effects of endogenous androgens and abdominal fat distribution on the inter-relationship between insulin and non-insulin-mediated glucose uptake in females. J Clin Endocrinol Metab 2013;98:1541-8 (PMID: 23450052).
254. Wang Y, Zhao X, Zhao H, Ding H, Tan J, Chen C, **Azziz R**, Yang D. Risks for gestational diabetes mellitus and pregnancy-induced hypertension are increased in lean women with polycystic ovary syndrome. Biomed Res Int 2013;2013:182582 (PMID: 24371816).
255. Brower M, Brennan K, Pall M, **Azziz R**. The severity of menstrual dysfunction as a predictor of insulin resistance in patients with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2013;98:E1967-71. (PMID: 24092831).
256. Salameh WA, Redor-Goldman MM, Clarke NJ, Mahur R, **Azziz R**, Reitz RE. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of the Polycystic Ovary Syndrome by the NIH 1990 criteria. Fertil Steril 2014; 101:1135-1141 (PMID: 24534279).
257. **Azziz R**. Polycystic Ovary Syndrome: What's in a Name? J Clin Endocrinol Metab 2014;99:1142-5. (PMID: 24491161).
258. Ezeh U, Pall M, Mathur R, **Azziz R**. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. Hum Reprod 2014, May 9. [Epub ahead of print] (PMID: 24813197)
259. Goodarzi MA, Carmina E, **Azziz R**. Adrenal Androgens, DHEA, and PCOS. J Steroid Biochem Mol Biol 2014 Jul 5 [Epub ahead of print] (PMID: 25008465).
260. Goss AM, Chandler-Laney PC, Ovalle F, Goree LL, **Azziz R**, Desmond RA, Wright Bates G, Gower BA. Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS. Metabolism. 2014 Jul 18. [Epub ahead of print] (PMID: 25125349)
261. Chen Y-H, Heneidi S, Diamond MP, Layman LC, Azziz R. The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab (in press).
262. Vagi SJ, Baumgartner EA, Sjodin A, Calafat AM, Dumesic D, Gonzalez L, Kato K, Silva MJ, Ye X, **Azziz R**. Exploring the potential association between Brominated Diphenyl Ethers, Polychlorinated Biphenyls, Organochlorine Pesticides, Perfluorinated Compounds, Phthalates, and Bisphenol A in Polycystic Ovary Syndrome: a case-control study. BMC Endocrine Disorders (in press).
263. Brower MA, Jones MR, Rotter JI, Krauss RM, Reproductive Medicine Network, Legro RS, **Azziz R**, Goodarzi MO. Further investigation in Europeans of Susceptibility variants for Polycystic Ovary Syndrome discovered in genome-wide association studies of Chinese individuals (submitted)
264. Chen Y-H, Chuang T-Y, Gamboa GM, Layman LC, Diamond MP, **Azziz R**. MicroRNA-223 expression is upregulated in insulin resistant human adipose tissue (submitted).
265. Calderon-Margalit R, Wellons MF, Merkin SS, Wang E, Daviglius ML, Schreiner PJ, Sternfeld B, Williams O, Lewis CE, **Azziz R**, Schwartz SM, Siscovick D. The prospective association of Polycystic Ovary Syndrome with coronary artery calcification and carotid-IMT: the CARDIA Women's Study (submitted).
266. Xu N, Geller DH, Jones MR, Funari VA, **Azziz R**, Goodarzi MO. Comprehensive assessment of expression of insulin signaling pathway components in subcutaneous adipose tissue of women with and without polycystic ovary syndrome (submitted).

267. Zhao X, Ni R, Huang L, Huang J, Hong Y, Di N, **Azziz R**, Yang D. prevalence of metabolic syndrome and overweightness among Chinese women of reproductive age: Relationship to urban vs. rural environment (submitted).
268. Geller DH, Hernandez MI, Codner E, Cassorla F, Oberfield SE, Mathew R, Ten S, Orio F, Baillargeon J-P, Magoffin DA, **Azziz R**, Goran MI. Flux in insulin dynamics through middle puberty in girls at high risk for developing PCOS: The impact of proband glucose tolerance status (submitted).
269. Chen Y-H, Lee J-M, Heneidi S, Chazenbalk G, Gamboa GM, **Azziz R**. Constitutive ERK1/2 activation down-regulates GLUT4 expression in adipocytes of women with polycystic ovary syndrome (submitted).



**PUBLICATIONS – Selected publications on higher education/healthcare education/training, leadership and administration:**

1. **Azziz R.** Editorial: Operative endoscopy - The pressing need for a structured training and credentialing process. Fertil Steril 58:1100-1102, 1992 (PMID: 1459254).
2. **Azziz R.** Training, certification and credentialing in gynecologic operative endoscopy. Clin Obstet Gynecol 38:313-318, 1995 (PMID: 7554599).
3. Ogunyemi D, Alexander C, Gonzalez G, Finke D, Fong A, Donnon T, **Azziz R.** From the eye of the nurses: 360-degree degree evaluation of residents. J Cont Ed Health Prof 29:105–110, 2009 (PMID: 19530193).
4. Ogunyemi D, Solnik J, Alexander C, Fong A, **Azziz R.** Promoting residents' professional development using a structured faculty mentoring program. Teach Learn Med 22:93-6, 2010 (PMID: 20614372).
5. Ogunyemi D, Alexander C, Fung E, Mak W, **Azziz R.** A faculty and resident development program to improve learning and teaching skills. J Grad Med Ed 1:127-131, 2009 (PMID: 21975719).
6. Ogunyemi D, Fong S, Elmore G, Korwin D, **Azziz R.** The associations between residents' behavior and the Thomas-Kilmann conflict MODE instrument. J Grad Med Ed 2: 118-125, 2010 (PMID: 21975897).
7. Ogunyemi D, Eno M, Rad S, Fong A, Alexander C, **Azziz R.** Evaluating professionalism, practice-based learning and improvement, and systems-based practice: utilization of a compliance form and correlation with conflict styles. J Grad Med Ed 2: 423-429, 2010 (PMID: 21976093).
8. Ogunyemi D, Finke D, **Azziz R.** Giving feedback (the good and the bad). MedEdPORTAL, Association of American Medical Colleges December 6, 2009 (webcast; <https://www.mededportal.org/publication/7710>).
9. **Azziz R,** Buckley P. New name, school still addressing physician shortages. J Med Assoc Ga. 2011;100:21, 37 (PMID: 21661595).
10. **Azziz R.** Guest Editorial - School's impact reaches beyond mere economics. Augusta Chronicle, June 26, 2011 (<http://chronicle.augusta.com/opinion/opinion-columns/2011-06-26/schools-impact-reaches-beyond-mere-economics>)
11. **Azziz R.** Georgia Health Sciences University's Competitive Edge: Collaboration. Shaping Infinity, Georgia Bio, 2011.
12. **Azziz R.** The Doctor Is In: Economic Development Strategies in Health Care. Federal Reserve Bank of Atlanta. December 2011 (podcast: [http://www.frbatlanta.org/podcasts/transcripts/economicdevelopment/111216\\_azziz.cfm?d=1&series=](http://www.frbatlanta.org/podcasts/transcripts/economicdevelopment/111216_azziz.cfm?d=1&series=))
13. **Azziz R.** Guest Editorial - Don't hide the giant – start trumpeting the greatness of GHSU. Augusta Chronicle, December 30, 2011 (<http://chronicle.augusta.com/opinion/opinion-columns/2011-12-30/dont-hide-giant-start-trumpeting-greatness-ghsu>)
14. **Azziz R.** Guest Editorial – The University and the city. Atlanta Business Chronicle, November 16 – 22, 2012 (<http://www.bizjournals.com/atlanta/print-edition/2012/11/16/the-university-and-the-city.html>)
15. **Azziz R.** Viewpoint – Alignment of academic medical centers and cities is key to economic growth. AAMC Reporter, January 2013.
16. **Azziz R.** Uninsured cost us all. Atlanta Business Chronicle, January 18, 2013.
17. Kim D, Madden A, Alexander C, Zois M, Ogunyemi D, **Azziz R.** Implementing a teaching service for voluntary faculty in obstetrics and gynecology: Long-term result. J Reprod Med 2013;58:371-6 (PMID: 24050024).
18. **Azziz R.** What Happens When 2 Colleges Become One? Chronicle Higher Education, May 20, 2013

19. **Azziz R.** A Call to Arms: Academe Must Meet Demands of Downsizing Military. DIVERSE magazine, Sept. 12, 2013, p. 19.
20. **Azziz R.** What is the value and role of academic medicine in the life of its university? Acad Med 2014;89:208-11 (PMID: 2436239).
21. Video: College Presidents Talk Leadership at ACE's Annual Meeting. by Nick DeSantis. March 10-11 2014. The Chronicle of Higher Education ([http://chronicle.com/blogs/bottomline/video-college-presidents-talk-leadership-at-aces-annual-meeting/?cid=at&utm\\_source=at&utm\\_medium=en](http://chronicle.com/blogs/bottomline/video-college-presidents-talk-leadership-at-aces-annual-meeting/?cid=at&utm_source=at&utm_medium=en))
22. **Azziz R.** Like making waves in a tarpit: Academia's internal communications problem. Change: The magazine of higher learning 2014;46:32-35.
23. **Azziz R.** Artist's Statement: Paranoia (essay accompanying cover art – on the power of consolidation). Acad Med 2014; 89:549.
24. **Azziz R.** Salary-at-risk as a catalyst for culture change. AASCU Public Purpose, Spring 2014, p. 22.
25. **Azziz R.** Implementing shared services in higher education. University Business online magazine, September issue (<http://www.universitybusiness.com/article/shared-services>).
26. Colenda CC, **Azziz R.** The role of the academic health center within the university, in Wartman SA, ed.: The Transformation of Academic Health Centers: The Institutional Challenge to Improve Health and Well-Being in Healthcare's Changing Landscape. Elsevier Pub. (in press).
27. Davis F, Moore D, Berdle H, Qadeer A, Gurley S, Cartwright S, Park MA, Florentino I, Howell C, Yu J, **Azziz R.** The implementation of an electronic medical record system in a tertiary academic medical center: Impact on operating room performance (submitted).

## **PUBLICATIONS – Scientific Chapters, and other Reviews and Commentaries:**

1. **Azziz R**, Wallach EE. The change in human female reproductive capacity with age: Fecundability and fertility. Postgrad Obstet Gynecol 7(16):1-7, 1987.
2. Moradi M, **Azziz R**. The change in human female reproductive capacity with age: Obstetrical outcome. Postgrad Obstet Gynecol 8(3):1-6, 1988.
3. **Azziz R**. Determining the cause of hirsutism and anovulation. Contemp Ob Gyn 31:126-139, 1988.
4. Rock JA, **Azziz R**. Wolffian duct cyst at the vaginal vault, in Nichols DH, ed: Clinical Problems, Injuries and Complications of Gynecological Surgery. 2nd Ed., Williams & Wilkins, Baltimore, MD., pp 144-146, 1988.
5. **Azziz R**. Gamete intrafallopian transfer: Current perspectives, in Damewood M, ed: The Johns Hopkins Handbook of In Vitro Fertilization and Assisted Reproductive Technologies. Little, Brown & Co., Boston, MA, pp 125-141, 1990.
6. **Azziz R**. Hirsutism. Audio-Digest Foundation, 37:8, 1990 (audiotape).
7. Siller B, **Azziz R**. A contemporary look at ectopic pregnancy. Medical Aspects of Human Sexuality, 1992
8. **Azziz R**. Pelviscopic Surgery, in Diamond M, ed. Infertility Surgery - Clinical Practice of Gynecology Series. Elsevier Publishing Co., Inc., New York, NY, pp 21-34, 1992.
9. **Azziz R**. Hirsutism in the pediatric or adolescent patient, in Carpenter SEK, Rock JA, eds. Pediatric and Adolescent Gynecology, Raven Press, New York, NY, pp 239-266, 1992.
10. **Azziz R**. Advantages and disadvantages of operative endoscopy, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, pp 1-6, 1992.
11. Murphy AA, Garzo VG, **Azziz R**. Establishing hemostasis at laparoscopy, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, pp 23-37, 1992.
12. **Azziz R**. Photo and video documentation in endoscopic surgery, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, pp 47-54, 1992.
13. Steinkampf MP, **Azziz R**. Laparoscopic ovarian and paraovarian surgery, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, pp 111-123, 1992.
14. Perry CP, **Azziz R**. Laparoscopic uterine nerve ablation, presacral neurectomy, and appendectomy, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, pp 143-150, 1992.
15. **Azziz R**. Training and certification in operative endoscopy, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, pp 217-219, 1992.
16. Blackwell RD, **Azziz R**. Role of GnRH analogs in gynecology, in Rayburn W, Zuspan FP, eds. Drug Therapy in Gynecology and Obstetrics Mosby-Year Book Publishing, St. Louis, MO, pp 503-517, 1992.
17. **Azziz R**. Reproductive endocrinology of female obesity, in Carr BR, Blackwell RE, eds: Textbook of Reproductive Medicine, Appleton & Lange, Norwalk, CT, pp 389-407, 1992.
18. **Azziz R**. Disorders of adrenal function, in Carr BR, Blackwell RE, eds: Textbook of Reproductive Medicine, Appleton & Lange, Norwalk, CT, pp 323-354, 1992.
19. **Azziz R**. Androgen excess, in Schlaff WD, Rock JA, eds. Decision Making in Reproductive Endocrinology. Blackwell Scientific Publications, Boston, MA, pp 246-253, 1993.
20. **Azziz R**. Late-onset adrenal hyperplasia, in Schlaff WD, Rock JA, eds: Decision Making in Reproductive Endocrinology. Blackwell Scientific Publications, Boston, MA, pp 254-260, 1993.
21. **Azziz R**. The role of the ovary in the genesis of hyperandrogenism, in Adashi EY, Leung PCK, eds: The Ovary. Raven Press, New York, NY, pp 581-605, 1993.

22. **Azziz R.** Climaterio en la perimenopausia y menopausia, in Contreras P, ed. Manual de aspectos no reproductivos en endocrinología ginecológica, Santiago, Chile.
23. **Azziz R.** Hirsutism, in Sciarra JJ, Dilts PV, eds: Gynecology and Obstetrics, Vol. 5: Endocrinology, infertility, genetics. J.B. Lippincott Co., Philadelphia, pp. 1-22, 1994.
24. CREOG. CREOG training guidelines: Advanced surgical techniques for residency training programs in obstetrics and gynecology. Council on Resident Education in Obstetrics and Gynecology, Washington, D.C., 1994.
25. **Azziz R, Peacock L, Rock JA.** Wolffian duct cyst at the vaginal vault, in Nichols DH, ed. Clinical Problems, Injuries and Complications of Gynecological Surgery - Third Edition, Williams & Wilkins, Baltimore, MD. pp. 213-216, 1995. English and Italian Translations.
26. **PROLOG: Reproductive Endocrinology and Infertility, Third Edition.** The American College of Obstetricians and Gynecologists, Washington, D.C., 1995.
27. **Azziz R, Zacur HA.** The hyperandrogenic chronic anovulatory syndrome (A.K.A. The polycystic ovary syndrome), in Wallach EE, Zacur HA, eds: Reproductive Medicine and Surgery. Mosby-Year Book, Inc., St. Louis, MO., 1995.
28. **Azziz R.** PCO: The adrenal connection, in Adashi EY, Rock JA, Rosenwaks Z, eds: Reproductive Endocrinology, Surgery, and Technology. Raven Press, New York, NY, 1995.
29. **Azziz R.** Tratamiento del hirsutismo. MEDICO Interamericano 10:439-446, 1996.
30. **Azziz R.** Demystifying fallacies surrounding nonclassic adrenal hyperplasia. Contemp Ob Gyn 41: 109-131, 1996.
31. **Azziz R.** Adrenocortical dysfunction in the polycystic ovary syndrome, in R. Jeffrey Chang, ed. Polycystic Ovary Syndrome - Serono Symposia USA. Springer, New York, NY, 1996, pp. 102-116.
32. **Azziz R.** Treatment of non-classic adrenal hyperplasia, in Bardin CW, ed. Current Therapy in Endocrinology and Metabolism - Sixth edition. Mosby-Year Book, Inc., New, York, NY, 1997, pp. 175-178.
33. **Azziz R.** Training, certification and credentialing in gynecologic operative endoscopy, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy - Second Edition. Springer-Verlag, New York, NY, pp 10-15, 1997.
34. **Azziz R.** Electrosurgery and thermocoagulation at operative endoscopy, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy - Second Edition. Springer-Verlag, New York, NY, pp 32-39, 1997.
35. Knochenhauer ES, **Azziz R.** Photo and video documentation in endoscopic surgery, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy - Second Edition. Springer-Verlag, New York, NY, pp 49-57, 1997.
36. Steinkampf MP, **Azziz R.** Laparoscopic ovarian and parovarian surgery, in Azziz R, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy - Second Edition. Springer-Verlag, New York, NY, pp 147-162, 1997.
37. **Azziz R.** Abnormalities of adrenocortical steroidogenesis in the polycystic ovary syndrome, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, PA, 1997, pp.403-414.
38. **Azziz R.** Hypothalamic-pituitary-adrenal axis dysfunction in the polycystic ovary syndrome, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, PA, 1997, pp.395-402.
39. **Azziz R.** Glucocorticoid suppression in the treatment of androgen excess, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, PA, 1997, pp.737-746.
40. Lookingbill DP, **Azziz R.** Measurement of peripheral androgen action, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, PA, 1997, pp.657-664.

41. Slayden SM, **Azziz R.** The role of androgen excess in acne, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, Pa, 1997, pp.131-140.
42. **Azziz R,** Carmina E. Idiopathic hirsutism: Definition, prevalence and inheritance, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, PA, 1997, pp.529-534.
43. **Azziz R.** Diagnosis, screening and treatment of 21-hydroxylase deficient non-classic adrenal hyperplasia, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, Pa, 1997, pp.181-192.
44. Kahsar-Miller M, **Azziz R.** Genetics of adrenal androgen excess, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Pub., Philadelphia, PA, 1997, pp.441-451.
45. Knochenhauer ES, **Azziz R.** Adenomyosis, leiomyomata and pelvic pain, in Blackwell RE, Olive DL, eds. Chronic Pelvic Pain: Evaluation and Management. Springer-Verlag, New York, NY, 1998, pp. 121-142.
46. Gower BA, **Azziz R.** Endocrine alterations in female obesity, in Carr BR, Blackwell RE, eds: Textbook of Reproductive Medicine - Second Edition, Appleton & Lange, Norwalk, CT, 1998, pp. 425-453.
47. **Azziz R.** Disorders of adrenal function, in Carr BR, Blackwell RE, eds: Textbook of Reproductive Medicine - Second Edition, Appleton & Lange, Norwalk, CT, 1998, pp. 351-388.
48. Knochenhauer ES, **Azziz R.** Evaluation of infertility: A cost effective approach. Références en Gynécologie Obstétrique 5:315-320, 1997.
49. Conway-Myers BA, **Azziz R,** Knochenhauer ES. Oocytes in hyperandrogenism, in Human oocytes: From physiology to IVF. Monduzzi Editore, 1997.
50. Saenger P, **Azziz R.** On The First International Symposium on the Developmental Aspects of Androgen Excess. Trends in Endocrinology and Metabolism 9:45-46, 1998.
51. **Azziz R.** Laparoscopic management of endometriosis-related infertility. OBG Management, April, 1998.
52. Speroff L, **Azziz R,** Dunaif A, Guidice LC, Sobel BE. Diagnosis and management of polycystic ovary syndrome. Contemp Ob Gyn, July 1998 Supplement.
53. **Azziz R.** The clinical spectrum of congenital adrenal hyperplasia in adolescence and adulthood, in R. Stanhope, ed. Adolescent Endocrinology, BioScientifica, Bristol, UK, 1998, pp.79-84.
54. **Azziz R.** Hirsutism in the pediatric or adolescent patient, in Carpenter SEK, Rock JA, eds Pediatric and Adolescent Gynecology - Second Edition, Lippincott-Raven Publishers, New York, NY. 2000:253-280.
55. **Azziz R.** Androgen excess of adrenal origins, in Quilligan EJ, Zuspan FP, eds. Current Therapy in Obstetrics and Gynecology - Fifth Edition, W.B. Saunders Co, Baltimore, MD, 2000, pp.2-7.
56. Slayden S, **Azziz R.** The economic impact of ectopic pregnancies, in Leach, Ory S, eds. Management of Ectopic Pregnancies, Blackwell Science, Inc., Malden, MA, 2000, pp.171-196.
57. Farah L, **Azziz R.** The polycystic ovary syndrome. The Female Patient 24:79-85, 1999.
58. PROLOG: Reproductive Endocrinology and Infertility, Fourth Edition. The American College of Obstetricians and Gynecologists, Washington, D.C., 2000.
59. **Azziz R.** Hyperandrogenism and the hirsute patient. International Hair Route February 2000, issue 82, p.9
60. **Azziz R.** Hirsutism, in Sciarra JJ, Dilts PV, eds. Gynecology and Obstetrics: Endocrinology, infertility, genetics. Lippincott-Raven Pub., Philadelphia, PA, 2000.
61. Sanchez LA, **Azziz R.** Complications of pelvic adhesions. The Female Patient 25:70-76, 2000.
62. **Azziz R.** Polycystic ovary syndrome in adolescents. Clinical Update Pediatric Endocrinology 3(4), 2000.

63. Azziz R, DeCherney A, Steege J, Tulandi T. Is surgery a viable treatment for or a neglected cause of infertility and pelvic pain? Issues in Reproductive Medicine. American Society for Reproductive, 2001.
64. **Azziz R.** Adrenal androgen excess in the polycystic ovary syndrome, in Chang J, Heindel JJ, Dunaif AD, eds. Polycystic Ovary Syndrome. Marcel Dekker, Inc., New York, 2002, pp.77-87.
65. **Azziz R.** Book review: Physiology and pathology of adrenal disorders. Trends in Endocrinology and Metabolism 13:135-6, 2002.
66. **Azziz R.** Advances in the evaluation and treatment of hirsutism. Contemp Ob Gyn 47:98-106, 2002.
67. **Ovalle F, Azziz R.** Exploring the relationship between the polycystic ovary syndrome and type 2 diabetes mellitus. Références en Gynécologie Obstétrique 9:29-33, 2002.
68. **Azziz R, Petricca T.** Electrology and the hirsute polycystic ovary syndrome patient. J Electrology. 17:2-12, 2002.
69. **Azziz R.** PCOS and normal menses: Another point of view. Contemp Ob Gyn 48:53-64, 2003.
70. **Azziz R.** Chief complaint: Hirsutism, in Phelan ST, Chiang S, eds. Clerkship Series-Solving Patient Problems: Obstetrics and Gynecology, Hayes Barton Press, Raleigh, NC, 2003; pp.145-163.
71. Legro RS, **Azziz R.** Androgen excess disorders, in Danforth DN, Gibbs RS, Karlan BY, Haney AF, eds. Danforth's Obstetrics and Gynecology-9th edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2003; pp. 663-683.
72. **Azziz R.** 21-Hydroxylase deficient non-classic adrenal hyperplasia: Screening, diagnosis, and treatment. Revista Argentina de Endocrinología y Metabolismo 40 (Suppl):9-13, 2003
73. **Azziz R.** Differential diagnosis and evaluation of hyperandrogenism, in Hall JE, Neiman LK, eds. Handbook of diagnostic endocrinology. Humana Press, Totowa, New Jersey, 2003, pp. 323-330.
74. **Azziz R.** Role of hyperinsulinism in the pathophysiology and treatment of PCOS: A critical assessment. Revista Argentina de Endocrinología y Metabolismo 40 (Suppl):72-75, 2003.
75. Chang W, **Azziz R.** Diagnostic Evaluation and Treatment of the Infertile Couple, in Carr B, Blackwell RE, Azziz R, eds. Essential Reproductive Endocrinology. McGraw-Hill Publishers, New York, NY, 2004; pp. 359-392.
76. Kumar A, Agarwal S, **Azziz R.** Tubal Disorders, in Carr B, Blackwell RE, Azziz R, eds. Essential Reproductive Endocrinology. McGraw-Hill Publishers, New York, NY, 2004; pp.517-534.
77. **Azziz R.** Androgen excess, Hirsutism, and the Polycystic Ovary Syndrome, in Carr B, Blackwell RE, Azziz R, eds. Essential Reproductive Endocrinology. McGraw-Hill Publishers, New York, NY, 2004; pp. 295-329.
78. Magoffin DA, Yildiz BO, Kumar A, **Azziz R.** Endocrinology of the Ovary, in Melmed S, Conn PM, eds. Endocrinology: Basic and Clinical Concepts- 2<sup>nd</sup> Edition. Humana Press, Totowa, NJ 2005, pp. 391-403.
79. Marin DeUgarte C, Chen I, **Azziz R.** What's the best way to diagnose insulin resistance and hyperinsulinemia? Contemp Ob Gyn, March, 2005, pp. 66-74.
80. **Azziz R.** *A Brief History of Androgen Excess*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 1-16.
81. Dewailly D, **Azziz R.** *The non-classic adrenal hyperplasias*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 91-106.
82. Moller DE, Vidal-Puig A, **Azziz R.** *Severe insulin-resistant hyperandrogenic syndromes*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006; pp. 129-138.
83. **Azziz R.** *Definition and epidemiology of the Polycystic Ovary Syndrome*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 145-154.

84. Futterweit W, Diamanti-Kandarkis E, **Azziz R.** *Clinical features of the Polycystic Ovary Syndrome*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 155-168.
85. Yildiz BO, Carmina E, **Azziz R.** *Hypothalamic-pituitary-adrenal dysfunction in the Polycystic Ovary Syndrome*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 213-222.
86. **Azziz R.** *Overview of long-term morbidity and economic cost of the Polycystic Ovary Syndrome*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 353-362.
87. **Azziz R.** *Clinical and hormonal evaluation of androgen excess*, in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 365-376.
88. Yildiz BO, **Azziz R.** *The polycystic ovary syndrome and ovulation induction*. in Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006, pp. 389-404.
89. **Azziz R.** *Polycystic ovary syndrome: insulin resistance and use of insulin sensitizers*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 217-219.
90. **Azziz R.** *Hirsutism*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 210-214.
91. **Azziz R.** *21-Hydroxylase deficient non-classic adrenal hyperplasia*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 214-216.
92. **Azziz R.** *Laparoscopic complications: Prediction and avoidance*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 177-179.
93. **Azziz R.** *Uterine anomaly*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 253-255.
94. **Azziz R.** *Gonadal dysgenesis: Turner's syndrome*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 227-230.
95. **Azziz R.** *Chronic pelvic pain: Causes*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 37-39.
96. **Azziz R.** *Cushing's Syndrome: Diagnostic evaluation*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2007, pp. 223-2226.
97. **Azziz R.** *Adenomyosis*, in Azziz R, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Scientific, New York, NY, 2006:159-162.
98. Yildiz BO, **Azziz R.** *Adrenocortical dysfunction in the polycystic ovary syndrome*, in Kovacs GT, Norman R, eds. Polycystic Ovary Syndrome-2<sup>nd</sup> Edition. Cambridge University Press, Cambridge, UK, 2007:288-315.
99. Chang WY, **Azziz R.** *Pathogenesis of hyperandrogenism in PCOS*, in Dunaif A, Chang RJ, Franks S, Legro RS, eds. From the ovary to the pancreas: Current Concepts and Controversies in the Polycystic Ovary Syndrome - Contemporary Endocrinology Series, Humana Press New York, NY 2007.
100. **Azziz R.** *Definition, diagnosis, and epidemiology of PCOS*, in **Azziz R**, ed. The Polycystic Ovary Syndrome: Currents Concepts on Pathogenesis and Clinical Practice. Springer, New York, 2007:1-15.
101. **Azziz R.** *Long-term morbidity of PCOS*, in **Azziz R**, ed. The Polycystic Ovary Syndrome: Currents Concepts on Pathogenesis and Clinical Practice. Springer, New York, 2007:117-129.
102. **Azziz R.** *Evaluation for insulin resistance and co-morbidities related to insulin resistance in PCOS*, in Nestler JE, Diamanti-Kandarakis E, Pasquali R, Panidis D, eds. Insulin Resistance and

Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment. Human Press, New York, 2007:145-157.

103. **Azziz R**. Hirsutism, in Goldman L, Ausiello D, eds, Cecil Medicine-23<sup>rd</sup> Edition. Saunders-Elsevier, New York, 2008:1853-1857.
104. Trivax B, **Azziz R**. The diagnosis of polycystic ovary syndrome. EndoTrends: Endocrine Fellows Foundation 14(2), 2007:4-7.
105. Trivax B, **Azziz R**. An update on the Polycystic Ovary Syndrome. US Endocrine Disease 2007. Touch Briefings: London, 2007:84-86.
106. **Azziz R**, Sánchez LA, Pérez Figueroa M. *Mecanismos fisiopatológicos de la resistencia a la insulina*, in Lopez HV, ed. Síndrome de ovario poliquístico, 2007:91-98
107. Pisarska MD, Alexander CJ, **Azziz R**, Buyalos RP Jr. *Chapter 31-Puberty and Disorders of Pubertal Development*. In, Hacker NF, Gambone JC, Hobel CJ, eds. Hacker and Moore's Essentials of Obstetrics and Gynecology-5<sup>th</sup> Edition, W. B. Saunders Company, 2010: 345-354.
108. Alexander CJ, Mathur R, Laufer LR, **Azziz R**. *Chapter 32-Amenorrhea, Oligomenorrhea, and Hyperandrogenic Disorders*. In, Hacker NF, Gambone JC, Hobel CJ, eds. Hacker and Moore's Essentials of Obstetrics and Gynecology-5<sup>th</sup> Edition, W. B. Saunders Company, 2010:355-367.
109. **Azziz R** (interview with Rona Williamson). Polycystic ovary syndrome, microbiomics and why you should be a little selfish with your time. Expert Rev Endocrinol Metab 8 (4): 329-331,2013.
110. **Azziz R**. Addressing practice gaps in PCOS. Endocrine Today (in press).

#### **PUBLICATIONS - Books:**

1. **Azziz R**, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy. Springer-Verlag, New York, NY, 1992
2. **Azziz R**, Murphy AA, eds. Practical Manual of Operative Laparoscopy and Hysteroscopy - Second Edition. Springer-Verlag, New York, NY, 1997 (also translated to Chinese).
3. **Azziz R**, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Lippincott-Raven Publishers, Philadelphia, Pa, 1997
4. Carr B, Blackwell RE, **Azziz R**, eds. Essential Reproductive Endocrinology. McGraw-Hill Publishers, New York, NY, 2004
5. **Azziz R**, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women - Second Edition. Humana Press, Totowa, NJ, 2006
6. Giudice LC, Legro RS, **Azziz R**, eds. Polycystic Ovary Syndrome and Hyperandrogenism, Best Practice & Research-Clinical Endocrinology & Metabolism, Vol. 20, number 2, Elsevier Pub., June, 2006
7. **Azziz R**, ed. Obstetrics & Gynecology: Cases, Questions, and Answers. McGraw-Hill Medical, New York, NY, 2007
8. **Azziz R**, ed. The Polycystic Ovary Syndrome: Currents Concepts On Pathogenesis And Clinical Practice. Springer, New York, NY, 2007
9. Cundiff G, **Azziz R**, Bristow R, eds. Te Linde's Atlas of Gynecologic Surgery. Lippincott Williams & Wilkins, Philadelphia, PA, 2013



## **BLOGS/COMMENTARIES:**

1. **'Sculpting in Clay'** (<http://azziz.gru.edu/>); *thoughts on leadership, management, transformation, academia, and healthcare, directed to the GRU community and its various stakeholders:*
  - A History of Nearly Identical Twins, 11/19/2010
  - Reveling in our diversity, embracing our commonality, 1/20/2011
  - The Power and Price of Information, 1/25/2011
  - Giving Shape to New Ideas: Sculpting in Clay, 2/8/2011
  - Closing the Loop: Getting it Done, 2/14/2011
  - Throwing a Pebble into a Tar Pit: The Challenges of Communicating in Large, Complex Heterogeneous and Transforming Enterprise, 3/1/2011
  - GHSU and the Community: A 2-Way Street, 3/15/2011
  - Recruiting New Talent: Ensuring a Strong and Vibrant Work Force, 3/21/2011
  - Retaining Great Employees: Creating an Open, Productive Work Environment, 3/31/2011
  - What has Surprised Me: The Loyalty and Dedication of GHSU Employees, 4/11/2011
  - The Masters Golf Tournament: A Model for Customer Service in our Community, 4/18/2011
  - Going Green, 4/21/2011
  - The Cost of Administration: Setting the Record Straight, 5/2/2011
  - 1 in 5: The Importance of Volunteerism, 5/19/2011
  - Embracing the Cool Factor, 6/9/2011
  - Our Values: Our Compass, 6/26/2011
  - Our Competitors: Ensuring our Competitiveness, 7/6/2011
  - Georgia Health Sciences University: Serving Both Georgias, 7/13/2011
  - Too Fast, Too Slow: Setting the Pace for Transformation, 7/22/2011
  - Progress versus Perfection: Revisiting Sculpting in Clay, 7/29/2011
  - Leading in Patient and Family Centered Care: Making a Difference, 8/5/2011
  - Visiting Far, Far Away (Part I): Learning of Transformation and our Forefathers, 8/19/2011
  - Visiting Far, Far Away (Part II): Learning of Transformation and What Makes a City Cool, 9/5/2011
  - Thoughts on Diversity and Inclusion During National Hispanic Heritage Month, 9/29/2011
  - Clinical and Translational Research: What Is It, And Why Should We Care? 10/6/2011
  - A Tragedy in Two Acts: The Power of Zero Tolerance and Reflex Action, 11/11/2011
  - How Do You Hide a Giant? 12/5/2011
  - On Being a Patient: Hyperacute, Hypersensitive, Hypercritical, 12/29/2011
  - Growing Small Business Through Big Business: Fostering the Growth of Academic Health Centers and Universities, 1/20/2011
  - The Consolidation of ASU and GHSU: A Bold Future-Oriented Move, 2/4/2012
  - The Challenges of Listening, 2/27/2012
  - Our New Consolidated University: Why is it Going to be a Research University and What Does That Mean? 3/9/2012
  - In Search of Thoughtful People: Educating for Thoughtfulness, 3/23/2012
  - What's in a Name? Naming our New University, 4/20/2012
  - What Will Change? The Consolidation of ASU and GHSU, 5/1/2012
  - Leveraging the Outsider: New Solutions to Old Problems, 5/16/2012

- Calculating Economic Impact: Not So Simple, 5/31/2012
- A University Education: How Much is it Worth? 7/10/2012
- Deconstructing the University: The Work of the Consolidation Work Teams, 7/31/2012
- New Name for New U: The Facts, 8/13/2012
- Building Bridges and Strengthening the Health Care Community in Augusta, 8/28/2012
- Of Promise, Journey, Legacy, and Gratitude: Family Day at our University, 9/11/2012
- A Flattening World: Wire from the Far East (Part I), 9/27/2012
- A Flattening World: Wire from the Far East (Part II), 10/3/2012
- Brand Name vs. Name: What's the Difference? 10/25/2012
- Growing up in an Upside-Down World, 10/31/2012
- Can we Maintain Access at a Research University?: The Case of the ASU-GHSU Consolidation (Part I), 11/15/2012
- Can we Maintain Access at a Research University?: The Case of the ASU-GHSU Consolidation (Part II), 11/28/2012
- Can we Maintain Access at a Research University?: The Case of the ASU-GHSU Consolidation (Part III), 12/10/2012
- Interdisciplinary and Transdisciplinary Units: What are they and why do we need them? 12/27/2012
- Watching out for Post-Consolidation Blues: Too Fast, Too Slow Revisited, 2/13/2013
- Academic Medical Centers: Why They Matter To the University, 2/27/2013
- One Man's Strategy is Another Man's Tactic: The Importance of Understanding What Strategy Is and Is Not, 3/21/2013
- On Strategic Thinking, 4/2/13
- Immigration – Ensuring America's competitiveness, 4/26/13
- Listening tour common questions: if we are now a research university how am i (the faculty) supposed to start doing research?, 5/28/13
- Listening tour common questions: If we are supposed to grow, how do we do it if there is no money?, 6/11/13
- Listening Tour Common Questions: As A University, What Are We Going To Look Like?, 7/29/13
- The Reverend Martin Luther King Jr. Had a Dream of Freedom and Opportunity For All: His Legacy to Our Hispanic Students, 8/28/13
- In The Aftermath Of Terror, 9/11/13
- GRU SACS Review Success. Why Does It Matter? And Now What?, 9/26/13
- GRU: Partnering with Georgia's Rural Communities, 10/21/13
- Where are all our future students?, 11/20/13
- When there is no magic bullet, 2/3/14
- Adding value with Shared Services, 2/27/14
- East Meets West at Georgia Regents University, 3/20/14
- Aspiring to Greatness at GRU: How far we have come and where we are heading, 4/16/14
- A Tale of two Consolidations, 5/12/14
- What I Miss Most, 6/27/14
- Discover What's Next: A Campus Culture for Student Success, 8/12/14

2. **Huffington Post** (<http://www.huffingtonpost.com/dr-ricardo-azziz/>); *thoughts on leadership and change management:*

- The Power and Price of Information, 11/6/2012
- Giving Shape to New Ideas: Sculpting in Clay, 11/8/2012

- Meeting the Challenges of Communicating in a Large, Complex, Heterogenous Enterprise, 2/25/2013
- Recruiting New Talent: Ensuring a Strong and Vibrant Work Force, 3/11/2013
- The Resignation of the Pope: Knowing When It's Time to Take a Different Role, 3/14/2013
- The Critical Art of Storytelling, 4/15/13
- Retaining Great Employees, 4/22/13
- Competitors and Competitiveness, 5/6/13
- Too Fast, Too Slow: The Challenge of Keeping Pace in Managing Change, 5/30/13
- Keeping Up Our Guard Against Terrorism -- and Its Corrupting Impact On Our Collective and Individual Psyche, 6/26/13
- In Search of Thoughtful People: Educating for Thoughtfulness, 9/10/13
- A Call to Arms: Academe Must Meet Demands of Downsizing Military, 10/2/13
- Don't Leave History in the Past, 11/26/13
- The Great Debate: Is College Still Worth It?, 1/9/14
- A Looming Challenge in Higher Education: Our Changing Student, 2/26/14
- The Trust Equation: A Critical Element for Building a High-Performing Team, 3/18/14
- Back to the Future: Why Is the Diversity of University Leadership Stuck in the '80s?, 4/24/14
- Is Shop Class the Answer?, 5/30/14
- Don't Underestimate the Millennials, 6/19/14
- The Myth of the Rational Health Care Consumer, 8/28/14

## **VISUAL ARTS**

In addition to his scientific, clinical and administrative roles, Dr. Azziz also serves as Professor of Medical Humanities in the Art Department at GRU, and has been producing works of visual art since the early '70s, with group and solo exhibitions. For a sampling of his work visit [www.razzizstudio.com](http://www.razzizstudio.com)

### **Selected art exhibitions:**

- 1992 - Group exhibition, Birmingham Art Association Semi-annual Members Exhibit, Birmingham, AL
- 1992 - Group exhibition, One Dome '92-Recent Works by Nine Artists, Birmingham Art Association, Birmingham, AL
- 2010 - Solo exhibition, Cedars-Sinai Medical Center Library, Los Angeles, CA
- 2010 - Individual exhibition 'Two Men In A Hangar' (with Craig Deman), personal art studio, Santa Monica, CA
- 2013 - Solo exhibition 'This Is Not A Pear In Cleveland: Works by Ricardo Azziz', Firehouse Gallery, Louisville, GA (<http://vimeo.com/77059884>)

### **Selected art-related publications:**

- Heneidi S, Bertolotto C, Chazenbalk G, Simmons C, **Azziz R**. Cover art–Year 2010. Nature Reviews-Endocrinology, Vol 6 (all issues) <http://www.nature.com/nrendo/journal/v6/n1/index.html>
- **Azziz R**. 'This Is Not A Pear In Cleveland - Ricardo Azziz 1983-2013: Thirty Years of Works On Paper', 2013
- **Azziz R**. Cover art. Acad Med April 2014 - Volume 89 - Issue 4.

## **PUBLICATIONS – Abstracts:**

1. **Azziz R**, Smith S, Fabro S. Antenatal detection of IUGR: The value of symphysial-fundal height measurements. District IV ACOG Annual Clinical Meeting, Baltimore, MD, 1985.
2. **Azziz R**, Mulaikal RM, Migeon CJ, Jones Jr HW, Rock JA. Congenital adrenal hyperplasia: Long-term results following vaginal reconstruction. Society of Reproductive Surgeons, American Fertility Society, 1986, No. 129.
3. **Azziz R**, Huth J, Zacur H. Reproducibility of bolus 1-24 ACTH stimulation test. American Fertility Society, 1987, No. 207.
4. **Azziz R**, Huth J, Boots L, Parker Jr CR, Bradley E, Zacur HA. Comparison of adrenal stimulation by 1 mg or 0.25 mg 1-24 ACTH: 21-hydroxylase (21-H), 11 $\beta$ -hydroxylase (11-H), 17/20-desmolase (17/20-D) and 3 $\beta$ -hydroxysteroid dehydrogenase (3HSD) activity. Society for Gynecological Investigation, 1988, No. 391.
5. Durmusoglu F, Smith BR, Huth J, **Azziz R**, Zacur HA. Effects of acute ACTH 1-24 documentation on serum determining hormone (LH) and prolactin (PRL) in healthy and anovulatory women. American Fertility Society, 1988, No. 0-44.
6. **Azziz R**, Markham S, Huth J, Smith B, Zacur HA. Long-term follow-up of hyperandrogenic women with adrenal 21-hydroxylase deficiency. American Fertility Society, 1988, No. P-144.
7. **Azziz R**, Rafi A, Smith B, Bradley E, Zacur HA. Acute adrenal stimulation test for the detection of 21-hydroxylase deficiency in hyperandrogenic women. American Fertility Society, 1988, No. P-137.
8. **Azziz R**, Steinkampf MP, Murphy A. Recovery time following diagnostic and operative laparoscopy. American Association of Gynecologic Laparoscopists, 1988.
9. Wells G, **Azziz R**, Hodge TW. Use of polymerase chain reaction (PCR) for the amplification of the 21-hydroxylase gene in late onset congenital adrenal hyperplasia (LOCAH). Society for Gynecologic Investigation, 1989, No. 305.
10. Wells G, **Azziz R**, Acton Jr RT, Zacur HA. Pseudogene/functional-gene ratios in 21-hydroxylase deficient late onset congenital adrenal hyperplasia (LOCAH). Society for Gynecologic Investigation, 1989, No. 427.
11. **Azziz R**, Boots L, Parker Jr CR, Bradley E, Zacur HA. 11-Hydroxylase (11-OH) deficiency in hyperandrogenism. American Fertility Society, 1989, No. P-159.
12. Steinkampf MP, Hammond KR, Blackwell RE, Younger JB, **Azziz R**. The vanishing fetus in multiple pregnancy: early diagnosis by transvaginal sonography. American Fertility Society, 1989, No. P-181.
13. Gay FL, Boots LR, **Azziz R**. The effects of prolonged testosterone administration on adrenocortical biosynthesis. Society for Gynecologic Investigation, 1990, No. 33.
14. Parker Jr CR, **Azziz R**, Boots L, Favor J, Clifton J. 11 OH-Androstenedione (11 OH-A): Development of an analytical method and assessment of serum 11 OH-A as a marker of adrenal androgen production. Society for Gynecologic Investigation, 1990.
15. Wells G, Zacur HA, **Azziz R**. 21-hydroxylase gene ratio abnormalities in hyperandrogenic women with mildly abnormal 17-hydroxyprogesterone response to adrenal stimulation. The Endocrine Society, 1990, No. 425.
16. **Azziz R**, Murphy AG. Long-acting GnRH analog treatment of severe hyperandrogenism associated with insulin resistance and acanthosis nigricans. American Fertility Society, 1990, No. P-079.
17. Boots LR, Potter HD, **Azziz R**. Differential binding of estradiol (E<sub>2</sub>) and testosterone (T) to sex-hormone binding globulin (SHBG) in relation to circulating E<sub>2</sub> levels. American Fertility Society, 1990, No. P-069.

18. Diamond MP, **Azziz R**, Cohen S, Curole DN, Franklin RR, Haney, AF, Malinak LR, Maxson WS, Patton GW, Rock JA, Rosenberg S, Webster BW, Yuzpe AA. Reduction of adhesion reformation following adhesiolysis at laparotomy by Interceed® (TC7): Final report of the Interceed® (TC7) adhesion barrier study group. Second Joint Meeting of the European Society of Human Reproduction and Embryology and the European Sterility Congress Organization, 1990. No. 161.
19. **Azziz R**, Murphy AA, Rosenberg SM, Patton Jr GW. Use of Interceed® (TC7) absorbable adhesion barrier at laparoscopy. American Association of Gynecologic Laparoscopists, 1990.
20. **Azziz R**, Wells G, Acton Jr RT. Concordance of 21-hydroxylase (21-OH) gene ratio, HLA-typing and adrenal testing results in a family with late-inset adrenal hyperplasia (LOAH). Society for Gynecologic Investigation, 1991, No. 168.
21. **Azziz R**, Bradley Jr EL, Potter HD, Boots LR. Deficient 3 $\beta$ -hydroxysteroid dehydrogenase (3 $\beta$ -HSD) activity in hyperandrogenism. Society for Gynecologic Investigation, 1991, No. 167.
22. Buyalos RP, Zacur A, Judd HL, **Azziz R**. No effect of two hour oral glucose tolerance test (OGTT) on serum dehydroepiandrosterone-sulfate (DHS) in women with obesity or polycystic ovarian syndrome (PCOS). Society for Gynecologic Investigation, 1991.
23. Buyalos RP, Funari VA, **Azziz R**, Watson JM, Martinez-Maza O. Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Society for Gynecologic Investigation, 1991. No. 120.
24. **Azziz R**, Bradley Jr EL, Boots LR. Effect of weight loss on adrenocortical steroidogenesis. The Endocrine Society, 1991.
25. **Azziz R**, Potter HD, Bradley Jr EL, Boots LR. Differential binding of sex-hormone binding globulin (SHBG) to estradiol (E<sub>2</sub>) and testosterone (T) in relation to circulating T levels. The American Fertility Society, 1991, No. O-053.
26. **Azziz R**, Potter HD, Bradley Jr EL, Boots LR. Androstenediol (ADIOL) in healthy eumenorrheic women: Relationship to body mass and hormonal profile. Society for Gynecologic Investigation, 1992, No. 367.
27. **Azziz R**, Bradley Jr EL, Parker Jr, CR, Boots LR. Adrenocortical hyperactivity in hyperandrogenism: The role of 17-hydroxylase (17-OH) and 17,20-desmolase (17,20-D) dysfunction. Society for Gynecologic Investigation, 1992, No. 622.
28. **Azziz R**, Boots LR, Bradley Jr EL. Adrenal androgens in hyperinsulinemic hyperandrogenic women. The Endocrine Society, 1992, No. 844.
29. Owerbach D, Ballard AL, **Azziz R**. Pro-453 to ser mutation in CYP21 is associated with nonclassic 21-hydroxylase deficiency. The Endocrine Society, 1992, No. 563.
30. **Azziz R**, Murphy AG. The hyperandrogenic-insulin resistant-acanthosis nigricans (HAIRAN) syndrome: Therapeutic response. The American Fertility Society, 1992, No. P-104.
31. Koulianos GT, Witt BR, Wolf GC, **Azziz R**, Thorneycroft IH. Adrenal androgen production in menopausal women before and after estrogen replacement therapy (ERT). The American Fertility Society, 1992, No. P-105.
32. Boots L, Potter HD, **Azziz R**. Critical factors in the assessment of hyper-androgenic syndromes in women. The Annual Meeting of The Alabama Academy of Science, 1992.
33. Boots L, Boots B, Potter HD, **Azziz R**. Development of androstenediol and 11-hydroxy-androstenedione assays for the study of hyperandrogenic syndromes. The Annual Meeting of the Alabama Academy of Science, 1992.
34. Moller DE, Cohen O, Yamaguchi Y, **Azziz R**, Eberle A, Flier JS. Prevalence of insulin receptor mutations in insulin resistant women with ovarian hyperandrogenism and acanthosis nigricans. The American Federation of Clinical Research, 1993.
35. Owerbach D, **Azziz R**. Molecular abnormalities of the 21-hydroxylase (21-OH) gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone (17-HP) response to acute adrenal stimulation. The Endocrine Society, 1993, No. P-1385.

36. **Azziz R**, Bradley Jr EL, Zacur HA, Parker Jr CR, Boots LR. Adrenocortical secretion of dehydroepiandrosterone (DHA) in healthy women: Variable sensitivity to ACTH. The Endocrine Society, 1993, No. O-1606.
37. **Azziz R**, Varner RE, Younger JB. Training in an Ob/Gyn residency: A first step toward credentialing in operative endoscopy. CREOG/APGO Annual Meeting, 1993.
38. **Azziz R**, Deal CL, Potter HD, Gargosky S, Rosenfeld RG. Regulation of extra-gonadal insulin like growth factor binding protein-3 by testosterone. Society for Gynecologic Investigation, 1994, No. P-14.
39. **Azziz R**, Johrer K, Pascoe L, White PC. Gene analysis in presumed 11 $\beta$ -hydroxylase (11-OH) deficient nonclassic adrenal hyperplasia (NCAH). The Endocrine Society, 1994. No. 812.
40. **Azziz R**, Potter HD, Parker Jr CR. Relative adrenocortical sensitivity and responsivity of dehydroepiandrosterone (DA), androstenedione (A4), and cortisol (F) to ACTH-(1-24) in healthy men. The Endocrine Society, 1994. No. 97, p. 225.
41. Allen SE, Potter HD, Naumann RW, **Azziz R**. Incidence of occult hyperandrogenemia in non-hirsute oligo-ovulatory women. American Fertility Society, 1994, No. O-133.
42. Ochoa TM, **Azziz R**. Comparison of three methods for measuring hair growth response to treatment in hirsutism. Society for Gynecological Investigation, 1995, No. P-368.
43. Kahsar MD, Sager LD, Boots LR, **Azziz R**. Inheritance patterns in women with familial hirsutism/oligomenorrhea. Society for Gynecological Investigation, 1995, No. P-367.
44. Boots LR, Potter HD, **Azziz R**. Chromatographic separation of four steroids from the same serum sample in studies of hyperandrogenic patients. Alabama Academy of Sciences, 1995.
45. **Azziz R**, Dewailly D, Zacur HA, Bradley Jr. EL, Potter HD, Boots LR. Testing for 21-hydroxylase (21-OH) deficiency should precede the evaluation of 3 $\beta$ -hydroxysteroid (3 $\beta$ -HSD) deficiency. The Endocrine Society, 1995, P2-69.
46. Boots LR, **Azziz R**, Potter S, Potter HD. Measurement of total serum testosterone (T) level in women: High degree of variability and inaccuracy among commercial assays. The Endocrine Society, 1995, P2-77.
47. Stahl E, **Azziz R**. Prevalence of hirsutism, acne and/or oligomenorrhea among relatives of patients with hyperandrogenic oligomenorrhea. The Endocrine Society, 1995, P2-82.
48. Gunnala S, Clements L, **Azziz R**. Excessive preovulatory adrenocortical secretion of progesterone (P4) in 21-hydroxylase (21-OH) deficient salt-wasting classic adrenal hyperplasia (SW-CAH): No effect on oocyte quality or fertilizability. The American Reproductive Medicine Society, O-086, 1995.
49. Knochenhauer ES, Potter HD, Lazenby AJ, **Azziz R**. Is heterozygosity for 21-hydroxylase (21-OH) deficient classic (CAH) adrenal hyperplasia a risk factor for hyperandrogenism? The American Reproductive Medicine Society, O-087, 1995.
50. Kahsar-Miller MD, Boots LR, **Azziz R**. Inheritance patterns in women with familial hirsutism/oligomenorrhea. Society for Gynecologic Investigation, 1996, No. P-202.
51. **Azziz R**, Rittmaster RS, Fox LM, Bradley Jr EL, Potter HD, Boots LR. Changes in dehydroepiandrosterone (DHA) sulfate (DHS) levels during ovarian suppression of hyperandrogenic women do not reflect alterations in the ACTH-stimulated secretion of DHA. The Endocrine Society, 1996, P3-550.
52. **Azziz R**, Carmina E, Dewailly D, Fruzzetti F, Marcondes JAM, Mendonca BB, Speiser PW, Zacur HA. The risk of delivering a child with classic 21-hydroxylase (21-OH) deficient adrenal hyperplasia (CAH) among women with non-classic adrenal hyperplasia (NCAH): a multicenter study. The Endocrine Society, 1996, P2-656.
53. **Azziz R**, Grice JE, Jackson RV, Hockings SI, Thorpy DJ, Fox LM, Boots LR. Androgen response to hypothalamic-pituitary-adrenal stimulation with Naloxone in patients with myotonic muscular dystrophy (DM). The Endocrine Society, 1996, P3-551.

54. **Azziz R**, Dewailly D, Cortet-Rudelli C, Fox LM, Bradley Jr EL, Boots LR. 11 $\beta$ -Hydroxylase (11-OH) activity is not exaggerated in 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). The Endocrine Society, 1996, P3-552.
55. Cortet-Rudelli C, Knochenhauer ES, Cunningham RD, Boots LR, Dewailly D, **Azziz R**. Heterozygosity for 21-hydroxylase (21-OH) deficient classic adrenal hyperplasia (CAH) may be a risk factor for hyperandrogenism. The Endocrine Society, 1996, OR-26-7.
56. Falany CN, **Azziz R**. Regulation of estrogen activity in human endometrium by sulfation. XIth International Symposium on Microsomes and Drug Oxidations, July 21-24, 1996, Los Angeles, CA.
57. Boots LR, Potter HD, **Azziz R**. Development of specific assays for 11 $\beta$ -hydroxyandrostenedione (11-ADIONE) and 5-androstene-3 $\beta$ -17 $\beta$ -diol (ADIOL) for the study of hyperandrogenic patients. The Endocrine Society, 1996, P2-661.
58. Parker Jr CR, Potter HD, Azziz R. Effects of aging on adrenal androgen production in men: Interim analysis. International Adrenal Cortex Conference, Scotland, UK, 1996.
59. Slayden SM, Sams Jr WM, **Azziz R**. Hyperandrogenemia (HA) is a frequent cause of acne, regardless of age of presentation. Proceedings of the 52nd Annual Meeting of the American Society for Reproductive Medicine, November 2-6, 1996, O-090, p. S46.
60. Kahsar-Miller MD, Boots LR, **Azziz R**. Clinical and biochemical indicators of androgen excess in family members of patients with hyperandrogenism. American Society of Human Genetics, 1996.
61. Slayden SM, Crabbe L, Potter HD, **Azziz R**, Parker Jr CR. Adrenal androgen production in women: Effects of age and race. Proceedings of 1997 Society for Gynecologic Investigation Annual Meeting - Abstract #103, in J Soc Gynecol Invest 4 (Supplement):104A, 1997.
62. **Azziz R**, Black VY, Hines GA, Downing HD, Bradley E Jr, Boots LR. The polycystic ovary syndrome (PCOS): Sensitivity and responsivity to ACTH-(1-24) and ovine corticotropin releasing hormone (CRH) stimulation in patients with and without excess dehydroepiandrosterone sulfate (DHS). The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997, P1-348.
63. Kahsar-Miller MD, Boots LR, **Azziz R**. Molecular analysis of CYP17 in polycystic ovary syndrome (PCOS) patients with and without adrenal androgen (AA) excess. The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997, P1-349.
64. Hines GA, **Azziz R**. Comparison of three different types of adrenal tissue preparations: Impact on dehydroepiandrosterone (DHA), DHA sulfate (DHS), androstenedione (A4) and cortisol (F) production. The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997, P2-112.
65. Hines GA, **Azziz R**. Influence of 5 $\alpha$ -dihydrotestosterone (DHT) and insulin on adrenal steroidogenesis *in vitro*. The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, P2-111.
66. Knochenhauer ES, Kahsar-Miller MD, Boots LR, Key TJ, **Azziz R**. Prevalence of hirsutism among unselected Black and Caucasian women in the southeastern United States (U.S.). The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997, P1-357.
67. Knochenhauer ES, Waggoner WT, **Azziz R**, Carmina E, Dewailly D, Fruzzetti F, Ibanez L, Marcondes JAM, Mendonca BB, Rohmer V, Speiser PW, Zacur HA. Clinical features and genotype of 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH): A multicenter study. The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997, P1-358.
68. Parker CR Jr, Slayden S, Crabbe L, **Azziz R**, Black V, Potter HD. Adrenal androgen production in aging men: Evidence suggestive of relatively enhanced 3 $\beta$ -hydroxysteroid dehydrogenase activity. The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11-14, 1997, P1-404.

69. **Azziz R**, Knochenhauer ES. Evaluation of infertility: A cost effective approach. 10th World Congress on In Vitro Fertilization and Assisted Reproduction, Vancouver, Canada; PS-15-3; J Assisted Reprod Genet 14:24S, 1997.
70. **Azziz R**. Is ART the best treatment for infertile couples: Not [always] so!. 10th World Congress on In Vitro Fertilization and Assisted Reproduction, Vancouver, Canada; PS-26-5. J Assisted Reprod Genet 14:39S, 1997.
71. **Azziz R**, Ochoa T. Idiopathic hirsutism (IH): An uncommon cause of hirsutism in Alabama. American Society for Reproductive Medicine, 1997:S128, P-075 .
72. Knochenhauer ES, Decanter C, Cortet-Rudeli C, Weil J, Waggoner WT, Conway-Myers BA, Dewailly D, **Azziz R**. Genotype and phenotype in women with 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). American Society for Reproductive Medicine, 1997:S39, O-078.
73. Slayden S, Crabbe L, Black V, Potter HD, **Azziz R**, Parker Jr CR. Sensitivity and responsiveness to ACTH of adrenal secretion of dehydroepiandrosterone (DHEA) and cortisol in aging women. Society for Gynecologic Investigation, March 11-14, 1998; F240, in J Soc Gynecol Invest 5 (Supplement):98A, 1998.
74. Morán C, Bradley Jr EL, Zacur HA, Boots LR, **Azziz R**. Excess dehydroepiandrosterone sulfate in hyperandrogenism is not simply an exaggeration of adrenocortical androgen secretion. 80th Annual Meeting of Endocrine Society, New Orleans, June 24-27, 1998; P1-379.
75. Farah L, Lazenby J, Boots LR, **Azziz R**, and the Birmingham Electrology Study Group. Prevalence of hyperandrogenism (HA) and the polycystic ovary syndrome (PCOS) among clients seeking electrology care. 80th Annual Meeting of Endocrine Society, New Orleans, June 24-27, 1998; P1-359.
76. Waggoner W, **Azziz R**. Total testosterone (T) and dehydroepiandrosterone sulfate (DHEAS) levels as predictors of androgen-secreting neoplasms: A populational study. 80th Annual Meeting of Endocrine Society, New Orleans, June 24-27, 1998; P1-353.
77. **Azziz R**, Hincapie LA, Conway-Myers B-A, Knochenhauer ES, Fox L, Dewailly D, Cortet-Rudelli C, Boots LR. Screening for 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH) in hyperandrogenic (HA) women: A prospective study. 80th Annual Meeting of Endocrine Society, New Orleans, June 24-27, 1998; OR03-6.
78. Moran C, Potter HD, Potter S, Boots LR, **Azziz R**. High levels of dehydroepiandrosterone sulfate (DHEAS) in hyperandrogenic (HA) women are not predictive of 3 $\beta$ -hydroxysteroid dehydrogenase (3 $\beta$ -HSD) non-classic adrenal hyperplasia (NCAH). 80th Annual Meeting of Endocrine Society, New Orleans, June 24-27, 1998; P1-368.
79. Knochenhauer ES, Decanter C, Cortet-Rudelli C, Morel Y, Conway-Myers B-A, Dewailly D, **Azziz R**. Genotype in women with 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). 80th Annual Meeting of Endocrine Society, New Orleans, June 24-27, 1998; P1-369.
80. Parker CR, **Azziz R**, Hines G, Slayden SM, Bae S. Effects of aging on adrenal androgen secretion in women. Annual Meeting of the Gerontologic Society of America, Nov. 20-24, 1998, Philadelphia, PA, abstract #8-9.
81. **Azziz R**, Black VY, Knochenhauer ES, Hines GA, Boots LR. Adrenal androgens do not play a significant role in the oligo-ovulation of the polycystic ovary syndrome (PCOS). Fifty-fourth Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA, October 3-9, 1998; P-866.
82. Morán C, Cruz RI, **Azziz R**, Hines GA, Boots LR, Romaguera J. Prevalence of 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH) and insulin resistance (IR) in hyperandrogenic (HA) women in Puerto Rico. Fifty-fourth Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA, October 3-9, 1998; P-869.



83. Farah LA, Black VY, Zayed A, Hines GA, Boots LR, **Azziz R**. Prevalence of insulin resistance (IR) in polycystic ovary syndrome (PCOS) patients in Alabama. Fifty-fourth Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA, October 3-9, 1998; P-863.
84. Kahsar-Miller MD, Boots LR, **Azziz R**. Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome (PCOS). Fifty-fourth Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA, October 3-9, 1998, P-1157.
85. Knochenhauer ES, Black VY, Waggoner W, **Azziz R**. The value of chin and lower abdomen hair growth alone in predicting significant full body hirsutism. Fifty-fourth Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA, October 3-9, 1998; P-569.
86. Hines GA, **Azziz R**. Relation of adrenal zonal mass and steroid production *in vitro* with human aging. Tenth International Congress on Hormonal Steroids, Quebec, Canada, June 17-21, 1998.
87. Hines GA, Moran C, Huerta R, Black VY, Folgman K, **Azziz R**. Computerized evaluation of hair growth in hirsutism. 46th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, GA, March 10-13, 1999; P-375.
88. Hines GA, Smith ER, **Azziz R**. Influence of insulin and testosterone on human adrenocortical steroidogenesis *in vitro*. 46th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, GA, March 10-13, 1999; P-630.
89. Farah LA, Knochenhauer ES, Boots LR, Potter HD, **Azziz R**. Normal adrenarche: A longitudinal study. 46th Annual Meeting of the Society for Gynecologic Investigation, Atlanta, GA, March 10-13, 1999; P-495.
90. Huerta R, Dewailly D, Decanter C, Knochenhauer ES, Boots LR, **Azziz R**. Adrenocortical hyper-responsivity to ACTH: A mechanism favoring the normal production of cortisol (F) in 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). The 81st Annual Meeting of the Endocrine Society, San Diego, June 12-13, 1999; OR29-6.
91. Huerta R, Dewailly D, Decanter C, Knochenhauer ES, Boots LR, **Azziz R**. Serum 11 $\beta$ -hydroxyandrostenedione (11-OHA4) and  $\Delta_5$ -androstenediol (ADIOL) as markers of adrenal androgen (AA) production: Studies in 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). The 81st Annual Meeting of the Endocrine Society, San Diego, June 12-13, 1999; P3-330.
92. Moran C, **Azziz R**, Carmina E, Dewailly D, Fruzzetti F, Ibanez L, Knochenhauer ES, Marcondes JAM, Mendonca BB, Pugeat M, Rhomer V, Speiser PW. Presenting features of 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH) and relationship to age: A multicenter study. The 81st Annual Meeting of the Endocrine Society, San Diego, June 12-13, 1999; P3-331.
93. Hines GA, Reyna R, **Azziz R**, Boots LR. Effect of freeze/thaw cycles and storage temperatures on hormone levels. The 81st Annual Meeting of the Endocrine Society, San Diego, June 12-13, 1999; P3-245.
94. **Azziz R**. Diagnosis and management of adolescent hirsutism. The 38th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Warsaw, Poland, Aug. 29-Sept. 1, 1999; published in Hormone Research 1999; 51 (suppl 2):8.
95. Moran C, Huerta R, Conway-Myers BA, Hines GA, **Azziz R**. Altered autophosphorylation of insulin receptor in ovary tissue of women with polycystic ovary syndrome (PCOS). The 47th Annual Meeting of the Society for Gynecologic Investigation, Chicago, March 23-25, 2000, No. 924; J Soc Gynecol Investig 2000; 7 (supplement):301A.
96. Pignatelli D, Maia M, Salcedo G, **Azziz R**. Prevalence of 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH) among hirsute women of Portugal. The 82<sup>nd</sup> Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000; No. 1663.
97. Moran C, Reyna R, Woods K, Boots LS, **Azziz R**. Generalized adrenocortical hyper-responsiveness to ACTH in polycystic ovary syndrome (PCOS) patients with high levels of dehydroepiandrosterone sulfate (DHEAS). The 82<sup>nd</sup> Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000; No. 1675.

98. Sanchez LA, Moran C, Ochoa T, Boots LR, **Azziz R**. Adrenal androgen production in 21-hydroxylase deficient non-classic adrenal hyperplasia (NCAH) is partially independent of ACTH stimulation. The 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000; No. 1660.
99. Speiser PW, Knochenhauer ES, Dewailly D, Fruzzetti F, Marcondes JAM, **Azziz R**. Genotype and phenotype in women with nonclassical congenital adrenal hyperplasia. The 82<sup>nd</sup> Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000; No. 1654.
100. Dooley JA, **Azziz R**, Fereshetian A. Effect of troglitazone on the quality of life (QOL) of women with polycystic ovary syndrome (PCOS): Results from a randomized, placebo-controlled trial. The 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000; No. 1669.
101. Moran C, Romaguera J, Diaz-Montes TP, **Azziz R**. The glucose to insulin ratio (GIR) is useful for predicting insulin resistance (IR) only in obese, but not non-obese, women with hyperandrogenism (HA). XVI FIGO World Congress, September 3-8, 2000, Washington, D.C.; International Journal of Gynecology and Obstetrics 70 (supplement 1):42 (Abstract FC2.12.04).
102. Moran C, Romaguera J, Diaz-Montes MT, **Azziz R**. Low sensitivity of the glucose to insulin ratio for the prediction of insulin resistance in non-obese women with polycystic ovary syndrome (PCOS). Presented at the "Polycystic Ovary Syndrome: Basic Biology and Clinical Intervention" meeting, National Institute of Environmental Health Sciences, Research Triangle Park, NC; September 17-20, 2000.
103. Traynor KD, Knochenhauer ES, Woods K, Key TJ, Boots LR, **Azziz R**. Prevalence of the polycystic ovary syndrome (PCOS) among 402 unselected consecutive premenopausal women. Presented at the "Polycystic Ovary Syndrome: Basic Biology and Clinical Intervention" meeting, National Institute of Environmental Health Sciences, Research Triangle Park, NC; September 17-20, 2000.
104. Beard AL, Boots LR, **Azziz R**. Dehydroepiandrosterone sulfate (DHS) levels in patients with the polycystic ovary syndrome and their sisters. Presented at the "Polycystic Ovary Syndrome: Basic Biology and Clinical Intervention" meeting, National Institute of Environmental Health Sciences, Research Triangle Park, NC; September 17-20, 2000.
105. Witchel SF, Kahsar-Miller MD, Aston CE, White C, **Azziz R**. Low prevalence of the V281L mutation of CYP21 among women with the polycystic ovary syndrome (PCOS) from the Southeastern United States. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract P2-443).
106. Moran C, Reyna R, Boots LS, **Azziz R**. Greater adrenocortical  $\Delta^5$ 17-hydroxylase ( $\Delta^5$ 17-OH) in patients with the polycystic ovary syndrome (PCOS) and adrenal androgen (AA) excess. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract P2-448).
107. **Azziz R**, Ehrmann DA, Legro RS, Fereshetian A, O'Keefe M, Ghazzi MN, for the Troglitazone/PCOS Study Group. Insulin resistance-related hyperinsulinemia stimulates adrenal androgen (AA) secretion in the polycystic ovary syndrome (PCOS). The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract OR32-6).
108. Ehrmann DA, Legro RS, **Azziz R**, Ghazzi MN, and The PCOS Troglitazone Study Group. A family history of Type 2 diabetes predicts insulin resistance and glucose intolerance in PCOS. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract P2-445).
109. Knochenhauer ES, Gatlin R, Sanchez LA, Moran C, **Azziz R**. Phenotypic classification of 932 consecutive untreated hyperandrogenic women. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract P2-447).
110. Gatlin R, Beard A, Kahsar-Miller MD, Reyna R, **Azziz R**. The heritability of DHEAS in families with the Polycystic Ovary Syndrome (PCOS): A study of affected and unaffected sisters. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract P2-446).

111. Woods KS, Reyna R, **Azziz R**. The effect of oral micronized progesterone (OMP) for the induction of withdrawal bleeding on androgens levels in hyperandrogenic (HA) women. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract P2-449).
112. Legro RS, **Azziz R**, Ehrmann DA, Fereshetian A, O'Keefe M, Ghazzi MN, for the Troglitazone/PCOS Study Group. Lack of response of dyslipidemia in PCOS to improvement in insulin sensitivity. The 83<sup>rd</sup> Annual Meeting of The Endocrine Society, Denver, CO, June 20-23, 2001 (Abstract OR-32-3)
113. Knochenhauer ES, Sanchez LA, **Azziz R**. The different phenotypes of the polycystic ovary syndrome (PCOS). The Annual Meeting of the American Society for Reproductive Medicine, Orlando, FL, October 20-25, 2001 (Abstract P-294). Fertil Steril 76:S208 (Supplement), 2001
114. Sanchez LA, Knochenhauer ES, Gatlin R, Moran C, **Azziz R**. Differential diagnosis of clinically evident hyperandrogenism: Experience with over 1000 consecutive patients. The Annual Meeting of the American Society for Reproductive Medicine, Orlando, FL, October 20-25, 2001 (Abstract O-294). Fertil Steril 76:S111 (Supplement), 2001.
115. Farah L, Reyna R, Knochenhauer ES, Bartolucci AA, **Azziz R**. The association of glucose effectiveness and adrenocortical biosynthesis in the polycystic ovary syndrome (PCOS). The 84<sup>th</sup> Annual Meeting of The Endocrine Society, San Francisco, CA, June 19-22, 2002, P2-619.
116. Woods KS, Stephens K, Bartolucci AA, **Azziz R**. Age-related decline in adrenal androgens: Effect of race. The 84<sup>th</sup> Annual Meeting of The Endocrine Society, San Francisco, CA, June 19-22, 2002, P3-44.
117. Knochenhauer ES, Sanchez L, **Azziz R**. Determinants of hirsutism in hyperandrogenic women. The 84<sup>th</sup> Annual Meeting of The Endocrine Society, San Francisco, CA, June 19-22, 2002, P2-631.
118. Stephens K, Taylor K, **Azziz R**. Long-term outcome of suppressive therapy in hyperandrogenic patients. The 84<sup>th</sup> Annual Meeting of The Endocrine Society, San Francisco, CA, June 19-22, 2002, P2-639.
119. Woods KS, Knochenhauer ES, Reyna R, Key TJ, Stephens KC, **Azziz R**. The prevalence of the polycystic ovary syndrome (PCOS) among 402 unselected consecutive premenopausal women. The 84<sup>th</sup> Annual Meeting of The Endocrine Society, San Francisco, CA, June 19-22, 2002, P2-626.
120. Moran C, Rodriguez J, **Azziz R**. Effect of body mass and hyperandrogenism over insulin resistance (IR) determined by insulin tolerance test (ITT). 84<sup>th</sup> Annual Meeting of The Endocrine Society, San Francisco, CA, June 19-22, 2002, P2-627.
121. Dharia S, Slane A, Jian M, Conner M, **Azziz R**, Parker CR Jr. The role of cytochrome b5 and 17-hydroxylase in the hyperandrogenism of polycystic ovary syndrome. The 50th Annual Meeting of the Society for Gynecologic Investigation, Washington, D.C, March 27-30, 2003; Abstract #130.
122. Kahsar-Miller MD, Boots LR, Bartolucci A, **Azziz R**. The role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate (DHS) levels in the polycystic ovary syndrome (PCOS). 85<sup>th</sup> Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19 - 22, 2003; P3-594.
123. Witchel SF, Kahsar-Miller MD, Aston CE, White C, **Azziz R**. Prevalence of CYP21 mutations and IRS-1 variants among women with the polycystic ovary syndrome (PCOS). 85<sup>th</sup> Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19 - 22, 2003; P3-592.
124. Moran C, **Azziz R**, Carmina E, Escobar-Morreale H, Dewailly D, Fruzzetti F, Ibañez L, Marcondes JAM, Mendonca BB, Pignatelli D, Pugeat M, Rohmer V, Speiser PW, Witchel SF. Reproductive outcome of women with 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH): a multicenter study. 85<sup>th</sup> Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19 - 22, 2003; OR18-6.

125. **Azziz R**, Boots LR, Bartolucci AA. The prevalence of androgen excess among patients presenting with minimal unwanted hair growth. 85<sup>th</sup> Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19 - 22, 2003; P3-595.
126. Ovalle F, Simonikova O, **Azziz R**. Prevalence of the polycystic ovary syndrome (PCOS) in women with type 2 diabetes mellitus (T2DM). 85<sup>th</sup> Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19 - 22, 2003; P3-597.
127. Pignatelli D, Beires J, **Azziz R**. Prevalence of polycystic ovaries in patients with the polycystic ovary syndrome (PCOS) or with 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). 85<sup>th</sup> Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19 - 22, 2003; P3-632.
128. Marin CM, Bartolucci AA, **Azziz R**. Prevalence of insulin resistance in Polycystic Ovary Syndrome (PCOS) patients using the Homeostatic Measurement Assessment (HOMA-IR). 59th Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October 11-15, 2003; P-467. *Fertil Steril* 80 (Suppl. 3):274-275, 2003
129. Kumar AV, Bartolucci AA, **Azziz R**. Prevalence of adrenal androgen excess in patients with the Polycystic Ovary Syndrome (PCOS) using age-specific DHEAS levels adjusted for body mass and ethnicity. 59th Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October 11-15, 2003, 0-119. *Fertil Steril* 80 (Suppl. 3):46, 2003
130. Norris L, Osler R, **Azziz R**, Gower B. Dietary intake in the Polycystic Ovary Syndrome (PCOS). 2003 National American Association for the Study of Obesity (NAASO) Annual Scientific Meeting, Ft. Lauderdale, FL, October 11-15, 2003, 223-P.
131. Lwin R, Oster R, Darnell B, Foster J, **Azziz R**, Gower B. The effect of oral estrogen on postprandial lipid oxidation, fat mass, and lean body mass in postmenopausal women. 2003 National American Association for the Study of Obesity (NAASO) Annual Scientific Meeting, Ft. Lauderdale, FL, October 11-15, 2003, 199-P.
132. **Azziz R**. The clinical management of hirsutism: Evidence-based practice. British Endocrine Societies 23<sup>rd</sup> Joint Meeting, Brighton, UK, 22-24 March, 2004. *Endocrine Abstracts* 7, S26, 2004
133. Ovalle F, Stephens K, **Azziz R**. Insulin resistance and  $\beta$ -cell function in type 2 diabetes mellitus (T2DM) patients with and without the polycystic ovary syndrome (PCOS). The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-558.
134. **Azziz R**, Yildiz BO, Simonikova O, Stephens K, Stanczyk F, Bartolucci A. Heritability of adrenal androgen (AA) secretion in polycystic ovary syndrome (PCOS). The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-570.
135. **Azziz R**, Yildiz BO, Keslie Woods, Stanczyk F, Bartolucci A. Long-term variability of adrenal androgen (AA) levels and their response to corticotropin in the polycystic ovary syndrome (PCOS). The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-572.
136. Chang WY, Stanczyk F, Bartolucci AA, **Azziz R**. Effect of bilateral oophorectomy on basal and adrenocorticotropin (ACTH)-stimulated adrenal androgen (AA) secretion in polycystic ovary syndrome (PCOS). The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-571.
137. Chang WY, Urusova I, Williams H, Perfetti R, **Azziz R**. Differences in insulin sensitivity between subcutaneous and omental adipose tissue arises from differential baseline and insulin-stimulated expression of glycogen synthase kinase-3 (Gsk3) but not glucose transporter-4 (Glut4). The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-85.

138. Ghadir S, Stephens K, **Azziz R**. Combined suppression therapy for the treatment of hirsutism in the polycystic ovary syndrome (PCOS): Clinical predictors of success. The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-573
139. Chen CGG, Slayden SM, Castracane VD, **Azziz R**, Parker Jr CR. The effect of reproductive aging on testosterone and free testosterone dynamics in women. The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, OR03-5.
140. Goodarzi MO, Quinones MJ, Yang H, **Azziz R**, Rotter JI, Hsueh WA. The prevalence of polycystic ovary syndrome in Mexican American women. The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-568.
141. Pignatelli D, Pall ME, Beires J, **Azziz R**. The diagnosis of the polycystic ovary syndrome (PCOS) in hirsute women: NIH 1990 vs. Rotterdam 2003 criteria. The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-574.
142. Marin DeUgarte C, Woods K, Bartolucci A, **Azziz R**. Distribution of facial and body terminal hair growth in a population of unselected black and white women: Towards a definition of hirsutism. The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P1-576.
143. Kumar A, Bartolucci A, **Azziz R**. Effect of race on the age-associated decline in androgens in reproductive-age women. The 86th Annual Meeting of The Endocrine Society, New Orleans, LA, June 16-19, 2004, P2-574.
144. Ghadir S, Huang A, **Azziz R**. Reproducibility of adrenal androgen levels and their response to the adrenocorticotrophic hormone (ACTH) stimulation test. 60th Annual Meeting of the American Society for Reproductive Medicine, October 16-20, 2004, Philadelphia, PA; P-470.
145. Pall M, Stephens K, **Azziz R**. Family size in the polycystic ovary syndrome (PCOS). 60th Annual Meeting of the American Society for Reproductive Medicine, October 16-20, 2004, Philadelphia, PA, P-486.
146. Chang WY, Williams HE, Perfetti R, **Azziz R**. Increased total and phosphorylated glycogen synthase kinase-3 (GSK-3) in the adipocytes of patients with the polycystic ovary syndrome (PCOS). 60th Annual Meeting of the American Society for Reproductive Medicine, October 16-20, 2004, Philadelphia, PA; O-223.
147. Kumar AV, Pignatelli D, DeCherney AH, **Azziz R**. Change in the diagnosis of patients with idiopathic hirsutism (IH) to polycystic ovary syndrome (PCOS) due to the use of the 2003 Rotterdam criteria. 60th Annual Meeting of the American Society for Reproductive Medicine, October 16-20, 2004, Philadelphia, PA; P-462.
148. Kuo J, Kumar A, DeCherney AH, **Azziz R**. Are patients with idiopathic hirsutism (IH) insulin resistant?: Comparing women with IH to body mass index-matched patients with polycystic ovary syndrome (PCOS) and controls. 60th Annual Meeting of the American Society for Reproductive Medicine, October 16-20, 2004, Philadelphia, PA; P-471.
149. Goodarzi MO, Quiñones MJ, **Azziz R**, Rotter JI, Hsueh WA, Yang H. Polycystic ovary syndrome in Mexican Americans: Prevalence and association with the severity of insulin resistance. 2nd Annual World Congress on the Insulin Resistance Syndrome, November 18-20, 2004, Los Angeles, CA.
150. Pall M, Trader B, Magoffin D, **Azziz R**. Effect of androgens and insulin on dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) production by HEPG2 cells. 52<sup>nd</sup> Annual Meeting of the Society for Gynecologic Investigation, March 23 - 26, 2005, Los Angeles, CA., #365
151. Kumar AV, Magoffin D, **Azziz R**. Modulation of adrenal DHEAS production by insulin and testosterone: A comparison of two models. 52<sup>nd</sup> Annual Meeting of the Society for Gynecologic Investigation, March 23 - 26, 2005, Los Angeles, CA, #11.

152. Kumar AV, Magoffin D, **Azziz R**. Extra-adrenal modulators of DHEAS production. 52<sup>nd</sup> Annual Meeting of the Society for Gynecologic Investigation, March 23 - 26, 2005, Los Angeles, CA., #12
153. Madden A, Davis J, **Azziz R**. Implementation of a teaching service at a private teaching hospital: effect on numbers of resident cases. CREOG & APGO Annual Meeting, March 2-5, 2005, Salt Lake City, UT.
154. Patel SS, Pall ME, **Azziz R**, Friedman TC. Androgen Levels in Women with Cushings Syndrome and the Polycystic Ovary Syndrome (PCOS). The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P2-363.
155. Goodarzi MO, Antoine HJ, Pall M, Trader B, **Azziz R**. Association of Calpain-10 Gene Haplotypes with Polycystic Ovary Syndrome. The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P2-371.
156. Chen Y-D I, Goodarzi MO, Farah-Eways L, Ding SR, Pall M, Trader BC, **Azziz R**. Abnormal insulin suppression of lipolysis in Women with Polycystic Ovarian Syndrome (PCOS). The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P3-223.
157. Pall ME, Pignatelli D, **Azziz R**. Phenotype of Hirsute Women: Comparing Polycystic Ovary Syndrome (PCOS) and 21-Hydroxylase Deficient Non-Classic Adrenal Hyperplasia (NCAH). The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P2-372.
158. Goodarzi MO, Antoine HJ, Pall M, Trader B, **Azziz R**. The Pro12Ala Variant in Peroxisome Proliferator Activated Receptor Gamma Influences Testosterone Level in Polycystic Ovary Syndrome. The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P2-355.
159. Liljenquist DR, Kasza K, **Azziz R**, Legro RS, Ghazzi MN, Ehrmann DA, and The PCOS-Troglitazone Study Group. Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome (PCOS). The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P2-365.
160. Ghadir S, **Azziz R**. Hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome: treatment of hyperandrogenic symptoms with combined oral contraceptives (OCs) and spironolactone (SPA). The 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005 P1-375.
161. Chen Y-D I, Trader B, **Azziz R**. Adiponectin, but not C-reactive protein, is associated with serum hormone binding globulin in the polycystic ovary syndrome (PCOS). The 3rd Annual Meeting of The Androgen Excess Society, San Diego, CA, June 3, 2005 Abs. 71.
162. Goodarzi MO, Antoine HJ, Pall M, Trader B, **Azziz R**. Calpain-10 gene haplotypes are associated with polycystic ovary syndrome, insulin resistance and hirsutism. The 3rd Annual Meeting of The Androgen Excess Society, San Diego, CA, June 3, 2005 Abs. 55.
163. Pall M, Pignatelli D, Beires J, **Azziz R**. A comparison of insulin action between women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) and polycystic ovary syndrome (PCOS). The 61st Annual Meeting of the American Society for Reproductive Medicine, October 15-19, 2005, Montreal, Quebec, Canada, P-738.
164. Bairey Merz CN, Johnson BD, Kaizar EE, Stanczyk F, Sharaf B, Bittner V, Berga SL, Braunstein GD, **Azziz R**, Hodgson TK, Pepine CJ, Kelsey SF, Sopko G. Endogenous androgens and coronary artery disease in women: a report from the NHLBI-sponsored WISE study. *Circulation* 2005;112:II-628.
165. Johnson BD, Bairey-Merz NC, Kaizar EE, Stanczyk FZ, Bittner V, Berga SL, Braunstein GD, Sharaf BL, **Azziz R**, Hodgson TK, Pepine CJ, Kelsey SF, von Mering GO, Sopko G. Testosterone, Estrogen, and Coronary Function in Women: A Report From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. *J Am Coll Cardiol* 2006; 47:A366.

166. Shah NA, Antoine HJ, Pall M, Trader BC, Chen Y-D I, **Azziz R**, Goodarzi MO. Genetic variation in 5 $\alpha$ -reductase influences development of PCOS and severity of hirsutism. The Western Society for Pediatric Research (WSPR), February 1-4, 2006, Carmel, CA.
167. **Azziz R**, Trader B, Pall M, Yildiz BO, Stanczyk F. Heritability of Adrenal Androgen (AA) Secretion in Sisters of Women with Polycystic Ovary Syndrome (PCOS). The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P1-555.
168. Pall ME, Trader BC, **Azziz R**. The Association of Polycystic Ovaries to the Prevalence of Impaired Insulin Action and Glucose Intolerance in the Polycystic Ovary Syndrome (PCOS): A Prospective Study. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P1-562.
169. Trader BC, Pall M, **Azziz R**. Prevalence of Polycystic Ovary Syndrome (PCOS) In a Group of Women Presenting With Oligomenorrhea or Hirsutism: NIH 1990 vs. Rotterdam 2003 Criteria. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P2-601.
170. Yildiz BO, Knochenhauer ES, **Azziz R**. Impact of Obesity on the Risk for Polycystic Ovary Syndrome (PCOS). The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P2-616.
171. Orio F, Palomba S, Cascella T, Vuolo L, Manguso F, Colao A, Lombardi G, Goodarzi MO, Rotter JI, **Azziz R**, Chen Y-D I. Non-obese PCOS Women are Insulin Resistant But Do Not Have Metabolic Syndrome. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P2-540.
172. Williams H, Magoffin DA, Pall M, Goodarzi MO, Trader BC, Chen Y-D I, **Azziz R**. AKT and ERK Do Not Appear To Play a Role in the Abnormal Insulin Signaling of Adipocytes in the Polycystic Ovary Syndrome (PCOS). The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P2-610.
173. Goodarzi MO, Antoine HJ, Pall M, Taylor KD, **Azziz R**. Haplotypes in the HMG-CoA Reductase (*HMGCR*) Gene Influence Component Phenotypes in Polycystic Ovary Syndrome. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P1-563.
174. Goodarzi MO, Williams H, Magoffin DA, Pall M, Chang W, Antoine HJ, Trader BC, Chen Y-D I, **Azziz R**. Role of Abnormal Glycogen Synthase Kinase 3 Beta In the Polycystic Ovary Syndrome: Physiologic and Genetic Evidence. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; OR11-2.
175. Goodarzi MO, Maher JF, Antoine HJ, **Azziz R**. *FEM1A*: A Novel Candidate Gene for Polycystic Ovary Syndrome. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; OR11-1.
176. Shah N, Antoine HJ, Pall M, **Azziz R**, Goodarzi MO. Role of the Androgen Receptor CAG Repeat Polymorphism in Polycystic Ovary Syndrome. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P1-551.
177. Goodarzi MO, Shah N, Antoine HJ, Pall M, **Azziz R**. Variants in the 5-Alpha-Reductase Type 1 and Type 2 Genes Influence the Development of Polycystic Ovary Syndrome and Severity of Hirsutism in Affected Women. The 88<sup>th</sup> Annual Meeting of The Endocrine Society, Boston, MA, June 24-27, 2006; P2-615.
178. Goodarzi MO, Antoine HJ, **Azziz R**. Genes for Enzymes That Metabolize DHEA Influence Levels of DHEA-Sulfate in PCOS. Fourth Annual Meeting of the Androgen Excess Society, Boston, MA, June 23, 2006.
179. Goodarzi MO, Antoine HJ, **Azziz R**. *SGTA*: A Novel Candidate Gene for Polycystic Ovary Syndrome That Influences Insulin Resistance. Fourth Annual Meeting of the Androgen Excess Society, Boston, MA, June 23, 2006.
180. Pall M, Mirocha J, **Azziz R**. Insulin Mediated Glucose Utilization in the Polycystic Ovary Syndrome (PCOS) Assessed By the Insulin Tolerance Test (ITT): Effect of Race and Obesity. Fourth Annual Meeting of the Androgen Excess Society, Boston, MA, June 23, 2006.

181. Trader BC, Rod A, Pall M, **Azziz R**. The Phenotype of the Polycystic Ovary Syndrome (PCOS) in White Hispanic Women is similar to That of White Non-Hispanic Women. Fourth Annual Meeting of the Androgen Excess Society, Boston, MA, June 23, 2006.
182. Antoine HJ, **Azziz R**, Goodarzi MO. Haplotype Analysis to Definitively Exclude Candidate Genes for PCOS: CYP17 AND HSD11B1. Fourth Annual Meeting of the Androgen Excess Society, Boston, MA, June 23, 2006. 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006.
183. Ketefian A, Huang A, Hu J, Bartolucci AA, **Azziz R**, and the Society of Reproductive Surgeons. Changes in the Outpatient and Inpatient Utilization of Female Reproductive Surgery, 1998-2002: Analysis of the Healthcare Cost and Utilization Project. 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; P-448.
184. Ketefian A, Hu J, Bartolucci AA, **Azziz R**, and the Society of Reproductive Surgeons. Fifteen-Year Trend in the Inpatient Utilization of Male Reproductive Surgery: Analysis of the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project. 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; O-197.
185. Ketefian A, Hu J, Bartolucci AA, **Azziz R**, and the Society of Reproductive Surgeons. Fifteen-Year Trend in the Inpatient Utilization of Female Reproductive Surgery: Analysis of the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project. 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; O-16.
186. Huang A, Brennan KM, **Azziz R**. Prevalence of Hyperandrogenemia in the Polycystic Ovary Syndrome. 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; P-868.
187. Landay M, Huang A, **Azziz R**. Combination Suppressive Therapy in the Polycystic Ovary Syndrome (PCOS): Predictors of Success. 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; P-869.
188. Brennan KM, Huang A, **Azziz R**. Dehydroepiandrosterone Sulfate (DHEAS) As a Predictor of Insulin Resistance in Patients with Polycystic Ovary Syndrome (PCOS). 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; P-870.
189. Huang A, Landay M, **Azziz R**. The Association of Androgen Levels with the Severity of Hirsutism in the Polycystic Ovary Syndrome (PCOS). 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21-25, 2006; O-26.
190. Shaw L, **Azziz R**, Braunstein G, Berga S, Bittner V, Johnson BD, Bairey-Merz N. Cardiovascular Event-Free Survival in Post-Menopausal Women with Polycystic Ovary Syndrome: Results from the Women's Ischemia Syndrome Evaluation (WISE) study. Scientific Sessions American Heart Association, Chicago, IL; Nov 12-15, 2006
191. Geller DH, **Azziz R**, Magoffin DA, Hernandez MI, Codner E, Cassorla F, Oberfield SE, Leibel N. Are adrenal androgens in pre-adolescent girls markers of risk for polycystic ovary syndrome (PCOS)? The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
192. Magoffin DA, DeBruin C, Liu Y, Chen Y-D I, **Azziz R**. Adipokine regulation of ovarian theca cell androgen production. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
193. Chen Y-D I, Guo X, Liu Y, Tsiang D T-W, Antoine HJ, **Azziz R**, Rotter JI, Goodarzi MO. Relationship between circulating adipokines, obesity and insulin resistance in young women with and without polycystic ovary syndrome (PCOS). The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.



194. Goodarzi MO, Antoine HJ, **Azziz R**. AKT2: First evidence of genetic association with polycystic ovary syndrome. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
195. Braunstein GD, Bairey Merz CN, Johnson BD, Stanczyk FZ, Bittner V, Berga SL, Shaw L, Hodgson TK, Paul-Labrador M, **Azziz R**. Androgens and estrogens track together in postmenopausal women: correlations among hormones in the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
196. Antoine HJ, **Azziz R**, Goodarzi MO. No association of the d19s884 microsatellite marker with polycystic ovary syndrome in Caucasian women from the southeastern United States. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
197. Orio F, Palomba S, Manguso F, Cascella T, Colao A, Rotter JI, **Azziz R**, Chen Y-D I. Relationship between glucose homeostasis parameters and metabolic and cardiovascular risk markers in the polycystic ovary syndrome (PCOS). The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
198. Pall M, **Azziz R**. A comparison of impaired insulin action and glucose intolerance in women with polycystic ovary syndrome (PCOS) diagnosed by the NIH 1990 vs. the Rotterdam 2003 criteria. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
199. Goodarzi MO, Shah NA, Liu Y, Rotter JI, **Azziz R**, Chen Y-D I. Comprehensive physiologic assessment of the metabolic response to metformin in polycystic ovary syndrome (PCOS). The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
200. Chazenbalk G, Williams H, Dinh U, **Azziz R**. Polycystic ovary syndrome (PCOS) and inflammation: suppressive effect of tumor necrosis factor-alpha (TNF $\alpha$ ), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) on glucose transport in adipocytes. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
201. Chazenbalk G, Dinh U, Williams H, **Azziz R**. Polycystic ovary syndrome (PCOS) and inflammation: Adipokine secretion by adipocytes and regulation by pro-inflammatory cytokines. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
202. Chazenbalk G, Dinh U, Bertolotto C, Heneidi S, Simmons C, Williams H, **Azziz R**. Polycystic ovary syndrome (PCOS) and inflammation: effect of adipokines on the cytokine production of adipose tissue resident macrophages. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
203. **Azziz R**, Bertolotto C, Heneidi S, Simmons C, Williams H, Dinh U, Chazenbalk G. Polycystic ovary syndrome (PCOS) and inflammation: co-culture of adipocytes and resident macrophages isolated from adipose tissue. The Endocrine Society 89th Annual Meeting, June 2-5, 2007, Toronto, Canada.
204. Salameh WA, Goldman M, Caulfield MP, Clarke NJ, **Azziz R**, Reitz R. Optimal cutoffs for diagnosis of hyperandrogenemia in patients with the polycystic ovary syndrome (PCOS) by liquid chromatography tandem mass spectrometry (LC/MSMS) vs. extraction/chromatography radioimmunoassay (RIA). 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.
205. Gonzalez LJ, Trivax B, **Azziz R**. Effect of race on the degree of hyperinsulinemia and insulin resistance in patients with polycystic ovary syndrome (PCOS). 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.
206. Gonzalez LJ, Trivax B, **Azziz R**. Insulin resistance in the polycystic ovary syndrome (PCOS) is directly proportional to androgens level. 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.
207. Goodarzi MO, Antoine HJ, **Azziz R**. Non-replication of the *HSD17B5* genetic association with PCOS. 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.

208. Chazenbalk G, Dinh U, Williams H, Trivax B, **Azziz R**. Polycystic ovary syndrome (PCOS) and inflammation: interaction between sexual hormones and adipokines. 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.
209. Boguslavkaya D, Maslova S, Lineva O, Tugushev M, Vershinin I, **Azziz R**. Adrenal response to 9-hour acth stimulation in oligomenorrheic women: bimodal relationship to circulating androgens. 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.
210. Chazenbalk G, Dinh U, Williams H, Trivax B, Lee WC, **Azziz R**. Co-culture of adipocytes and resident macrophages: the effect on IL-6 secretion by adipocytes in the polycystic ovary syndrome. 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada.
211. Pall M, **Azziz R**. A comparison of phenotypic and metabolic features in Hispanic and non-Hispanic women with polycystic ovary syndrome. 5th Annual Meeting of the Androgen Excess Society, June 1, 2007, Toronto, Canada
212. Ogunyemi D, Ioffe Y, Alexander C, **Azziz R**. Deconstruction and reconstruction of ACGME competencies using self-reflection and mentoring. 7<sup>th</sup> ACGME-ABMS Joint Conference - Physician Competence: From Deconstruction to Reconstruction, September 15-16, 2007, Rosemont, Illinois; Poster 23.
213. Trivax BS, Dinh U, Williams H, Chazenbalk G, **Azziz R**. Co-culture of adipocytes and resident macrophages affects monocyte chemoattractant protein-1 secretion in polycystic ovary syndrome. 63rd Annual Meeting of the American Society for Reproductive Medicine, October 13-17, 2007, Washington, DC.
214. Goodarzi MO, Maher JF, Antoine HJ, Cui J, Chen Y-DI, Hsueh WA, Guo X, Rotter JI, **Azziz R**. Genetic evidence that insulin secretion plays a role in the development of polycystic ovary syndrome: the *FEM1B* gene. 57th Annual Meeting American Society of Human Genetics, October 23-27, 2007, San Diego, CA, O-206.
215. Chazenbalk G, Bertolotto C, Heneidi S, Dinh U, Williams H, Simmons CF, **Azziz R**. Direct co-culture of human adipocytes, resident macrophages and adipocyte stem/progenitor cells promotes generation of new preadipocytes. International Federation of Adipose Therapeutics and Science 5<sup>th</sup> Annual Meeting, Oct. 18-20, 2007, Indianapolis, Indiana.
216. Johnson BD, Bairey Merz N, **Azziz R**, Braunstein G, Shaw LJ, Pepine C, Sopko G, Kelsey S. Menstrual cycling and mechanisms of cardiovascular disease events in post-menopausal women: results from the NIH-NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Association Scientific Sessions, November 4-7, 2007, Orlando, FL. (*Circulation* 2007;116:II-828)
217. Ogunyemi D, Alexander C, Gonzalez G, Finke D, Fong A, **Azziz R**. The nursing evaluation: A unique perspective on residents' communication, interactions and professionalism. CREOG & APGO Annual Meeting, March 5-8, 2008, Lake Buena Vista, FL.
218. Ogunyemi D, Alexander C, Fung E, Mak W, **Azziz R**. Teaching teachers to teach: Faculty and residents development program. CREOG & APGO Annual Meeting, March 5-8, 2008, Lake Buena Vista, FL.
219. Ogunyemi D, Alexander C, Ketefian A, Dvorak N, **Azziz R**. The juniors from the eyes of the chief residents: A 360 evaluation of residents by residents. CREOG & APGO Annual Meeting, March 5-8, 2008, Lake Buena Vista, FL.
220. Ogunyemi D, Alexander C, Fong A, Gonzalez G, **Azziz R**. Promoting residents' professional development using a structured faculty mentoring program. ACOG 56th Annual Clinical Meeting, May 3-7, 2008, New Orleans, LA.

221. Bretsky P, Johnson D, Shaw LJ, **Azziz R**, Braunstein GD, Bairey-Merz CN. DHEA-S levels and cardiovascular mortality in post-menopausal women: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI) – sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. American College of Cardiology 57<sup>th</sup> Annual Scientific Session, March 29-April 1, 2008, Chicago, IL.
222. Jones MR, **Azziz R**, Goodarzi MO. Replication of association between metabolic phenotypes of PCOS and HSD17B6 in an independent cohort. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
223. Lee W-C C, Chazenbalk GD, Farkas DL, Burton K, Lindsley EH, Wawrowsky KA, **Azziz R**. Assessing Translocation of Glucose Transporter GLUT4 in human adipocytes. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
224. Chazenbalk C, Bertolotto C, Heneidi S, Simmons C, Williams H, Dinh U, **Azziz R**. Cross-talk between macrophages, adipocytes, and adipose stem progenitor cells results in greater adipogenesis in patients with PCOS. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
225. Goodarzi MO, Taylor KD, **Azziz R**. Fibrillin-3: genetic associations with polycystic ovary syndrome and androgen levels. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
226. Pall ME, Mathur R, Gonzalez S, **Azziz R**. A comparison of the phenotype of Hispanic and non-Hispanic White women diagnosed with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
227. Mathur R, Hwang L, Low K, Yano J, **Azziz R**, Pimentel M. Evidence linking Polycystic Ovarian Syndrome and Irritable Bowel Syndrome. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
228. Goodarzi MO, Kwon S, Taylor KD, Cui J, Chen Y-DI, Guo X, **Azziz R**. Pathway-based genetics: simultaneous examination of 41 insulin signaling pathway genes for association with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
229. Geller DH, **Azziz R**, Magoffin DA, Hernandez MI, Cassorla F, Mathew R, Ten S, Oberfield SE, Baillargeon J-P, Goran MI. A longitudinal comparison of insulin dynamics in adolescents at high risk for Polycystic Ovary Syndrome (PCOS) vs. those at risk for Type 2 Diabetes (T2DM). The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
230. Chazenbalk G, Wang C, Lee C, Williams H, Dinh U, **Azziz R**. Altered expression of genes involved in inflammation, obesity, and sex hormones in adipose tissue from women with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
231. Pall M, Mathur R, Benton M, Nguyen M, **Azziz R**. Prevalence of Polycystic Ovary Syndrome (PCOS) in women self-reporting excess or unwanted body or facial hair growth and/or menstrual dysfunction. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
232. Xu N, Chen Y-DI, **Azziz R**, Goodarzi MO. Association of resistin gene variants with insulin-related traits in Polycystic Ovary Syndrome. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
233. Yu J, Chen Y-DI, Liu Y, Zung L, Su X, Pall M, Mathur R, **Azziz R**, Goodarzi MO. Metformin improves the inflammatory state in non-diabetic women with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.
234. Pall ME, Mathur R, Benton M, Nguyen M, **Azziz R**. Accuracy of a phone questionnaire to predict excess body or facial hair growth and ovulatory dysfunction in women. The Endocrine Society 90th Annual Meeting, June 15-18, 2008, San Francisco, CA.

235. Sproul K, Jones M, **Azziz R**, Goodarzi MO. Anti-mullerian hormone gene polymorphisms have no impact on clinical reproductive endpoints in polycystic ovary syndrome. Androgen Excess & PCOS Society 4<sup>th</sup> Special Scientific Meeting “Ovarian and adipose tissue dysfunction: potential roles in PCOS”, June 14, 2008, San Francisco, CA.
236. Jones MR, **Azziz R**, Goodarzi MO. Association of the diabetes and obesity susceptibility gene *FTO* with PCOS, BMI and testosterone levels. Androgen Excess & PCOS Society 4<sup>th</sup> Special Scientific Meeting “Ovarian and adipose tissue dysfunction: potential roles in PCOS”, June 14, 2008, San Francisco, CA.
237. Chazenbalk G, Dinh U, Wang C, **Azziz R**. Altered expression of genes involved in inflammation in adipose tissue from non-obese women with polycystic ovary syndrome (PCOS). Androgen Excess & PCOS Society 4<sup>th</sup> Special Scientific Meeting “Ovarian and adipose tissue dysfunction: potential roles in PCOS”, June 14, 2008, San Francisco, CA.
238. Goodarzi MO, **Azziz R**. Visfatin genetic variation influences insulin secretion and testosterone level in polycystic ovary syndrome. Androgen Excess & PCOS Society 4<sup>th</sup> Special Scientific Meeting “Ovarian and adipose tissue dysfunction: potential roles in PCOS”, June 14, 2008, San Francisco, CA.
239. Sir-Petermann T, Pérez V, Maniqueo M, Echiburú B, Corner E, Cassorla F, Galvéz C, Crisosto N, **Azziz R**. Adrenal function during childhood and the onset of puberty in daughters of women with polycystic ovary syndrome. Annual Meeting of the European Society for Paediatric Endocrinology, Sept. 20-23, 2008, Istanbul, Turkey; Poster P2-d2-468.
240. Kwon S, Cui J, Taylor KD, **Azziz R**, Goodarzi MO, Guo X. Application of Bayesian Classification with Singular Value Decomposition Method to Polycystic Ovary Syndrome. 17th Annual Meeting of the International Genetic Epidemiology Society, September 15-16, 2008, St. Louis, MO.
241. Trivax B, Alexander C, Dinh U, William H, Chazenbalk G, **Azziz R**. The synergistic effects of co-culture on adiponectin secretion in polycystic ovary syndrome. 64th Annual Meeting of the American Society for Reproductive Medicine, November 8-12, 2008, San Francisco, CA.
242. Hurley E, Alexander CJ, Mathur R, Pall M, **Azziz R**. Facial hair growth in hirsute women with polycystic ovary syndrome (PCOS) correlates with hyperinsulinemia. 64th Annual Meeting of the American Society for Reproductive Medicine, November 8-12, 2008, San Francisco, CA.
243. Chazenbalk G, Wang C, Chen Y-H, Dinh U, **Azziz R**. Role of Interleukin-6 in the insulin resistance of Polycystic Ovary Syndrome (PCOS). 6<sup>th</sup> Annual World Congress on the Insulin Resistance Syndrome, September 25-27, 2008, Los Angeles, CA.
244. Yu J, Goodarzi MO, Liu Y, Su X, **Azziz R**, Chen Y-DI. Cytokines in the Polycystic Ovary Syndrome (PCOS). 6<sup>th</sup> Annual World Congress on the Insulin Resistance Syndrome, September 25-27, 2008, Los Angeles, CA.
245. Pall M, Mathur R, Goodarzi MO, Chen YDI, Gonzalez SL, Liu Y, Su X, **Azziz R**. Relationship between the adipokines visfatin, and omentin and body fat distribution in the Polycystic Ovary Syndrome: A pilot study. 6<sup>th</sup> Annual World Congress on the Insulin Resistance Syndrome, September 25-27, 2008, Los Angeles, CA.
246. Chazenbalk G, Bertolotto C, Heneidi S, Simmons CF, **Azziz R**. Direct co-culture of human adipocytes, adipose tissue macrophages and adipose stem/progenitor cells (ASPCs) reveals a mechanism for generation of new preadipocytes and a novel population of CD34 (+) ASPCs. 6th Annual meeting of the International Federation of Adipose Therapeutics and Sciences (IFATS). October 24-26<sup>th</sup>, 2008, Toulouse, France.
247. Hernandez MI, Cassorla F, **Azziz R**, Ten S, Oberfield SE, Baillargeon J-P, Goran MI, Geller DH. A longitudinal comparison of insulin dynamics in adolescents at high risk for polycystic ovary syndrome (PCOS) vs. those at risk for Type 2 Diabetes (T2DM). XX Sociedad Latino-Americana de Endocrinología Pediátrica (SLEP) Meeting, October 11-14, 2008, Lima, Peru.
248. Hurley EM, Ogunyemi D, Lee J, Alexander C, Hernandez I, **Azziz R**. Self-reflection by residents: Is it helpful? 2009 CREOG & APGO Annual Meeting, March 11-14, 2009, San Diego, CA.

249. Finke DL, Ogunyemi D, Alexander C, Tangchitnob E, **Azziz R**. Using a compliance form to teach and evaluate professionalism, practice-based learning, & improvement, and systems-based practice. 2009 CREOG & APGO Annual Meeting, March 11-14, 2009, San Diego, CA.
250. Ogunyemi D, Alexander C, Solnik J, Elmore R, **Azziz R**. Can we predict residents' behavior using the Thomas-Kilmann conflict mode instrument. 2009 CREOG & APGO Annual Meeting, March 11-14, 2009, San Diego, CA.
251. Painovich J, **Azziz R**, Shufelt C, Braunstein G, Karlan B, Goodarzi M, Chang Y, Mou Y, Bairey Merz N. The Effects of Traditional versus Sham Acupuncture on Menopausal Symptoms: A Randomized, Single Blind Controlled Pilot Study Design. 2009 North American Research Conference On Complementary And Integrative Medicine, May 12-15, 2009, Minneapolis, MN
252. Sproul K, Jones MR, **Azziz R**, Goodarzi MO. Growth Differentiation Factor 9 (*Gdf9*) And Bone Morphogenetic Protein 15 (BMP 15) Gene Polymorphisms Are Associated With Polycystic Ovary Syndrome (PCOS) and Its Component Traits. 6<sup>th</sup> Annual Meeting of the Androgen Excess & PCOS Society, November 9, 2008, San Francisco, CA.
253. Pall ME, Mathur R, **Azziz RA**. Incidence of PCOS ascertained by the 1990 NIH criteria is independent on hirsutism scores in Black or White Hispanic and Hispanic women. 6<sup>th</sup> Annual Meeting of the Androgen Excess & PCOS Society, November 9, 2008, San Francisco, CA.
254. Johnson BD, Dwyer K, Paul-Labrador M, Stanczyk F, Bittner V, Berger S, Braunstein GD, **Azziz R**, Yang Y-C, Bretsky P, Bairey Merz CN. Endogenous and Exogenous Reproductive Hormones and Preclinical Atherosclerosis in Women: A Report from the Los Angeles Atherosclerosis Study (LAAS). American Heart Association Scientific Sessions, November 8-12, 2008, New Orleans, LA.
255. Johnson BD, Dwyer K, Paul-Labrador M, Stanczyk F, Bittner V, Berger S, Braunstein GD, **Azziz R**, Yang Y-C, Bretsky P, Bairey Merz CN. Transition to Menopause and Preclinical Atherosclerosis in Women: A Report from the Los Angeles Atherosclerosis Study (LAAS). American Heart Association Scientific Sessions, November 8-12, 2008, New Orleans, LA.
256. Mathur R, Ko A, Hwang L, Low K, Morales W, Pall M, Pokunurri V, **Azziz R**, Pimentel M. Fecal androgens in women with and without PCOS. The Endocrine Society 91<sup>th</sup> Annual Meeting, June 10-13, 2009, Washington, DC.
257. Sproul K, Jones M, **Azziz R**, Goodarzi MO. Receptor Type II Gene polymorphisms similar among women with the Polycystic Ovary Syndrome (PCOS) and controls. 57<sup>th</sup> Annual meeting of the Pacific Coast Reproductive Society, April 22-26, 2009, Indian Wells, CA; O-6
258. Jones MR, **Azziz R**, Goodarzi MO. Novel candidate genes in polycystic ovary syndrome: Harnessing expression data. 59<sup>th</sup> Annual Meeting of the American Society of Human Genetics, Oct. 20-24, 2009, Honolulu, HI.
259. Painovich J, Shufelt, **Azziz R**, Yang Y, Goodarzi M, Braunstein G, Karlan B, Bairey Merz N. a randomized, single blind controlled trial examining the effects of acupuncture on the symptoms and pathophysiology of menopause. Society for Acupuncture Research 2010 International Conference, March 19-21, 2010, Chapel Hill, NC.
260. Kim M, Christman P, Anest P, Cirricione M, Rotmensch R, Burnes-Bolton L, Ogunyemi D, **Azziz R**. Implementing A Certified Nurse Midwife (CNM) Hospitalist Program For Obstetrical Triage And Labor & Delivery: Impact On Residency Training. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1331.
261. Walsh C, Kim M, Solnik J, **Azziz R**. Implementing a Mentoring Program for Junior Faculty: Format and Preliminary Results. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1508.
262. Ogunyemi D, Rad S, Chung C, **Azziz R**, Alexander C, Solnik MJ, Hsu Y-S. Using The Healthcare Matrix Case Review Format To Teach And Improve Patient Safety Culture In An Ob/Gyn Residency Training Program. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1207.

263. Tangchitnob EP, Eno M, Baicy K, Ogunyemi D, Zois M, **Azziz R**. Behavior profiles in academic medicine. A comparison of conflict styles, communication modes and influence patterns amongst GME administrators, residents and board certified physicians. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #880.
264. Mahller Y, Eppey R, Tangchitnob E, Wohlmuth C, Ogunyemi D, **Azziz R**. Is The DISC Assessment Predictive Of Ob/Gyn Residents' Performance? A Collaborative Study. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #635.
265. **Azziz R**, Gallegos M, Morrow J, Cass I, Dunbar K, Zaki F, Emma L, Ogunyemi D. The Use of a Simplified Productivity Model to Enhance Faculty Productivity and Satisfaction. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1496.
266. Sproul K, Huang A, Chaudhuri G, **Azziz R**. Perceptions On Lifestyle, And Leader And Mentor Qualities, In Trainees Vs. Faculty. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1128.
267. Sproul K, **Azziz R**. Mentorship As It Relates To Satisfaction In Obstetrics And Gynecology (Ob/Gyn) Training. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1134.
268. **Azziz R**, Madden A, Alexander C, Zois M, Ogunyemi D. Implementing A Teaching Service For Voluntary Faculty In Obstetrics And Gynecology: Long-Term Results. 2010 CREOG & APGO Annual Meeting, March 3-6, 2010, Orlando, FL; abstract #1489.
269. Auchus RJ, Wichel S, White PC, Baker LA, Baratz A, Berebaum SA, Eugster EA, Geffner ME, Loechner KJ, Merke D, Nenadovich T, Poppas DP, Riepe FG, Rink R, Rivkees SA, Sandberg DE, Schaeffer T, Schlusser RN, VanRyzin C, Vogiatzi MG, Aisenberg JE, Bachega T, Lee PS, Miller WL, Quigley CA, Seely E, **Azziz R**, Fracassa S, Leight K, Lin GA, Snyder D, FX Schneck, Katz AL, Pass K, Lloyd-Puryear MA, Breault D, Kalro B, Harris KB, Therrell BL, and The CAH CCC Committee. Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA (*submitted*).
270. **Azziz R**, Davidson P, Morrison J, Wang C, Salusky I, Norris K, Braun J. The UCLA Clinical & Translational Sciences Institute (CTSI) Leadership In Research Organizations Development Program: Determining The Competencies. ACRT/SCTS Joint Annual Meeting, April 5-7, 2010, Washington, DC.
271. Jones MR, Chazenbalk G, Taylor KD, Wang C, Chen YH, Xu J, Lee J-M, Mathur R, Pall M, **Azziz R**, and Goodarzi MO. Key Steroidogenic Regulatory Factor C-Fos Is Underexpressed In Polycystic Ovary Syndrome (PCOS) Adipose Tissue And Associated With Susceptibility To PCOS. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
272. Chazenbalk G, C Wang, Pall M, Chen Y-H, Xu J, Lee J-M, **Azziz R**. Abnormal expression of genes in inflammation, lipid metabolism, and Wnt signaling in the lean women with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
273. Jun H-S, Chen Y-H, Lee J-M, **Azziz R**, Chazenbalk G. Comparing The Gene Expression Profiles Of Adipose Tissues From Non-Obese And Obese Women With The Polycystic Ovary Syndrome (PCOS) The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
274. Xu N, Geller DH., Kwon S, Guo X, Abbott DH., Dumesic DA, **Azziz R**, and Goodarzi MO. Specific Alterations in the Epigenome of Polycystic Ovary Syndrome (PCOS)-like Female Rhesus Monkeys. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
275. Mathur R, Weitsman S, Salameh W, Clarke R, Pall M, Morales W, Pokkunuri V, Reitz R, Chua S, Chang C, **Azziz R**, Pimentel M. Validation of assays for isolating and measuring androgens in stool. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.

276. Goodarzi MO, Jones MR, Chen YDI, Cui J, Guo X, and **Azziz R**. Integration of Risk and Protective Alleles Predicts Susceptibility to Polycystic Ovary Syndrome. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
277. Dumesic DA, **Azziz R**, Padmanabhan V, Kannan K, Vagi S, Tarantal AF, and Abbott DH. Differential Regulation of Bisphenol A in PCOS Women and by Androgen Excess in Pregnant Nonhuman Primates. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
278. **Azziz R**, Ezeh U, Pall M, Dumesic DA, Goodarzi MO. Effect of Race on the Metabolic Dysfunction of Polycystic Ovary Syndrome (PCOS): Comparing African-American (AA) and Non-Hispanic White (NHW) Patients. The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
279. Goodarzi MO, Louwers YV, Taylor KD, Jones MR, Cui J, Kwon S, Chen YD-I, Guo X, Stolk L, Uitterlinden AG, Laven JSE, **Azziz R**. Replication of Association of Insulin Receptor Gene Polymorphisms with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
280. Lee J-M, Chen Y-H, Chazenbalk G, and **Azziz R**. Abnormalities in the Mitogen Activated Protein Kinase (MAPK) Pathway in Adipocytes of Women with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
281. Chen Y-H, Lee J-M, Chazenbalk G, and **Azziz R**. Abnormal Glucose Transporter Isoform Type 4 (GLUT4) Expression in Adipocytes of Women with Polycystic Ovary Syndrome (PCOS). The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
282. **Azziz R**, Ezeh U, Pall M, Dumesic D, Chazenbalk G, Yildiz B. Obesity In Women With Polycystic Ovary Syndrome (PCOS): A Referral Bias? The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
283. **Azziz R**, Witchel SF, Geller D. Premature adrenarche (PA) as a precursor of the polycystic ovary syndrome (PCOS). The Endocrine Society 92<sup>nd</sup> Annual Meeting, June 19-22, 2010, San Diego, CA.
284. Ketefian A, Torralba CA, Pall M, Ezeh U, **Azziz R**. The phenotype of polycystic ovary syndrome (PCOS) in Hispanic vs. non-Hispanic white women. American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO.
285. Ketefian A, Ezeh U, Torralba CA, Pall M, **Azziz R**. Value of 1-hour versus 2-hour insulin levels during the oral glucose tolerance test (OGTT) for identifying the degree of hyperinsulinemia (HI) in PCOS women. American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO; O-240.
286. Ezeh U, Dumesic D, Pall, M, Torralba CA, Berman D, Agnihotri S, **Azziz R**. Body fat distribution and lean body mass as determinants of insulin resistance (IR) in polycystic ovary syndrome (PCOS). American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO.
287. Brower M, Brennan K, Ezeh U, Pall M, **Azziz R**. The severity of menstrual dysfunction serves as a predictor of insulin resistance in the polycystic ovary syndrome (PCOS). American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO.
288. Brennan K, Pall M, Torralba CA, **Azziz R**. Relationship of ovarian morphology to degree of menstrual cycle dysfunction and insulin resistance in polycystic ovary syndrome (PCOS). American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO.
289. Mehta J, Ketefian A, Pall M, Ezeh U, **Azziz R**. Use of fasting blood glucose levels to detect the presence of glucose intolerance in polycystic ovary syndrome (PCOS). American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO; O-243.

290. Ketefian A, Jones MR, **Azziz R**, Goodarzi MO. Variants in genes involved in androgen signaling as genetic determinants of polycystic ovary syndrome (PCOS). American Society for Reproductive Medicine 66th Annual Meeting, October 23-27, 2010, Denver, CO.
291. Painovich J, Shufelt C, **Azziz R**, Yang Y, Goodarzi M, Braunstein G, Karlan B, Bairey Merz CN. A randomized, single blind controlled pilot trial examining the effects of traditional acupuncture on the menopause symptoms and pathophysiology. WFAS 2010 International Acupuncture Conference, November 6-7, 2010, San Francisco, CA.
292. Chazenbalk G, Jamubay M, Keller E, Yoshimura K, **Azziz R**, Dumesic D. Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages (ATMs), adipose stem cells (ASCs) and adipocytes: Evidence of cell plasticity. The Endocrine Society 93<sup>rd</sup> Annual Meeting, June 4-7, 2011, Boston, MA (submitted).
293. Chen Y-H, Heneidi S, **Azziz R**. Transcriptional activator MEF2A is overexpressed in adipocytes of PCOS patients. The Endocrine Society 93<sup>rd</sup> Annual Meeting, June 4-7, 2011, Boston, MA.
294. Chen Y-H, Heneidi S, **Azziz R**. Expression of miRNAs in the adipose tissue of lean patients with PCOS. The Endocrine Society 93<sup>rd</sup> Annual Meeting, June 4-7, 2011, Boston, MA.
295. Witchel SF, DeFranco DB, **Azziz R**. Management of CAH During Pregnancy: Optimizing Outcomes. The Endocrine Society 93<sup>rd</sup> Annual Meeting, June 4-7, 2011, Boston, MA (submitted).
296. Chen Y-H, Lee J-M, Heneidi S, Chazenbalk G, Gamboa GM, **Azziz R**. Constitutive ERK1/2 Activation Down-Regulates GLUT4 Expression in Adipocytes of Women with PCOS. 9<sup>th</sup> Annual AEPPOS Society, October 13-14, 2011, Orlando, FL.
297. Eastwood J, Johnson B, Rutledge T, Ahmed B, Brecht M, Wei J, Braunstein G, **Azziz R**, Berga S, Sharaf B, Bittner V, Bairey C. Psychosocial Stress and Coronary Artery Atherosclerosis in Premenopausal Women. Society of Psychophysiological Research. Sept. 14-18, 2011, Boston, MA.
298. Amin M, Ketefian A, Chang J, Manning D, **Azziz R**, Pisarska M, Alexander C. Triglyceride to high-density lipoprotein cholesterol ratio as predictor of insulin resistance in women with polycystic ovarian syndrome. American Society for Reproductive Medicine 67<sup>th</sup> Annual Meeting. Oct. 15-19, 2011, Orlando, FL.
299. Chen Y-H, Heneidi S, Gamboa GM, **Azziz R**. Role of microRNA in PCOS: miR-93 overexpression regulates GLUT4. The Endocrine Society 94<sup>th</sup> Annual Meeting, June 23-26, 2012, Houston, TX.
300. Chen Y-H, Heneidi S, Gamboa GM, **Azziz R**. Role of microRNA in PCOS: microRNA-93 Over-Expression Induces IL6 in Adipocytes. The Endocrine Society 94<sup>th</sup> Annual Meeting, June 23-26, 2012, Houston, TX.
301. Goss AM, Chandler-Laney PC, Ovalle F, Goree LL, **Azziz R**, Desmond RA, Granger WM, Bates GW, Gower BA. Effects of a eucaloric reduced carbohydrate diet on body composition and fat distribution in women with PCOS. The Endocrine Society 95th Annual Meeting, June 15-18, 2013, San Francisco, CA.
302. Gower BA, Chandler-Laney PC, Ovalle F, Goree LL, **Azziz R**, Desmond RA, Granger WM, Goss AM, Bates GW. Favorable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. The Endocrine Society 95th Annual Meeting, June 15-18, 2013, San Francisco, CA.
303. Chen Y-H, Heneidi S, **Azziz R**. Down-regulation of Elavl1 Gene in the adipose tissue of women with PCOS. The Endocrine Society 95th Annual Meeting, June 15-18, 2013, San Francisco, CA.
304. Bhasin G, Wang E, Alexander C, Pall M, **Azziz R**, Pisarska M. Women with PCOS have lower basal metabolic rates compared to eumenorrheic controls. American Society for Reproductive Medicine 68<sup>th</sup> Annual Meeting, October 12-17, 2013, San Diego, CA.
305. Chen YH, Heneidi S, Diamond MP, Layman LC, **Azziz R**. The micro-RNA 93 host gene *MCM7* is paradoxically down-regulated in the adipose tissue of women with polycystic ovary syndrome (PCOS). 11th Annual Meeting of the Androgen Excess & PCOS Society, October 17-18, 2013, Newport, RI.



306. **Azziz R**, Ezeh U, Goodarzi MO, Chen Y-H. Adipose tissue dysfunction in Polycystic Ovary Syndrome (PCOS). 16th International Congress of Endocrinology & The Endocrine Society 96th Annual Meeting, June 21-24, 2014, Chicago, IL
307. Chuang T-Y, Gamboa GM, Layman LC, Diamond MP, **Azziz R**, Chen Y-H. MicroRNA-223 expression is upregulated in human adipose tissue of insulin resistant women with and without Polycystic Ovary Syndrome (PCOS). 16th International Congress of Endocrinology & The Endocrine Society 96th Annual Meeting, June 21-24, 2014, Chicago, IL.

#### **PATENTS:**

- Patent application title: **METHODS OF PRODUCING PREADIPOCYTES AND INCREASING THE PROLIFERATION OF ADULT ADIPOSE STEM/PROGENITOR CELLS**  
Inventors: Gregorio Chazenbalk, Cristina Bertolotto, **Ricardo Azziz**, Charles F. Simmons, Jr., Saleh Heneidi  
Agents: DAVIS WRIGHT TREMAINE LLP/Los Angeles  
Assignees: CEDARS-SINAI MEDICAL CENTER  
Origin: LOS ANGELES, CA US  
IPC8 Class: AA61K3512FI  
USPC Class: 424 937  
Patent application number: 20090317367  
Read more: <http://www.wipo.int/pctdb/en/wo.jsp?WO=2008103807> and <http://www.fags.org/patents/app/20090317367>
- Patent application title: **METHOD AND DEVICE FOR TREATING WOUNDS**  
Inventors: Gregorio Chazenbalk, Joel A. Aronowitz, Daniel L. Farkas, Cristina Bertolotto, Charles F. Simmons, Saleh Heneidi.  
Status: Provisional application, expired on March 6, 2010

**GRANTS:  
SELECTED GRANTS PENDING REVIEW, OR IN REVISION:**

Source of support: NIH/NIDDK  
Identifying number: 1-R01-DK097664-01  
Project Title: Role of miR-93 in the regulation of GLUT4  
Principal Investigator: R. Azziz  
Percent effort: 5%  
Total direct costs: \$1,250,000  
Years of award: 09/01/2012-08/31/2017

*This application proposes to determine: 1) the mechanisms underlying the role of miR-93 in regulating GLUT4 expression and insulin resistance (IR); and 2) what factors may modulate the action of miR-93 on IR, in adipose tissue of PCOS.*

---

Source of support: NIH/NIDDK  
Identifying number: 2-R01-DK073632-07  
Project Title: Adipose Tissue Dysfunction in PCOS  
Principal Investigator: R. Azziz  
Percent effort: 5%  
Total direct costs: \$1,250,000  
Years of award: 9/1/11-8/30/16

*This application proposes to define the cellular mechanisms underlying adipose tissue dysfunction in PCOS. Aims include: 1) To determine intrinsic abnormalities of adipogenesis in PCOS derived adipose; 2) to determine the role of adipokines in PCOS adipocyte dysfunction; and 3) to determine the impact of weight loss on adipose function of obese PCOS.*

---

**PREVIOUS:**

Source of support: NIH/NICHD  
Identifying number: 3-R01-HD29364  
Project Title: Adrenal Androgen Excess in PCOS: Role of Genetics  
Principal Investigator: R. Azziz  
Percent effort: 15%  
Total direct costs: \$1,009,550  
Years of award: 4/1/07-3/31/14

*The major goals of this project are to determine the heritability, and molecular genetics using haplotype-based family studies, of adrenal androgen excess in PCOS.*

---

Source of support: CARES Foundation, Inc  
Identifying number: N/A  
Project Title: The Relationship between Age of Diagnosis and Response of the HPO Axis to Glucocorticoids Suppression in Non Classic Congenital Adrenal Hyperplasia  
Principal Investigator: R. Azziz  
Percent effort: 1%  
Total direct costs: \$19, 802  
Years of award: 6/1/008-5/31/14

*To determine in NCAH whether there is an association between age of diagnosis, and the phenotype of presentation and the outcome to treatments.*

---

Source of support: NIH/NICHD  
Identifying number: 1-R01-HD054960-01  
Project Title: Reduced Carbohydrate Diet Intervention for PCOS  
Principal Investigator: B. Gower  
Percent effort: 5% (Co-I)  
Total direct costs: \$955,653  
Years of award: 09/28/09 – 08/31/13

*The objective is to develop a diet that optimizes reproductive and metabolic health among women with PCOS in the absence of weight loss.*

---

Source of support: MCG Pilot Study Research Program (Intramural Grants Program)  
Identifying number: N/A  
Project Title: Novel Mechanism of Insulin Resistance in Adipocytes from PCOS  
Principal Investigator: R. Azziz  
Percent effort: 1%  
Total direct costs: \$25,000  
Years of award: 10/1/2011 - 9/30/2012

*To determine the role of miRNA in GLUT4 expression in mouse 3T3-L1 adipocytes, and the role of TNF $\alpha$  in GLUT4 expression and examine the effect of TNF $\alpha$  on miR-21, miR-199, and miR-223 in human adipocytes.*

---

Source of support: NIH/NIDDK  
Identifying number: 1-R01-DK073632  
Project Title: Insulin Signaling Defects in PCOS  
Principal Investigator: R. Azziz  
Percent effort: 20%  
Total direct costs: \$995,275  
Years of award: 7/1/06-6/31/12  
*The aims of this project are to elucidate the molecular mechanisms underlying the defect in insulin action observed in PCOS.*

---

Source of support: Iris-Cantor-UCLA Women's Health Center/UCLA National Center of Excellence in Women's Health Pilot Research Project  
Identifying number: N/A  
Project Title: Menstrual Cycle Irregularity: Prevalence and Associated Risk Factors  
Principal Investigator: S. Stein Merkin  
Percent effort: 1% (as co-I, donated)  
Total direct costs: \$20,000  
Years of award: 7/1/08-6/30/09  
*To explore the prevalence of menstrual irregularity in a representative sample of the U.S. population between 1999 and 2002, and assess the association between menstrual irregularity and diabetes/CVD risk factors and outcomes; and to examine racial/ethnic and socioeconomic disparities with regard to irregular menses, and associated lifestyle factors, to explore environmental and social associations that might be related to menstrual irregularity and possibly to PCOS.*

---

Source of support: NIH/NICHD  
Identifying number: 1-R13-HD051235  
Project Title: Annual Meeting of the Androgen Excess Society  
Principal Investigator: R. Azziz  
Percent effort: 3% (donated)  
Total direct costs: \$35,000  
Years of award: 7/1/05-6/30/10  
*This application requests support for the scientific program of the annual meeting of the Androgen Excess Society, the premier organization fostering research and education in the study of androgen excess disorders.*

---

Source of support: NIH/NIDDK  
Identifying number: 2-T32-DK00770-62A  
Project Title: Training Grant in Endocrinology and Diabetes  
Principal Investigator: S. Melmed  
Percent effort: 1% (donated) as Training Faculty  
Total direct costs: \$794,200  
Years of award: 7/1/006-6/30/11  
*This application requests support for the development and implementation of a postdoctoral training program in endocrinology and diabetes.*

---

Source of support: NIH/NHLBI  
Identifying number: 5 R01HL073108  
Project title: Reproductive Hormones and Pre-Clinical CVD in Women  
Principal Investigator: N. Bairey Merz  
Percent effort: 1% (donated, co-I)  
Total direct costs: \$306,000  
Years of award: 9/1/03-8/31/07  
*The major goals of this project are to better understand the role of hormones and heart disease.*

---

Source of support: NIH/NHLBI  
Identifying number: N01HV68161, N01HV68162, N01HV68163, N01HV68164  
Project title: Women's Ischemic Symptom Evaluation (WISE)-Blood Hormone Level Determination  
Principal Investigator: N. Bairey Merz  
Percent effort: 1% (donated, co-I)  
Total direct costs: \$113,200  
Years of award: 5/1/05-4/31/07  
*The major goals of this project are to improve our understanding of heart disease in women. Study objectives include developing improved heart disease detection techniques in women, improving our understanding of the role arterial function plays in heart disease in women, and exploring the influence of hormones on heart disease in women.*

---

Source of support: NIH/NICHD  
Identifying number: 1-K24-HD01346  
Project Title: Midcareer Investigator Award In Patient-Oriented Research: Mentoring in Androgen Excess Disorders Research  
Principal Investigator: R. Azziz  
Percent effort: 25%  
Total direct costs: \$420,924  
Years of award: 4/1/00-3/31/06 (with a one-year no-cost extension)  
*The major goals of this project are to mentor physician-scientists with the clinical, laboratory, and intellectual skills necessary to develop into an accomplished academician, teacher and independent clinical researcher.*

---

Source of support: NIH/NICHD  
Identifying number: 1-R03-HD42077  
Project Title: Molecular defects of insulin signaling in PCOS  
Principal Investigator: R. Azziz  
Percent effort: 5% (donated)  
Total direct costs: \$100,000  
Years of award: 4/1/03-3/31/05  
*The goal of this study is to preliminarily determine whether abnormal insulin signaling is present in the polycystic ovary syndrome (PCOS), and whether the defect involves the PI-3 kinase/Akt/Glut-4 cascade.*

---

Source of support: NIH/NICHD  
Identifying number: 2-R01-HD29364 (also supported in part by UAB GCRC protocol #848)  
Project Title: Adrenal Androgen Excess in the Hyperandrogenism of Women  
Principal Investigator: R. Azziz  
Percent effort: 25%  
Total direct costs: \$708,707  
Years of award: 12/1/98-11/30/03 (incl. a one-year no-cost extension)  
*The major goals of this project are to determine the prevalence, heritability, and association with the CYP17-A2 polymorphism, of adrenal androgen excess in the Polycystic Ovary Syndrome.*

---

Source of support: NIH/NICHD  
Identifying number: U10-HD94016  
Project Title: Cooperative Multicenter Reproductive Medicine Network  
Principal Investigator: M. P. Steinkampf  
Co-Investigator: R. Azziz  
Percent effort: 5% (donated)  
Total direct costs: \$798,799  
Years of award: 4/4/00-3/31/05  
*The major goals of this project are to participate in the performance of multicenter clinical trials in the treatment of infertility and/or gynecology.*

---

Source of support: NIH/NICHD  
Identifying number: 1-K12-HD01258  
Project Title: Women's Reproductive Health Research (WRHR) Career Development-OB/GYN Faculty Research Career Development Program  
Principal Investigator: J. Hauth  
Co-Investigator: R. Azziz  
Percent effort: 5% (donated)  
Total direct costs: \$1,851,115  
Years of award: 7/01/99 - 6/30/04  
*The goal of this project is to support the research career development of recently completed postgraduate trained obstetrician-gynecologists.*

---

Source of support: NIH/NICHD  
Identifying number: 1-K12 HD01402  
Project Title: Building Interdisciplinary Research Careers in Women's Health (BIRCWHR)-UAB Women's Health Research Scholars' Program  
Principal Investigator: W. Deal  
Co-Investigator: R. Azziz  
Percent effort: 5% (donated)  
Total direct costs: \$2,314,815  
Years of award: 8/10/00 - 7/31/05  
*The major goal of this grant is to create a women's health research career development program to develop skills of junior faculty in the areas of health problems in women.*

---

Source of support: Insmmed Pharmaceuticals, Inc.  
Identifying number: INS1-PO-19  
Project Title: A randomized, placebo-controlled, double-blind, parallel-group clinical study to assess the effect of nine months of repeated daily oral 500 and 1000 mg doses of *D-chiro*-inositol (INS-1) on the ovulatory, endocrine and metabolic abnormalities of women with PCOS.  
Principal Investigator: R. Azziz  
Percent effort: 5%  
Total direct costs: \$26,884  
Years of award: 6/1/00-12/1/01

*The major goal of this study was to determine whether, in a multicenter prospective randomized placebo-controlled fashion, oral 500 and 1000 mg doses of D-chiro-inositol (INS-1) improved the ovulatory, endocrine and metabolic abnormalities of the polycystic ovary syndrome (PCOS)*

---

Source of support: Solvay Pharmaceuticals, Inc. (investigator-initiated)  
Project Title: Effects of oral micronized progesterone on androgen levels in PCOS  
Principal Investigator: R. Azziz  
Percent effort: 2% (donated)  
Total direct costs: \$5,000  
Years of award: 3/1/00-2/28/01

*The major goal of this project was to prospectively determine the effects of oral micronized progesterone on androgen levels in women with the polycystic ovary syndrome (PCOS).*

---

Source of support: NIH/NICHD  
Identifying number: U54-HD28934  
Project Title: Insulin Ovarian/Metabolic Responses in PCOS (*Subproject*: Effects of chronic insulin reduction on the spontaneous and clomiphene-induced ovulatory rates in women with PCOS who failed clomiphene induction previously)  
Principal Investigator: J. Marshall (*Subproject P.I.*: J.E. Nestler)  
Co-Investigator: R. Azziz  
Percent effort: 5% (donated)  
Total direct costs: \$653,598  
Years of award: 4/4/00-3/31/05

*The goals of the subproject were to determine whether oral metformin administration improved the ovulatory function of clomiphene-resistant women with the polycystic ovary syndrome (PCOS).*

---

Source of support: Parke-Davis Pharmaceutical Research  
Identifying number: 991-101 (Clinical Laboratory Agreement)  
Project Title: A 44-week, randomized, double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of troglitazone (CI-991) in Polycystic Ovary Syndrome  
Principal Investigator: R. Azziz  
Percent effort: 5%  
Total direct costs: \$88,200  
Years of award: 5/1/97-6/30/99

*The goal of this grant was to provide laboratory support for a multicenter prospective randomized trial determining the effect of three doses of troglitazone in polycystic ovary syndrome (PCOS).*

---

Source of support: Parke-Davis Pharmaceutical Research  
Identifying number: 991-101 (Clinical Investigator Agreement)  
Project Title: A 44-week, randomized, double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of troglitazone (CI-991) in Polycystic Ovary Syndrome  
Principal Investigator: R. Azziz  
Percent effort: 5%  
Total direct costs: \$110,000  
Years of award: 5/1/97-6/30/99  
*The goal of this multicenter prospective randomized trial was to determine the effect of three doses of troglitazone on ovulatory rates, hyperandrogenemia, and other clinical signs of androgen excess in 400 patients with the polycystic ovary syndrome (PCOS).*

---

Source of support: NIH/NIA  
Identifying number: 1-R01-AG12142  
Project Title: Adrenal Androgen Production in Aging  
Principal Investigator: C.R. Parker, Jr.  
Co-Investigator: R. Azziz  
Percent effort: 20%  
Total direct costs: \$624,438  
Years of award: 5/1/95-4/30/98  
*The goals of this project were to attempt to establish the etiology of the age-related decrease in adrenal androgens (AAs), and whether this response can be normalized by estrogen replacement.*

---

Source of support: NIH/NICHD  
Identifying number: 1-R01-HD29364 Adm. Suppl.  
Project Title: Adrenal Androgen Excess in Hyperandrogenic Oligo-ovulation-Administrative Supplement  
Principal Investigator: R. Azziz  
Percent effort: 40%  
Total direct costs: \$50,000  
Years of award: 10/1/95-9/30/96  
*The goals of this project were to determine whether carriers of CYP21 mutations are at risk for developing clinically evident hyperandrogenism.*

---

Source of support: NIH/NICHD  
Identifying number: 1-R01-HD29364  
Project Title: Adrenal Androgen Excess in Hyperandrogenic Oligo-ovulation  
Principal Investigator: R. Azziz  
Percent effort: 40%  
Total direct costs: \$276,808  
Years of award: 5/1/93-4/30/97  
*The goals of this project were to determine the prevalence of adrenal androgen (AA) excess in the polycystic ovary syndrome (PCOS); whether AA excess is due to alterations in adrenocortical/pituitary sensitivity/responsivity to ACTH; whether AA suppression with glucocorticoids restores ovulatory function in PCOS patients with AA excess; and whether AA excess results from gonadotropin-sensitive ovarian factors.*



---

Source of support: TAP Pharmaceuticals (investigator-initiated)  
Project Title: Randomized study of Lupron-Depot versus oral contraceptive pills for the treatment of female hyperandrogenism  
Principal Investigator: R. Azziz  
Total direct costs: \$13,663  
Years of award: 1990-1994  
*The goals of this study were to prospectively determine the effects of a long-acting GnRH analog (leuprolide), in comparison to oral contraceptive pills, on the endocrine and dermatological features of hyperandrogenic women.*

---

Source of support: Ethicon, Inc.  
Identifying number: 90-22121-B  
Project Title: Adhesion Prevention at Operative Laparoscopy with Tolmetin Sodium  
Principal Investigator: R. Azziz  
Total direct costs: \$32,000  
Years of award: 1992-1993  
*The goals of this multicenter, randomized, controlled study was to determine the effect of the intraperitoneal instillation of tolmetin sodium on post-operative adhesion reformation.*

---

Source of support: UAB General Clinical Research Center/NCRR  
Identifying number: 421  
Project Title: Adrenal steroidogenesis in simple and hyperandrogenic obesity  
Principal Investigator: R. Azziz  
Total direct costs: \$7,882  
Years of award: 1989-1990  
*The goal of this pilot study was to prospectively determine the type and prevalence of abnormalities of adrenocortical steroidogenesis, as assessed by the acute ACTH test, in hyperandrogenic women.*

---

Source of support: Johnson & Johnson Co.  
Identifying number: 5279.11B/1311.01  
Project Title: Evaluation of the laparoscopic application of TC-7 (INTERCEED)  
Principal Investigator: R. Azziz  
Total direct costs: \$5000  
Years of award: 1989-1990  
*The goals of this multicenter observational study were to determine the optimum method of laparoscopically applying a resorbable anti-adhesion barrier (INTERCEED) intraperitoneally.*

---

Source of support: Johnson & Johnson Co.  
Identifying number: 3067.11A/1311.00  
Project Title: Evaluation of TC7 adhesion barrier for the reduction of postoperative sidewall adhesions in gynecologic surgery  
Principal Investigator: R. Azziz  
Total direct costs: \$12,500  
Years of award: 1988-1989  
*The goals of this multicenter, randomized, controlled study were to determine the effect of a resorbable barrier on post-operative adhesion reformation.*

---

Source of support: UAB Nutritional Sciences Core Center/NCI  
Identifying number: CA28103-10  
Project Title: R. Azziz  
Total direct costs: \$23,200  
Years of award: 1988-1990

*The goal of this pilot study was to determine the effect of obesity on adrenocortical steroidogenesis, as assessed by the acute ACTH test, in healthy women.*

---

Source of support: March of Dimes  
Identifying number: 8-78-5 and 8-79-4  
Project Title: Dexamethasone receptor levels in palatal fibroblasts of adult A/J and C57 BL/6J mice  
Principal Investigator: R. Azziz  
Total direct costs: \$2,500  
Years of award: 1978-1979

*The goal of this pilot study was to determine whether glucocorticoid receptor levels differed in the palatal fibroblasts of two mice strains (A/J and C57 BL/6J) with significantly different susceptibility to glucocorticoid-induced cleft palate.*

---

## **SELECTED TRAINEES:**

### **Reproductive Endocrinology & Infertility (REI) Clinical Fellows:**

- Eric S. Knochenhauer, MD, REI Fellow 7/94-6/96. *Present position: Associate Professor and Div. Director, Staten Island University Hospital*
- Scott M. Slayden, MD, REI Fellow 7/95-6/97. Formerly Asst. Professor, Div. of REI, Medical College of Georgia, 7/97-6/2001. *Present position: Private practice*
- Lisa Farah, MD, REI Fellow 7/97-6/99. *Present position: Private practice*
- Luis Alfredo Sanchez, MD, REI Fellow 5/99-6/01. *Present position: Private practice*
- Wendy Chang, MD, REI Fellow 7/02-6/04. *Present position: Asst. Clinical Professor (Voluntary), UCLA*
- Ashim Kumar, MD, REI Fellow 7/02-6/05. *Present position: Asst. Clinical Professor (Voluntary), UCLA*
- Catherine Marin DeUgarte, MD, REI Fellow 7/02-6/05. *Present position: Assist. Clinical Professor, UCLA*
- Shahin Ghadir, MD, REI Fellow 7/03-6/06. *Present position: Asst. Clinical Professor (Voluntary), UCLA*
- John Kuo, MD, REI Fellow 7/05-6/07 *Present position: Asst. Professor, UCLA*
- Susan Sarajari, MD, REI Fellow 7/05-6/07. *Present position: Physician, Washington Fertility Center*
- Andrew Huang, MD, MBA, REI Fellow 7/04-6/08. *Present position: Asst. Clinical Prof. (Voluntary), UCLA*
- Bradley Trivax, MD, REI Fellow 7/04-6/08. *Present position: Private practice*
- Kari Sproul, MD, REI Fellow 7/06-6/09. *Present position: Private practice*
- Deirdre Conway, MD, REI Fellow 7/07-6/10. *Present position: Asst. Clinical Professor, UCSD*
- Aline Ketefian, MD, REI Fellow 7/08-6/10. *Present position: Physician, Kaiser Permanente, Los Angeles*
- Kathleen Brennan, MD, REI Fellow 7/08-6/10; *Present position: Asst. Professor, UCLA*

### **Medical Endocrinology Clinical Fellows (VA/UCLA and CSMC programs):**

- Betsy Batcher, MD (VA/UCLA), 7/04-6/06, *Present position: Asst. Clinical Professor, UCLA, based at Harbor-UCLA Med Ctr.*
- Saima Sajid-Crockett, MD (VA/UCLA), 7/04-6/06, *Present position: Private practice*
- Neil Tran, MD (VA/UCLA), 7/05-6/07, *Present position: Private practice*
- Elaine Wong, MD (VA/UCLA), 7/05-6/07, *Present position: Private practice*
- Emily Tan, MD (VA/UCLA), 7/06-6/08, *Present position: Private practice*
- Vasantha Narayan, MD (VA/UCLA), 7/06-6/08, *Present position: Private practice*
- Patricia Park, MD (CSMC), 7/06-6/08, *Present position: Private practice*
- Odelia Cooper, MD (CSMC), 7/06-6/08, *Present position: Clinical Instructor, UCLA based at CSMC*
- Christian Gastelum, MD (MLK/CSMC), 7/06-6/08, *Present position: Private practice*
- Rosa Lin, MD (VA/UCLA), 7/07-6/09
- Samira Kirmiz, MD (VA/UCLA), 7/07-6/09
- Llanyee Liwampo, MD (CSMC/VA/UCLA-combined program), 7/08-6/10
- Rashmi Mullur, MD (CSMC/VA/UCLA-combined program), 7/08-6/10

### **Post-Doctoral Research Fellows:**

- Gretchen L. Wells, PhD, UAB, 5/89-5/90, *Present position: Assoc. Prof., Cardiology, Wake Forest Univ.*
- Gene Hines, PhD, UAB, 4/96-4/98, *Present position: Director, IACUC, Univ. of Alabama at Birmingham*
- Tatiana Ochoa Capelo, MD, 6/94-8/96, *Present position: Dept. of Ob/Gyn, Univ. Central del Ecuador, Quito, Ecuador*
- Raquel Huerta, MD, 8/98-7/99, *Present position: Instituto de Investigaciones Medicas, Univ. de Guanajuato, Leon, Mexico*
- Carlos Moran, MD, 10/97-10/00, *Present position: Director, Coord. de Investigación en Salud, Instituto Mexicano del Seguro Social, México, DF*
- Leonardo Gonzalez, MD, 2/06-11/07, *Present position: Coordinator, Unidad de Ginecología y Obstetricia de SES- Hospital de Caldas, Manizales, Colombia*
- Nissar A. Shah, MD, 7/06-6/07, *Present position: Private practice*
- Marita Pall, MD, 10/03-6/10, *Present position: Private practice*

- Jung Lee, MD, 11/08- 6/10, *Present position: Assistant Professor, Catholic University, Soeul, Korea*
- Jun Sun-Hse, MD, 2/09-6/10, *Present position: Post Doctoral Fellow, CSMC*
- Yen-Hao Chen, 9/08-6/10, *Present position: Assistant Prof., GRU, Augusta, GA*

**Other Foreign Research Fellows:**

- Emad Abdel Mageed, MD, Dept. of Ob/Gyn, Mataria Teaching Hospital, Guiza, Cairo, Egypt, 10/89 - 2/90
- Luis C. Hincapie, MD, Dept of Ob/Gyn, Universidad del Valle, Santiago de Cali, Colombia, 1/95 - 6/95
- Frank Capelo Ochoa, MD, Dept. of Ob/Gyn, Univ. Central del Ecuador, Quito, Ecuador, 6/01 - 7/02

**Doctoral Candidates:**

- Melissa Kahsar-Miller, PhD, Medical Genetics, UAB, 5/94 - 3/99 (Thesis Advisor: "Genetics aspects of the Polycystic Ovary Syndrome")

**Select Other Students:**

- Wende Waggoner, Undergraduate Honors Research Student (UAB), 11/96-6/98
- Christa Nixon, Medical Student (UAB), Summer 1996 (awarded Ob/Gyn Women's Health Care Initiative Award for outstanding research concerning women's health)
- Lolita Crabbe, Medical Student (UAB), Summer 1996 (awarded Kochakain Award for outstanding research in clinical medicine)
- Belynda Trader, Undergraduate Research Student (USC), 3/04 to 9/04

## **SELECTED INVITED LECTURES:**

### **As Chair - Selected Postgraduate Courses/Symposia/Annual Meetings:**

**1993:**

American Fertility Society (currently the American Society for Reproductive Medicine) Regional Postgraduate Course, Birmingham, AL, "Hands-On Course in Advanced Pelviscopic Surgery"

**1994:**

American Fertility Society (currently the American Society for Reproductive Medicine) Regional Postgraduate Course, Birmingham, AL, "Hands-On Course in Advanced Pelviscopic Surgery"

**1996:**

American College of Obstetricians and Gynecologists Regional Postgraduate Course, Birmingham, AL, "Advanced Operative Laparoscopy and Hysteroscopy"

American Association of Gynecologic Laparoscopists Annual Meeting Postgraduate Course, Chicago, IL, "Advanced Operative Laparoscopy: A Multi-Disciplinary Approach"

**1997:**

American Society for Reproductive Medicine Annual Meeting, Cincinnati, OH, General Program Chair, Endocrine Society Annual Meeting Satellite Symposium, Minneapolis, MN, "First International Symposium on the Developmental Aspects of Androgen Excess"

**1998:**

American Society for Reproductive Medicine Annual Meeting Postgraduate Course, San Francisco, CA, "Current Concepts in Endocrinology: The Fundamentals"

American College of Obstetricians and Gynecologist Regional Postgraduate Course, Birmingham, AL, "Advanced Operative Laparoscopy and Hysteroscopy"

American Association of Gynecologic Laparoscopists, Annual Meeting, Plenary Symposia, Atlanta, GA

**2000:**

Endocrine Society Annual Meeting/Satellite Symposium, Toronto, Canada, "Second International Symposium on the Developmental Aspects of Androgen Excess"

**2001:**

Endocrine Society Annual Meeting Symposium, Denver, CO, "Hair: Too Much, Too Little"

**2002:**

American Society for Reproductive Medicine Annual Meeting Symposium, Seattle, WA, "Adhesion Prevention: The Standard of Care"

Endocrine Society Annual Meeting Symposium, San Francisco, CA, "Etiology of Polycystic Ovarian Syndrome"

**2008:**

Member of the Programme Planning Committee of the 2008 International Congress of Endocrinology, Rio de Janeiro, Brazil

Androgen Excess & PCOS Society, San Francisco, CA, 4<sup>th</sup> Special Scientific Meeting "Ovarian and adipose tissue dysfunction: potential roles in PCOS"

The Endocrine Society 90th Annual Meeting, San Francisco, CA, Clinical Symposia "PCOS across the Lifespan"

NIDDK/Network of Minority Research Investigators (NMRI), Washington DC, Chair, Program Committee

**2009**

64th Ob-Gyn Assembly of Southern California, Marina del Rey, CA

**As Faculty/Lecturer - Selected Postgraduate Courses/Lectures/Seminars/Symposia/Roundtables:**

**1981:**

American Medical Student Association, National Convention, Houston, TX, "The Hispanic Patient",  
AAMC, Annual Business Meeting, Minority Affairs Section, Washington, D.C., "The Hispanic Patient: An Interrogative"

**1985:**

The Johns Hopkins University Reproductive Endocrinology Lecture Series, "Aging and Reproduction" and  
"Polycystic Ovarian Disease"

**1986:**

Georgetown University Hospital Ob/Gyn Grand Rounds, "Update on PCOD", Washington, D.C.

**1987:**

Georgetown University Hospital Ob/Gyn Grand Rounds, "Adrenal Hyperplasia"

**1989:**

Hospital de Clínicas, Montevideo, Uruguay, "Current Concepts in Hyperandrogenemia"

University of Oklahoma, "Pelvic Adhesions: Pathogenesis to Prevention"

Mount Sinai Hospital, Chicago, IL, "Tubal Reconstructive Surgery"

University of California at Davis, "Adhesion Prevention"

**1990:**

Alabama Association of Obstetricians and Gynecologists Postgraduate Course, "Operative Laparoscopy"  
Birmingham, AL

Albany Medical College, Albany, NY, "Pelvic Adhesions: Pathogenesis to Prevention"

University of Minnesota, "Current Concepts in Adhesion Prevention"

Woman's Hospital, University of Southern California, "Pelvic Adhesions: Pathogenesis to Prevention"

University of California at Los Angeles, "Prevention of Pelvic Adhesions", "Late-Onset Adrenal Hyperplasia"

Tulane University Medical Center, "Late-Onset Adrenal Hyperplasia", "Current Advances in Adhesion  
Prevention"

Eastern Virginia Medical School, Norfolk, VA, "Pelvic Adhesions: Pathogenesis to Prevention"

University of South Alabama, Mobile, AL, "Late-Onset Adrenal Hyperplasia"

Magee Women's Hospital, Pittsburgh, PA, "Pelvic Adhesions: Pathogenesis to Prevention"

University of Colorado Health Sciences Center, "Current Advances in Adhesion Prevention"

**1991:**

Wake Forest Medical Center, Winston-Salem, NC, Frank R. Lock 15th Annual Ob/Gyn Symposium

Northeast Louisiana Ob/Gyn Society, Monroe, LA, "Prevention of Postoperative Adhesions",

"Management of Uterine Leiomyomas", and "Diagnosis and Management of Ectopic Pregnancy"

University of South Alabama, Mobile, AL, "Hirsutism", "Reproductive Surgery"

Mount Sinai Medical Center, New York, NY, "Pelvic Adhesions: Pathogenesis to Prevention"

Pennsylvania State University, College of Medicine, Hershey, PA, "Adhesion Prevention",  
"Hyperandrogenism"

University of Texas Medical School, Houston, TX, "Current Concepts in Adhesion Prevention"

Baylor College of Medicine, Houston, TX, "Anti-adhesive Therapy"

University of California at Irvine, "Pelvic Adhesions: Pathogenesis to Prevention"

New Jersey Ob/Gyn Society Meeting, Cherry Hill, NJ, "Operative Laparoscopy"

University of Tennessee, Memphis, College of Medicine, "Hirsutism", "An Update on the Medical Therapy  
of Endometriosis"

**1992:**

American Society for Reproductive Medicine Regional Postgraduate Course, Williamsburg, VA, "Clinical Problem Solving in Reproductive Endocrinology & Infertility",  
Alabama Association of Obstetricians and Gynecologists, Birmingham, AL, "Laparoscopic Evaluation of the Adnexal Mass"  
Georgetown University Hospital, "Current Concepts in the Management of Hirsutism"  
Sinai Hospital, Baltimore, MD, "Late-Onset Adrenal Hyperplasia"  
The University of South Dakota School of Medicine, "Pelvic Adhesions: Pathogenesis to Prevention"  
State University of New York at Stony Brook Medical Center, Stony Brook, NY, "Advances in Hysteroscopic Surgery"  
Roosevelt Hospital, Manhattan, NY, "Treatment & Diagnosis of Uterine Leiomyomata"  
Hospital of the University of Pennsylvania, Philadelphia, PA, "Late-Onset Adrenal Hyperplasia"  
University of Miami School of Medicine, "Hormonal Replacement Therapy: Cancer Risk"  
Kaiser Permanente Hospital, San Francisco, CA, "Pelvic Adhesions: Pathogenesis to Prevention"

**1993:**

III Jornadas de Actualización en Endocrinología, Montevideo, Uruguay  
Council on Resident Education in Obstetrics and Gynecology (CREOG) Regional Postgraduate Courses, Cincinnati, OH, "Endoscopic Training for OB/GYN Faculty"  
Alabama Association of Obstetricians and Gynecologists, Birmingham, AL, "Training and Certification in Laparoscopic Surgery", "Estrogen Replacement and Cancer"  
Albany Medical College, Albany, NY, "Hirsutism: Diagnosis and Management"  
Medical University of South Carolina, Charleston, SC, "Adult Onset of Congenital Adrenal Hyperplasia"  
Wake Medical Center Raleigh, NC, "Pelvic Adhesions: Pathogenesis to Prevention"  
Uniformed Services Academy of Family Physicians XVIIIth Scientific Assembly, Corpus Christi, TX, "Current Perspectives in Postmenopausal Estrogen Replacement Therapy", "Basic Infertility Evaluation"

**1994:**

The Endocrine Society Annual Meeting, "Meet-the-Professor - Hirsutism"  
XIII Congreso Panamericano De Endocrinología, IX Congreso Chileno De Endocrinología y Metabolismo, Santiago, Chile, Plenary Lecture, "Non-classic adrenal hyperplasia"  
Council on Resident Education in Obstetrics and Gynecology (CREOG) Regional Postgraduate Courses, Cincinnati, OH, "Endoscopic Training for OB/GYN Faculty"  
University of California at Los Angeles, "Contemporary Management of Late Onset Adrenal Hyperplasia and Androgen Disorders"  
Greater Baltimore Medical Center, Baltimore, MD, "Hirsutism"  
Southern Illinois University School of Medicine, Springfield, IL, "Adhesions: Pathogenesis to Prevention"

**1995:**

American College of Obstetrics and Gynecology Regional Postgraduate Course, Quebec, Canada, "Endocrinology for Office Practice",  
American Society for Reproductive Medicine Regional Postgraduate Course, San Antonio, TX, "Basic Reproductive Endocrinology and Infertility for Primary Care Physicians"  
The Endocrine Society Annual Meeting, Plenary Symposia, "Non-Classical Adrenal Hyperplasia"  
Serono Symposia, Boston, MA, "Polycystic Ovary Syndrome"  
Society of Gynecologic Investigation, Annual Meeting, Round Table, "Hirsutism"  
Council on Resident Education in Obstetrics and Gynecology (CREOG) Annual Meeting Symposia, Orlando, FL, "Teaching Advanced Gynecologic Endoscopy"  
Emory University, Atlanta, GA, "Adhesions: Pathogenesis to Prevention"  
Medical College of Georgia, University Hospital, Augusta, GA, "Pelvic Adhesions: Pathogenesis to Prevention"  
The University of Alabama, Tuscaloosa, AL, "Estrogen Replacement Treatment and Osteoporosis"

University of Puerto Rico, Mayaguez, PR, "Hirsutism"

Texas Tech University, Amarillo, TX, "Evaluation and Management of the Hirsute Patient", "Current Concepts of Nonclassic Adrenal Hyperplasia"

**1996:**

American Society for Reproductive Medicine (formerly the American Fertility Society) Regional Postgraduate Course, Birmingham, AL, "Hands-On Course in Advanced Pelviscopic Surgery"

American Society for Reproductive Medicine (formerly the American Fertility Society) Annual Meeting, Postgraduate Course, Boston, MA, "Endocrinology for the Reproductive Endocrinologist: The Clinical Approach"

Cambridge University, Queens' College, Cambridge, UK, "The Clinical Spectrum of CAH in Adolescence and Adulthood"

Puerto Rico Medical Association, Sunshine Seminar, San Juan, Puerto Rico, "Hormone Replacement Therapy"

American Academy of Dermatology Annual Meeting Symposia, Washington, DC, "Current concepts in Hirsutism"

Johns Hopkins University Hospital Emil Novak Memorial Course, Baltimore, MD, "The Polycystic Ovary Syndrome"

University of Cincinnati, "Credentialing and Training in Laparoscopy"

University of California, San Diego, "Adrenal Hyperfunction in PCO and Treatment of Hirsutism"

Mayo Clinic, Rochester, MN, "Adrenal Dysfunction in Polycystic Ovary Syndrome"

Stanford University, School of Medicine, "Current Advances in the Treatment of the Hirsute Patient"

American College of Obstetrics and Gynecology Regional Postgraduate Course, Birmingham, AL, "Advanced Operative Laparoscopy and Hysteroscopy"

**1997:**

American Electrology Association Annual Meeting, Orlando, FL, Plenary Lecture, "Hirsutism, Shaving, FDA/Laser and the Electrologist"

American College of Obstetrics and Gynecology Regional Postgraduate Course, Tucson, AZ, "Reproductive Endocrinology and Infertility for the Practicing OBGYN"

The 79<sup>th</sup> Annual Meeting of the Endocrine Society, Minneapolis, MN, "Meet-the-Professor - The Polycystic Ovary Syndrome"

10th World Congress IVF & ART Plenary Symposia, Vancouver, Canada, "Evaluation of Infertility: A Cost Effective Approach", and "Is ART the Best Treatment for Infertile Couples? I Think Not"

Georgetown University Medical Center, "Androgenism and Hirsutism Treatment in the Infertility Patient"

Penn State University School of Medicine, Hershey, PA, "Current Concepts in Diagnosis and Treatment of Non-classic Adrenal Hyperplasia"

Miami Obstetrical and Gynecological Society Annual Meeting, Miami, FL, "Excess Hair Growth in Women: Current Concepts"

**1998:**

Society of Gynecologic Investigation Annual Meeting Symposia, "Adrenal Dysfunction in PCOS"

University of Minnesota, The Louis L. Friedman Lecture, "Current concepts in the evaluation and treatment of hirsutism"

Xth International Congress on Hormonal Steroids Symposia, Quebec City, Canada, "The Adrenal in PCOS"

Middle East Medical Assembly, Beirut, Lebanon, Plenary Lecture, "Non-Classic Adrenal Hyperplasia"



I Congreso Mexicano de la Asociación de Médicos Militares Gineco-Obstetras, Conferencia Plenaria y Simposio, México City, México, "Síndrome de Ovario Poliquístico" (and others)  
XXXV Reunión Anual de la Asociación Mexicana de Medicina de la Reproducción, Conferencia Plenaria y Simposio, Huatulco, México, "Síndrome de Ovario Poliquístico", "Hiperplasia Adrenal Tardia" (and others)

**1999:**

European Society for Pediatric Endocrinology Annual Meeting, Clinical Practice Session, Warsaw, Poland, "Diagnosis and management of adolescent hirsutism"

**2000:**

National Institute of Environmental Health Sciences (NIEHS) conference, Research Triangle Park, NC, "Polycystic Ovary Syndrome: Basic Biology and Clinical Intervention"

**2001:**

Medical University of South Carolina, Charleston, SC, "Hirsutism: Assessment and Treatment"  
2do Congreso Internacional de Médicos Militares Gineco-Obstetras, México City, México, "Inducción De Ovulación"  
Clínica Alemana De Santiago, Santiago, Chile, "Criterios Diagnósticos Y Epidemiológica Del Síndrome De Ovario Poliquístico", "Evidencias De Resistencia Insulínica En El Síndrome De Ovario Poliquístico" & "Mecanismo de Acción De Las Thiazolidinedionas Y Sus Efectos Terapéuticos En El Síndrome De Ovario Poliquístico"

**2002:**

American Association for Reproductive Medicine Annual Meeting, Postgraduate Course, "Advances in the Treatment of Polycystic Ovary Syndrome"  
Pediatric and Adolescent Gynecology Symposium, Seattle, WA, "Congenital Adrenal Hyperplasia"  
Johns Hopkins University, "PCOS vs. CAH"  
University of South Alabama College of Medicine, Mobile, AL, "The Polycystic Ovary Syndrome"  
University of Pennsylvania School of Medicine, "PCOS and Insulin Resistance"  
Kaiser Permanente Physician Education, Anaheim, CA, "Contemporary Issues in the Management of Polycystic Ovary Syndrome and Insulin Sensitizing Agents"  
University of Southern California, Keck School of Medicine Postgraduate Course, Los Angeles, CA, "The Polycystic Ovary Syndrome"

**2003:**

American Society for Reproductive Medicine Annual Meeting, San Antonio, TX, Postgraduate Course, "Polycystic Ovary Syndrome: Restoring and Preserving Reproductive Potential", and ESHRE Symposium, "Diagnostic Criteria, Nomenclature & Long-term Health Risks of PCOS"  
University of California, San Diego/San Diego Gynecological Society Annual Symposium, "Practical Aspects of Hormone Replacement Therapy"  
Los Angeles Obstetrical and Gynecological Society, Los Angeles, CA, "Current Evaluation and Treatment of Women with Androgen Excess"  
Endocrine Society of Australia Annual Meeting, New Lampton Heights, Australia, "The Adrenal in Hyperandrogenism", "Phenotyping Androgen Excess"  
Pacific Coast Reproductive Society Annual Meeting, Rancho Mirage, CA, "Hirsutism, PCO, and Insulin Resistance: Making Sense of the Evidence", "Insulin Resistance and PCOS: What is the Reality?"  
ASRM/ESHRE PCOS Consensus Meeting, Rotterdam, Netherlands, "Hyperandrogenemia"  
University of California, San Diego/VA Hospital, "Phenotyping the Androgen Excess Patient"  
Hacettepe University, School of Medicine, International Symposium, Antalya, Turkey, "PCOS: A Diagnostic Challenge"  
13th Congress Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina. 'Meet the Professor' session - La Mujer Hirsuta'

XVII FIGO Congress, Santiago, Chile. Postgraduate satellite course in Reproductive Endocrinology and Infertility - Interpreting Androgen Measures in Hyperandrogenic Women  
Endocrine Society Annual Meeting, Philadelphia, Pennsylvania. Symposium speaker, "Hyperandrogenism: Congenital Adrenal Hyperplasia"

**2004:**

City of Hope Endocrine Clinical Conference, Duarte, CA, "Current Concepts in the Polycystic Ovary Syndrome"

90<sup>th</sup> Annual Meeting of the Korean OB/GYN Society, The 10<sup>th</sup> Seoul International Symposium, Seoul Korea, "Current Concepts in the Diagnosis and Management of the Woman with 21-hydroxylase deficient Non-Classic Adrenal Hyperplasia (NCAH)", and "Polycystic Ovary Syndrome: To Use or Not to Use Insulin Sensitizers"

P&G Advisory Board meeting, Chicago, Illinois, "Long-term considerations for TTP"

International Society of endocrinology, Lisbon, Portugal, 'Meet the Professor' session: "Polycystic Ovarian Syndrome".

23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies, Brighton, United Kingdom; Symposium: The Clinical Management of Hirsutism: Evidence Based Practice.

7th Annual Polycystic Ovarian Syndrome Association International Conference, Rye Brook, New York, Life Stages of PCOS: Research Advances Session

NIDDK Network of Minority Investigators (NMRI) Workshop, Bethesda, Maryland: "Scientific Reasoning: Getting to the Core of the Question", "Selling Your Science", "Grant Writing Workshop: Turning an early draft or preliminary data into a successful proposal-Clinical Sciences", "Resource Management Workshop: Hiring Decisions, Human Resource-Related Issues, and Conflicts"

**2005:**

Endocrine Society Meeting, San Diego, CA "Differential Diagnosis and Evaluation of Hyperandrogenism"

Pacific Coast Reproductive Society (PCRS) Meeting, Indian Wells, CA, "Epidemiology, Heritability, and Diagnosis of PCOS"

Androgen Excess Society 2nd Special Scientific Meeting - PCOS: A Multifaceted Disease from Adolescence to the Elderly, Ravello, Italy, "Prevalence and Diagnosis of PCOS"

University of Palermo, Palermo, Italy, "Pervolenza e Diagnosi della PCOS"

Androgen Excess Society 3rd Annual Meeting, San Diego, CA, "Report of an AES Special Task Force: The PCOS phenotype"

Endocrine Society's 87th Annual Meeting, San Diego, CA; Symposium, "Hyperandrogenism & Hirsutism: Differential Diagnosis & Evaluation"

European Society of Human Reproduction and Embryology. Copenhagen, Denmark, "Is ART the best treatment for infertile couples? Not always so!"

American Association of Gynecologic Laparoscopists 34<sup>th</sup> Annual Mtg, Chicago, IL, "The Polycystic Ovary Syndrome: What Is It and Can it Be Treated."

American Society Reproductive Medicine/Canadian Fertility and Andrology Society 2005 Annual Meeting, Montréal, Canada, "Managing the Hirsute Woman" and "The Polycystic Ovarian Syndrome"

Electrology Association of California State Symposium, Los Angeles, CA, "The Polycystic Ovary Syndrome: What is it and Why Should I Care?" and "The Role of the Electrologist in the Evaluation and Care of the Hirsute Patient"

NIDDK Network of Minority Investigators (NMRI) Workshop, Bethesda, Maryland: "Transition From Student to Postdoctoral Researcher to First Faculty Appointment", "Laboratory Growth Management: Hiring Decisions, Human Resource-Related Issues, and Conflicts"

**2006:**

Endocrine Society's 88th Annual Meeting, Boston, MA: "Meet the Professor - Nonclassical Congenital Adrenal Hyperplasia in Adults"

American Society Reproductive Medicine 2006 Annual Meeting, New Orleans, LA, "The Evaluation & Treatment Of Hirsutism And Hyperandrogenism In PCOS" and "Diagnostic Dilemmas In PCOS Or How I Learned To Stop Worrying And Love A Syndrome"

Polycystic Ovarian Syndrome International Congress, Athens, Greece, Plenary Lecture, "Evaluation for insulin resistance and comorbidities to insulin resistance".

NIDDK Network of Minority Investigators (NMRI) Workshop, Bethesda, Maryland: "Administrative Issues: Being a Department Chair or Division Director"

**2007:**

Update on Polycystic Ovarian Syndrome, Thessaloniki, Greece, "Insulin Resistance"

2nd ESHRE/ASRM PCOS Consensus Meeting - Infertility Treatment in Women with PCOS, Thessaloniki, Greece, "Role of concomitant GnRH agonists administration during ovulation induction with gonadotropins in PCOS"

Ob/Gyn Assembly, Los Angeles, CA, "What to do for the patient complaining of increased hair growth"

NASPAG 2007 Annual Clinical Meeting, Atlanta, GA, "The Sir John Dewhurst, M.D. Lectureship - The Changing Face of Polycystic Ovary Syndrome"

5<sup>th</sup> Androgen Excess Society Annual meeting, Toronto, Canada, "A Brief History of the Study of Androgen Excess Disorders: Antiquity Through 1960"

Endocrine Society's 89th Annual Meeting, Toronto, Canada: "Meet the Professor - Nonclassical Congenital Adrenal Hyperplasia in Adults"

The Annual Meeting of the Russian Association of Human Reproduction, Kazan, Russia, Plenary lecture: "The Polycystic Ovary Syndrome"

The CARES Foundation Annual Meeting: "Nonclassic Adrenal Hyperplasia" (and others)

The American Association of Clinical Endocrinologists-West: "Current Concepts in the Polycystic Ovary Syndrome"

The Royal College of Obstetricians & Gynaecologists, Polycystic Ovary Syndrome - A Condition of our Time, London, UK, "The Economic Burden of PCOS"

**2008:**

University of Southern California, Endocrine Grand Rounds, "Non-classic Adrenal Hyperplasia"

Los Angeles Obstetrics & Gynecology Society, "PCOS and Metformin: What is the Controversy?"

Simposio Síndrome de Ovario Poliquístico, Puesta al Día, Guatemala, "Uso de la Metformina y los Tiazolidinediones, donde Encajan en el Tratamiento del SOP", "Insulina Resistencia, SOP y Síndrome Metabólico", Evaluación y Tratamiento del Hirsutismo", "La Adrenal y SOP", and "Evaluación del Exceso Androgénico"

North American Society for Pediatric and Adolescent Gynecology, Newport Beach, CA, "PCOS in Adolescents"

Simposio Internacional Síndrome Hiperandrogénico, Buenos Aires, Argentina, "Enfoque práctico frente a una paciente con sospecha de PCOS", "Insulino-Resistencia en PCO (Fisiopatología-Incidencia-Diagnóstico)", "Conferencia: Terapias actuales de la PCO sin deseo de embarazo", and "Hirsutismo e Hiperandrogenismo: Evaluación y Tratamiento"

6th Annual World Congress on the Insulin Resistance Syndrome, Los Angeles, CA, "Insulin Resistance and PCOS"

The Society of Reproductive Endocrinology and Infertility (SREI) Associate Member annual meeting, San Francisco, CA, "Physicians as Leaders".

Androgen Excess & PCOS Society meeting, San Francisco, "Adipocytokines in Androgen Excess Disorders"

NIDDK/Network of Minority Research Investigators (NMRI), Washington DC, “Developing an Academic Career”, “Academic Medicine Financing: How do we pay for it?”, “Hiring Decisions, Human Resource-Related Issues, and Conflict Resolution”  
Women’s Health Summit, New York, NY “PCOS: Lifelong Management”

**2009:**

64th Ob-Gyn Assembly of Southern California, Marina del Rey, CA, “Androgen Excess in Women – A Historical Perspective”  
NIDDK/Network of Minority Research Investigators (NMRI), Bethesda, MD, “Fostering a Diverse Faculty”,  
James R. Givens Distinguished Visiting Professor, Department of Medicine Grand Rounds, University of Tennessee Health Science Center Memphis, TN, “Polycystic Ovary Syndrome: An Ancient Disorder with Modern-day Consequences”  
Charles Drew University, Los Angeles, CA “Adrenocortical Dysfunction in PCOS: Twenty years of Study”  
5<sup>th</sup> International Meeting of the AE-PCOS Society, Krakow, Poland, "PCOS Phenotypes & Their Impact on Cardiovascular & Metabolic Risk"  
21st Annual NICHD Aspen Conference on Maternal-Fetal-Neonatal-Reproductive Medicine, Aspen, CO, “Excess Adrenal Androgen Production in PCOS: A 20 Year Journey”.

**2010:**

American Association of Clinical Endocrinology (AACE)-Southern Conference Annual Meeting, New Orleans, LA, "Polycystic Ovary Syndrome as a Metabolic Disorder: Current Concepts"  
Joint Meeting of the Indian College of Ob-Gyn and AE-PCOS Society, Goa, India, Inaugural Lecture "Polycystic Ovary Syndrome: A Historic and Evolutionary Perspective", and "The Adipose Tissue"  
NIDDK/Network of Minority Research Investigators (NMRI), Bethesda, MD, Plenary Lecture “Your Role as a Research Leader: Recruiting, Screening, & Releasing Staff”  
American College of Physicians Annual Meeting, Toronto, CA, “Polycystic Ovary Syndrome and Other Hyperandrogenic States”  
2010 Annual Meeting of the Society for Gynecologic Investigation, Orlando, FL, “Insulin Resistance, Insulin Signaling Dysfunction & PCOS”  
Endocrine Clinical Conference at Harbor-UCLA, Torrance, CA, "PCOS, Metabolic Dysfunction, and Cardiovascular Disease"  
The 92<sup>nd</sup> Annual Meeting of the Endocrine Society, San Diego, CA, “Premature Adrenarche and PCOS”  
2<sup>nd</sup> Annual Diversity Symposium Georgia Institute of Technology, Atlanta, GA, “Fostering a Diverse Faculty: Bridging the Divide”  
Georgia Bio, Georgia Life Sciences Summit 2010, Atlanta, GA, “Innovations for a healthier world: Meeting the Challenge”  
Augusta State University, James M. Hull School of Business, Augusta, GA, “Healthcare Forum”

**2011:**

Georgia Hospital Association Annual Meeting, Atlanta, GA – “Academic Health Centers: Partners for Better Health”  
Georgia Nursing Summit, Atlanta, GA – “Interdisciplinary panel on translation of the challenges in Georgia”  
Georgia Public Health Association Annual Meeting, Atlanta, GA – “Georgia Health Sciences University: Partner in Public Health”  
The Commerce Club, Atlanta, GA – “The Business of Academic Health Centers: Better Health through Partnership”  
Richmond County Medical Society, Augusta, GA – “GHSU: A Partner for Better Communities and Better Health”  
Mercer University, Dept. of Ob/Gyn Resident Research Day, Macon, GA – “Leading to Excellence”

Georgia Obstetrical & Gynecological Society 2011 Annual Meeting, Amelia Island, FL – Polycystic Ovary Syndrome: 25 Year Experience”

AAMC, Council of Academic Societies Spring Meeting, Providence, RI – “The Needs and Expectations of Current and Future Faculty Leaders”

XIII Curso Intensivo De Diabetes, Endocrinología Y Enfermedades Metabólicas, Miami, FL – “Síndrome De Ovario Poliquístico (SOP)” and “Evaluación Clínica Y De Laboratorio De La Mujer Hirsuta”

**2012:**

Georgia Budget and Policy Institute Conference, Quality of Life Panelist, Atlanta, GA

Leadership Augusta, Executive Forum Panel on Higher Education, Augusta, GA

Paine College Commencement Keynote Speaker, Augusta, GA

Corporate Volunteer Council Healthcare Symposium - State of Healthcare in Georgia, Executive Panelists, Atlanta, GA

The NIH Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome – “The 2006 Androgen Excess & PCOS Society Criteria for Polycystic Ovary Syndrome”, Bethesda, MD

**2013:**

Technology and the Transformation of the Academic Health Center - 2013 Annual Meeting of the Association of Academic Health Centers (AAHC) - “A Conversation with Ricardo Azziz”, Boston, MA

**2014:**

Blanchard Leadership Institute Breakfast, “Sculpting in Clay-Leadership in Transformative Times”, Columbus State University, Columbus, GA.

American Council of Education 96th Annual Meeting, Presidential facilitator, mini-case discussions, Institute for New Presidents session, San Diego, CA

Administrators in Medicine 2014 Annual Meeting, “Sculpting in Clay-Leadership in Transformative Times”. Denver, CO

16th International Congress of Endocrinology & The Endocrine Society 96th Annual Meeting, “Adipose tissue dysfunction in Polycystic Ovary Syndrome”, Chicago, IL

## **Selected Institutional Lectures:**

### **GRU**

#### **2011:**

Department of Medicine, Grand Rounds, "Polycystic Ovary Syndrome"  
Vascular Biology Center, "Insulin Resistance, Insulin Signaling Dysfunction & PCOS"  
Inaugural Presidential Lecture, "Sculpting in Clay – Transformative Leadership for Shifting Times"

#### **2012:**

McDonough Lectureship Symposium, "The Needs and Expectations of Current and Future Faculty Leaders"

### **Cedars-Sinai Medical Center:**

#### **2002:**

Department of Obstetrics and Gynecology, Grand Rounds, "Current Concepts in the Pathophysiology of Non-classic Adrenal Hyperplasia"  
Department of Endocrinology, Diabetes & Metabolism Grand Rounds, "Polycystic Ovary Syndrome"

#### **2003:**

Burns & Allen Research Institute, Research Grand Rounds, "Phenotyping Androgen Excess Disorders"  
Department of Obstetrics and Gynecology Grand Rounds, "The Economics of Academic Medicine"

#### **2004:**

Department of Pathology and Laboratory Medicine Grand Rounds, "The Economics of Academic Medicine"  
Society for the History of Medicine, "A History of Hirsutism: Bearded Ladies to Polycystic Ovary Syndrome"

#### **2005:**

PCOS Conference combined with the Department of Internal Medicine Grand Rounds, "New Concepts in the Diagnosis & Management of PCOS"  
PCOS Conference, "Evaluation & Treatment of Hirsutism"

#### **2006:**

Gynecologic Oncology Conference, "Critical Reading of Medical Literature"  
Department of Medicine Grand Rounds, "History of Androgen Excess: From Bearded Women to PCOS"  
Department of Ob/Gyn Grand Rounds, "Is ART the best treatment for infertile couples? Not always so!"  
Department of Endocrinology Grand Rounds, "A Brief history of the study of hirsutism and other androgen excess disorders"

#### **2007:**

Endocrinology and Metabolism Update, "Current Concepts in the Diagnosis and Treatment of the Polycystic Ovary syndrome"  
Medicine Grand Rounds "PCOS throughout the ages"

#### **2008:**

Endocrine Grand Rounds - "Nonclassic Adrenal Hyperplasia"

#### **2009:**

Department of Psychiatry Grand Rounds "PCOS and the Psychiatrist"  
Endocrine Grand Rounds - "A Historical Perspective on Androgen Excess"

#### **2010:**

Center for Androgen-Related Disorders Lecture Series, "Excess Adrenal Androgen Production in PCOS: A 20 Year Journey".

**UCLA:**

**2002:**

Department of Obstetrics and Gynecology Grand Rounds, "Polycystic Ovary Syndrome: The Role of Insulin Resistance"

Harbor/UCLA Medical Center, Endocrine Grand Rounds, "Polycystic Ovarian Syndrome"

**2003:**

Harbor/UCLA Medical Center Obstetrics and Gynecology Grand Rounds, "PCOS: To Use or Not To Use Insulin Sensitizers"

**2004:**

UCLA Endocrinology Grand Rounds, "Polycystic Ovary Syndrome: Defining a Syndrome".

Harbor/UCLA Medical Center Obstetrics and Gynecology Alumni Collegium, "Polycystic Ovary Syndrome: Diagnostic Challenge"

**2007:**

Harbor/UCLA Medical Center, Endocrine Grand Rounds, "Polycystic Ovary Syndrome" Current Developments"

**2009:**

UCLA Endocrine Grand Rounds "Update on Polycystic Ovary Syndrome"

**MISCELLANEOUS:**

Fluent in Spanish